

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 528 678 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
23.05.2001 Bulletin 2001/21

(51) Int Cl.7: **C07D 477/00, C07D 207/14,
A61K 31/40**

(21) Application number: **92307547.7**

(22) Date of filing: **18.08.1992**

(54) **A pyrrolidylthiocarbapenem derivative with antibacterial activity**

Pyrrolidylthiocarbapenemderivat mit antibakterieller Wirkung

Dérivé de pyrrolidylthiocarbapénème ayant une activité antibactérienne

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **20.08.1991 JP 20797291
21.02.1992 JP 3536692**

(43) Date of publication of application:
24.02.1993 Bulletin 1993/08

(73) Proprietor: **SHIONOGI SEIYAKU KABUSHIKI
KAISHA trading under the name of
SHIONOGI & CO. LTD.
Osaka 541 (JP)**

(72) Inventors:
• **Nishitani, Yasuhiro
Izumi-shi, Osaka (JP)**
• **Irie, Tadashi
Suita-shi, Osaka (JP)**
• **Nishino, Yutaka
Neyagawa-shi, Osaka (JP)**

(74) Representative: **Nash, David Allan et al
Haseltine Lake & Co.,
Imperial House,
15-19 Kingsway
London WC2B 6UD (GB)**

(56) References cited:
**EP-A- 0 182 213 EP-A- 0 280 771
EP-A- 0 433 759**

- **THORNBUR: "ISOSTERISM AND MOLECULAR
MODIFICATION IN DRUG DESIGN", CHEMICAL
SOCIETY REVIEWS, , , vol. 18, no. , pages 563 to
80**

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 528 678 B1

Description





BACKGROUND OF THE INVENTION

1. Field of the Invention:

[0001] The present invention relates to a new pyrrolidylthiocarbapenem derivative having a wide range of antibacterial spectrum, an antibacterial agent comprising the carbapenem derivative, a new pyrrolidine derivative which is an intermediate for producing the carbapenem derivative, and a method for producing the pyrrolidylthiocarbapenem derivative and the pyrrolidine derivative.

2. Description of the Prior Art:


[0002] Various compounds are known as carbapenems, a kind of a β -lactam antibiotic. For example, imipenem, meropenem, the mesylate (mesylamino), and the urea derivatives of a carbapenem as shown below are known.



[0003] All of these compounds have a wide range of antibacterial spectrum, and are effective against both Gram-positive bacteria and Gram-negative bacteria. A carbapenem derivative having a wider range of antibacterial spectrum and a stronger antimicrobial activity has been desired.

SUMMARY OF THE INVENTION


[0004] The pyrrolidylthiocarbapenem derivative of this invention is represented by Formula I:



wherein R^1 is hydrogen or lower alkyl; R^2 , R^3 and R^4 are independently hydrogen, lower alkyl which can be substituted by hydroxy, or an amino protecting group, or R^2 and R^3 together with a nitrogen atom to which R^2 and R^3 are bonded form a cyclic group selected from the group consisting of pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, im-


idazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl, morpholino and thiomorpholino, or R^2 and R^4 , or R^3 and R^4 together with two nitrogen atoms and one sulfur atom in the sulfamide group form a cyclic group selected from the group consisting of 1,1-dioxothiadiazinyl, 1,1-dioxodihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazoliziny, 1,1-dioxothiadiazoliny, and 1,1,3-trioxothiadiazoliny; X^1 is hydrogen or a hydroxy protecting group; X^2 is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and Y^2 is hydrogen or an amino protecting group.

[0005] In another aspect of the present invention, the pyrrolidine derivative of the present invention is represented by Formula II:



wherein R^2 , R^3 , R^4 and Y^2 are as defined above, and Y^1 is hydrogen or a mercapto protecting group.


[0006] Alternatively, the present invention provides a method for producing a pyrrolidine derivative represented by Formula II:



wherein R^2 , R^3 , R^4 , Y^1 and Y^2 are as defined above ;

the method comprises the steps of: converting a hydroxy group at the 4-position of a 4-hydroxypyrrolidine-2-carboxylic acid derivative into a mercapto group; converting a carboxy group at the 2-position into a hydroxymethyl group; converting a hydroxy group in the hydroxymethyl group into an amino group or a sulfamoyl group; and converting the amino group into a sulfamoyl group.

[0007] Alternatively the present invention provides a method for producing a pyrrolidylthiocarbapenem derivative comprising the step of: allowing a carbapenem derivative to react with the pyrrolidine derivative of Formula II to obtain the pyrrolidylthiocarbapenem derivative of Formula I; the carbapenem derivative being represented by Formula III:



wherein R^1 , X^1 and X^2 are as defined above, and X^3 is a leaving group (e.g., reactive ester group of hydroxy, alkylsulfinyl arylsulfinyl, alkylsulfonyl, or arylsulfonyl).

[0008] The present invention also relates to a new pyrrolidine derivative which is an intermediate for producing the carbapenem derivative and a method for producing the pyrrolidine derivative. The present invention also relates to the carbapenem derivatives defined above, other than those pyrrolidylthiocarbapenem derivatives in which any one or more of R^2 , R^3 , R^4 , X^1 , X^2 and Y^2 is a protecting group, for use as an antibacterial agent.

[0009] These and other advantages of the present invention will become apparent to those skilled in the art upon reading and understanding the following detailed description.

DESCRIPTION OF THE PREFERRED EMBODIMENTS


[0010] Followings are abbreviations used herein:

Ac	acetyl
Alz	allyloxycarbonyl
Boc	t-butoxycarbonyl
Et	ethyl
Ft	phthalyl
Me	methyl
Ms	methanesulfonyl
NPrc	protected amino
Ph	phenyl
PMB	p-methoxybenzyl
Pmz	p-methoxybenzyloxycarbonyl
PNB	p-nitrobenzyl
Pnz	p-nitrobenzyloxycarbonyl
Tr	trityl
Ts	p-toluenesulfonyl

[0011] A preferred scope of each group herein is as follows:

[0012] The number of carbon atoms of "lower alkyl" is 1 to 6. Examples of such an alkyl group include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, pentyl and hexyl. The number of carbon atoms of the lower alkyl is preferably 1 to 4. The most preferred lower alkyl is methyl or ethyl. The lower alkyl may be substituted by hydroxy. The number of carbon atoms of "aralkyl" is 7 to 15. Examples of "an amino protecting group" and "a hydroxy protecting group" include lower alkoxycarbonyl, lower alkenyloxycarbonyl, halogenoalkoxycarbonyl, aralkyloxycarbonyl, trialkylsilyl and diazo. An example of the lower alkoxycarbonyl includes t-butyloxycarbonyl; an example of the lower alkenyloxycarbonyl includes allyloxycarbonyl; examples of the halogenoalkoxycarbonyl include 2-iodoethyloxycarbonyl and 2,2,2-trichloroethyloxycarbonyl; examples of the aralkyloxycarbonyl include benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl and diphenylmethoxycarbonyl; examples of the trialkylsilyl include trimethylsilyl, triethylsilyl and t-butyldimethylsilyl.

[0013] In a definition of a group represented as follows:



a cyclic group formed from R² and R³ together with a nitrogen atom to which R² and R³ are bonded can be selected from pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, imidazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl morpholino and thiomorpholino.

[0014] In the definition of the group IIa, a cyclic group formed from R² and R⁴, or R³ and R⁴ can be selected from 1,1-dioxothiadiazinyl, 1,1-dioxodihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazoliziny, 1,1-dioxothiadiazolinyl, and 1,1,3-trioxothiadiazolinyl.

[0015] The "carboxy protecting group" is selected from those used in the art and serve the function of blocking the carboxyl group while reactions are carried out at other sites of the molecule. Such group generally contains less than about 19 carbon atoms and bind to a carboxyl group reversibly without affecting the other parts of the molecule. Typical examples include following groups: optionally substituted C₁ - C₈ alkyl, for example, methyl, methoxymethyl, ethyl, ethoxymethyl, iodomethyl, propyl, isopropyl, butyl, isobutyl, ethoxyethyl, methylthioethyl, methanesulfonylethyl, trichloroethyl, t-butyl, and the like; optionally substituted C₃ - C₈ alkenyl, for example, propenyl, allyl, isoprenyl, hexenyl, phenylpropenyl, dimethylhexenyl, and the like; optionally substituted C₇ - C₁₉ aralkyl, for example, benzyl, methylbenzyl, dimethylbenzyl, methoxybenzyl, ethoxybenzyl, nitrobenzyl, aminobenzyl, diphenylmethyl, phenylethyl, trityl, di-t-


butylhydroxybenzyl, phthalidyl, phenacyl, and the like; optionally substituted $C_6 - C_{12}$ aryl, for example, phenyl, toluyl diisopropylphenyl, xylyl, trichlorophenyl, pentachlorophenyl, indanyl, and the like; optionally substituted $C_1 - C_{12}$ amino which is, e.g., an ester with acetone oxime, acetophenone oxime, acetoaloxime, N-hydroxysuccineimide, N-hydroxyphthalimide, or the like; optionally substituted $C_3 - C_{12}$ hydrocarbonated silyl, for example, trimethylsilyl, dimethylmethoxysilyl, t-butyl dimethylsilyl, and the like; optionally substituted $C_3 - C_{12}$ hydrocarbonated stannyl, for example, trimethylstannyl, and the like. Another carboxy protecting group is a pharmaceutically active ester forming group. Examples of such a group include following groups: 1-(oxygen-substituted)- C_2 to C_{15} alkyl groups, for example, a straight, branched, ringed, or partially ringed alkanoyloxyalkyl, such as acetoxymethyl, acetoxylethyl, propionyloxymethyl, pivaloyloxymethyl, pivaloyloxyethyl, cyclohexaneacetoxylethyl, cyclohexanecarbonyloxycyclohexylmethyl, and the like; $C_3 - C_{15}$ alkoxy carbonyloxyalkyl such as ethoxycarbonyloxyethyl, and the like; $C_2 - C_8$ alkoxyalkyl, such as methoxymethyl, methoxyethyl, and the like; $C_4 - C_8$ 2-oxacycloalkyls, such as tetrahydropyranyl, tetrahydrofuranyl, and the like; substituted $C_6 - C_{12}$ aralkyls, for example, phenacyl, phthalidyl, and the like; $C_6 - C_{12}$ aryl, for example, phenyl, xylyl, indanyl, and the like; $C_2 - C_{12}$ alkenyl, for example, allyl, isoprenyl, 2-oxo-1,3-dioxolyl-4-yl-methyl, and the like. Among the above, a protecting group used to block the carboxyl group during reactions is usually removed at the final step of the reaction, and therefore its structure is not essential. Thus, as one of skilled in the art can easily appreciate, the carboxy protecting group can be selected from various equivalent groups including amides, acid anhydrides formed with carbonic acid or carboxylic acids, and the like as long as an aimed carboxyl group is protected properly.

[0016] An example of the lower alkyl includes t-butyl; examples of the lower alkenyl include allyl, isopentenyl and 2-butenyl; examples of the halogeno lower alkyl include 2-iodoethyl and 2,2,2-trichloroethyl; examples of the lower alkoxy methyl include methoxymethyl, ethoxymethyl and isobutoxymethyl; examples of the lower aliphatic acyloxymethyl include acetoxymethyl, propionyloxymethyl, butyryloxymethyl and pivaloyloxymethyl; examples of the 1-lower alkoxy carbonyloxyethyl include 1-methoxycarbonyloxyethyl and 1-ethoxycarbonyloxyethyl; and examples of the aralkyl include benzyl, p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl and diphenylmethyl. Examples of "an alkali metal" include lithium, sodium and potassium, and sodium or potassium is preferred. Examples of "an alkaline-earth metal" include magnesium and calcium.

[0017] As "a mercapto protecting group", a conventional one, e.g., acyl and aryl substituted lower alkyl such as benzyl, phenethyl, trityl and benzhydryl are included. As "a reactive ester group of hydroxy", a conventional one, e.g., a residue such as substituted or unsubstituted arylsulfonyloxy, lower alkanesulfonyloxy, halogeno lower alkanesulfonyloxy, dialkylphosphonyloxy, diarylphosphoryloxy and halogeno are included. Examples of the arylsulfonyloxy include benzenesulfonyloxy, p-toluenesulfonyloxy, p-nitrobenzenesulfonyloxy and p-bromobenzenesulfonyloxy; examples of the lower alkanesulfonyloxy include methanesulfonyloxy and ethanesulfonyloxy; an example of the halogeno lower alkanesulfonyloxy includes trifluoromethanesulfonyloxy; an example of the dialkylphosphoryloxy includes diethylphosphoryloxy; an example of the diarylphosphoryloxy includes diphenylphosphoryloxy; and examples of the halogeno include chloro, bromo and iodo.

[0018] An example of "an alkylsulfinyl group" includes methylsulfinyl, and an example of "an arylsulfinyl group" includes phenylsulfinyl.

[0019] The pyrrolidylthiocarbapenem derivative of the present invention is represented by the following Formula I:




wherein R^1 is hydrogen or lower alkyl; R^2 , R^3 and R^4 are independently hydrogen, lower alkyl which can be substituted by hydroxy or an amino protecting group, and preferably R^4 is hydrogen, or R^2 and R^3 together with a nitrogen atom to which R^2 and R^3 are bonded form a cyclic group selected from the group consisting of pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, imidazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl, morpholino and thiomorpholino, or R^2 and R^4 , or R^3 and R^4 together with two nitrogen atoms and one sulfur atom in the sulfamide group form a cyclic group selected from the group consisting of 1,1-dioxothiadiazinyl, 1,1-dioxodihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazoliziny, 1,1-dioxothiadiazoliny,


and 1,1,3-trioxthiadizoliny; X¹ is hydrogen or a hydroxy protecting group; X² is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and Y² is hydrogen or an amino protecting group.

[0020] When the above pyrrolidylthiocarbapenem derivative I has a free -OH, -COOH, amino group, imino group, or substituted amino group, the pyrrolidylthiocarbapenem also includes pharmaceutically acceptable salts thereof. The same is the case with an intermediate compound for synthesizing the pyrrolidylthiocarbapenem derivative such as the pyrrolidine derivative represented by Formula II. Examples of the pharmaceutically acceptable salts include a salt with a base, a salt with an acid, a salt with a basic or acidic amino acid and an intermolecular or intramolecular quarternary salt. Examples of the salt with a base include alkali metal salts such as sodium salt and potassium salt; alkaline-earth metal salts such as calcium salt and magnesium salt; ammonium salt; and organic amine salts such as triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt and dibenzylamine salt. Examples of the salt with an acid include inorganic acid addition salts such as hydrochloride, hydrobromide, sulfuric acid salt and phosphoric acid salt; and organic acid addition salts such as formic acid salt, acetic acid salt, trifluoroacetic acid salt, maleic acid salt, tartaric acid salt, methanesulfonic acid salt, benzenesulfonic acid salt and toluenesulfonic acid salt. Examples of the salt with an amino acid include a salt with arginine, aspartic acid or glutamic acid.

[0021] The pyrrolidylthiocarbapenem derivative (I) of the present invention can be produced in the steps of: by using, for example, 4-hydroxypyrrolidine-2-carboxylic acid or the derivative thereof as a starting material, obtaining a pyrrolidine derivative II represented by the following formula:




wherein R², R³ and R⁴ are hydrogen, lower alkyl which can be substituted, or an amino protecting group independently, and R⁴ is preferably hydrogen, or R² and R³ together with a nitrogen atom to which R² and R³ are bonded form a saturated or unsaturated cyclic group, or R² and R⁴, or R³ and R⁴ together with two nitrogen atoms and one sulfur atom in the sulfamide group form a saturated or unsaturated cyclic group; each cyclic group can further include one atom selected from the group consisting of oxygen, sulfur and nitrogen, and each cyclic group can be substituted; Y¹ is hydrogen or a mercapto protecting group; and Y² is hydrogen or an amino protecting group; and allowing the obtained pyrrolidine derivative II to react with a carbapenem derivative represented by the following Formula III:



wherein R¹ is hydrogen or lower alkyl; X¹ is hydrogen or a hydroxy protecting group; X² is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and X³ is leaving group (e.g., a reactive ester of hydroxy, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, or arylsulfonyl).

[0022] The present invention also includes a pyrrolidine derivative represented by the following Formula II:




10 wherein R^2 , R^3 and R^4 are independently hydrogen, lower alkyl which can be substituted by hydroxy, or an amino protecting group independently, and R^4 is preferably hydrogen, or R^2 and R^3 together with a nitrogen atom to which R^2 and R^3 are bonded form a cyclic group selected from the group consisting of pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, imidazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl, morpholino and thiomorpholino, or R^2 and R^4 , or R^3 and R^4 together with two nitrogen atoms and one sulfur atom in the sulfamide group form a group selected from the group consisting of 1,1-dioxothiadiazinyl, 1,1-dioxodihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazoliziny, 1,1-dioxothiadiazoliny, and 1,1,3-trioxothiadiazoliny; Y^1 is hydrogen or a mercapto protecting group; and Y^2 is hydrogen or an amino protecting group.

15 [0023] The pyrrolidine derivative II is prepared according to the steps of converting a hydroxy group at the 4-position of a 4-hydroxypyrrolidine-2-carboxylic acid derivative into a mercapto group; converting a carboxy group at the 2-position into a hydroxymethyl group; directly sulfamidating a hydroxy group in the hydroxymethyl group or sulfamoylating it after converting it into an amino group; and removing the protecting group Y^1 if necessary. The order of these steps can be properly changed.

25 Synthesis of pyrrolidine derivative II

[0024] Pyrrolidine derivative II is synthesized, for example, in the following process, but is not limited to.

30 Route 1




55 [0025] In the above scheme, R^2 , R^3 and R^4 are the same as defined for Formula I, and R^5 is a group for forming an ester together with a carboxy group such as lower alkyl. Y^1 and Y^2 are the same as defined for Formulas I and II, but denote a mercapto protecting group and an amino protecting group, respectively, at the intermediate of the reaction route.

[0026] In this process, for example, 4-hydroxypyrrolidine-2-carboxylic acid derivative IV is first provided. A mesyl group or the like is introduced to the hydroxy group at the 4-position of compound IV, and then a protected mercapto

group such as a tritylthio group is introduced to the 4-position. In this way, a compound V is obtained. Then, a compound VI is obtained by reducing a carboxylate group at the 2-position. An azide group is introduced to the compound VI, and the azide group is converted to an amino group, or phthalimide is reacted with the compound VI, and the formed phthalyl group is removed from the compound VI, thereby introducing an amino group at a position of the hydroxy group of the compound VI. Thus, a compound VII is obtained. A sulfamoyl group is then introduced to the compound VII to obtain a compound II.

[0027] Furthermore, the process of Route I can be variously modified. For example, after introducing a protected mercapto group to the 4-position of the compound IV, a carboxylate group is reduced and then a sulfamide group is introduced to obtain the compound II. Alternatively, after reducing the compound IV, a protected mercapto group and a sulfamide group are successively introduced to obtain the compound II.


Route 2



[0028] In the above scheme, R², R³ and R⁴ are the same as defined in Formula I, and R⁵ is a group for forming ester together with a carboxy group such as lower alkyl. Y¹ and Y² are the same as defined in Formulas I and II, but denote a mercapto protecting group and an amino protecting group, respectively, at the intermediate of the reaction route. X⁴ is a hydroxy protecting group.

[0029] In this process, for example, a mesyl group or the like (represented by X⁴) is first introduced to the 4-position of the 4-hydroxypyrrolidine-2-carboxylic acid derivative IV, then a carboxylate group is reduced to a hydroxymethyl group as is in Route 1 to obtain a compound VIII. Then, a protected amino group such as a phthalimide group is introduced to a position of a hydroxy group in the hydroxymethyl group. Thus a compound IX is obtained. In introducing the protected amino group, it is effective to introduce a leaving group to the hydroxy group of the compound VIII to increase the reactivity. Next, a mercapto group protected by thioacetate and the like (represented by Y¹S) is introduced to the 4-position (see a compound X), and removing the protection to obtain a compound XI. By introducing a sulfamoyl group to the compound XI, a compound II-1 (a compound II wherein the -SY' at the 2-position of the pyrrolidine ring is SH) is obtained.

[0030] Furthermore, the process of Route 2 can be variously modified. For example, by introducing a protected mercapto group to the 4-position of the compound VIII, further introducing a sulfamoyl group and removing the protection, the compound II-1 is obtained.


Route 3

[0031] In the above scheme, R^2 , R^3 and R^4 are the same as defined in Formula I. Y^2 is the same as defined in Formula I but denotes a protecting amino group at the intermediate of the reaction route.

[0032] In this method, chloroformate or the like is first allowed to react with 4-hydroxypyrrolidine-2-carboxylic acid IV-1 having protected nitrogen in the pyrrolidine ring. A carboxy group at the 2-position is then converted into a hydroxymethyl group by reduction. Next, after converting a hydroxy group in the hydroxy-methyl group into a reactive ester and introducing a protected amino group, a compound XIII is obtained by removing the protection. A sulfamoyl group is introduced to the compound XIII resulting in a compound XIV, then, a protected mercapto group is introduced to a position of the hydroxy group at the 4-position. A compound II-1 is obtained by removing the protection of the mercapto group.

Synthesis of a pyrrolidylthiocarbapenem derivative

[0033] The protection of the 4-position of the pyrrolidine derivative is removed to obtain an SH compound, if necessary, then, the pyrrolidine derivative is allowed to react with a carbapenem derivative represented by the following Formula III to give a pyrrolidylthiocarbapenem derivative I of the present invention:



wherein R^1 is hydrogen or lower alkyl; X^1 is hydrogen or a hydroxy protecting group; X^2 is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; X^3 is a leaving group (e.g., reactive ester group of hydroxy, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, or arylsulfonyl).

[0034] The protection is removed from the compound I if necessary to give a compound having free carboxy, hydroxy and/or amino.

An antibacterial agent comprising the pyrrolidylthiocarbapenem derivative

[0035] A pharmaceutical composition comprising as an active ingredient, the pyrrolidylthiocarbapenem derivative (including pharmaceutically acceptable salts thereof) of the present invention other than these pyrrolidylthiocarbapenem derivatives in which any one or more of R^2 , R^3 , R^4 , X^1 , X^2 and Y^2 is a protecting group is administered as an

antibacterial agent. An administration method is in oral administration or parenteral administration; as injection (a formulation in an ampoule or vial, a liquid, a suspension or the like for an intravenous injection, an intramuscular injection, a drip infusion, or subcutaneous injection), an external or local administration agent (an ear drop, a nasal drop, an ophthalmic solution, an ointment, an emulsion, a spray, a suppository and the like), and an oral preparation. Preferably, the composition is administered by injection, through skin or mucosa. The pharmaceutical composition includes at least 0.01% by weight of the pyrrolidylthiocarbapenem derivative and further includes an appropriate excipient, auxiliary agent, stabilizer, wetting agent, emulsifier, and other additives depending upon the administration method. These additives must be pharmaceutically and pharmacologically acceptable materials which do not inhibit the effect of the pyrrolidylthiocarbapenem derivative and which show no adverse effects on patients. For example, lactose, stearic acid, magnesium stearate, clay, sucrose, cornstarch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, tartaric acid, citric acid and fumaric acid can be contained in the oral preparation. For parenteral administration, a solvent (e.g., alcohol, a buffer, methyl oleate, water or the like), a buffer solution, a dispersing agent, a dissolving auxiliary agent, a stabilizer (e.g., methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, sorbic acid or the like), an absorbefacient (mono- or dioctanoate of glycerin), an antioxidant, a perfume, an analgetic, a dispersing agent, an adverse effect inhibitor, an action potentiator (an agent for regulating absorption and elimination, an inhibitor for enzyme decomposition, a β -lactamase inhibitor, and other kinds of antimicrobial agents) and the like can be contained in the formulation.

[0036] A dose of the pyrrolidylthiocarbapenem derivative of the present invention depends upon the age of a patient, the type and the state of the disease and the kind of compounds to be used. Generally, daily dose ranges from 1 mg/patient to about 4000 mg/patient, but more can be administered if necessary. For example, a dose of 1 mg (the external application) is administered 4 times a day, and a dose of 1000 mg (intravenous injection) is administered 2 to 4 times a day to treat an infection.

Characteristics of the pyrrolidylthiocarbapenem derivative

[0037] The characteristics of the pyrrolidylthiocarbapenem derivative of the present invention as an antibacterial agent will now be described as compared with same known compounds.

(1) Antimicrobial activity:

[0038] A minimum growth inhibitory concentration and an effect for preventing bacterial infection of the pyrrolidylthiocarbapenem derivative of the present invention are compared with those of meropenem (Japanese Laid Open Patent Publication No. 60-233076) and imipenem (Japanese Laid Open Patent Publication No. 55-9090), respectively to find that the derivative of the present invention is superior to meropenem against Gram positive bacteria and superior to imipenem against Gram negative bacteria. The derivative of the present invention has an antibacterial potency against Pseudomonas aeruginosa, a kind of a Gram negative bacteria, equal to or twice as that of imipenem, meropenem and the mesylamino derivative of a carbapenem (Japanese Laid Open Patent Publication No. 63-179876). When compared with the urea derivative of a carbapenem (Japanese Laid Open Patent Publication No. 62-155279), the derivative has equal to or twice the antibacterial potency against Gram positive bacteria, twice the potency against the Gram negative bacteria and twice to eight times the potency against Pseudomonas aeruginosa.

(2) Rabbit nephrotoxicity test:

[0039] An administration of the derivative of the present invention of 250 mg per 1 kg of the body weight of a rabbit reveals no toxicity. The same result is obtained by an administration of meropenem. When 150 mg/kg of imipenem is administered, medium renal toxicity is revealed. Sugar and protein are found in urine and a white microgranular change in the kidney is found.

(3) Rate of decomposition by mouse renal dehydropeptidase 1:

[0040] The enzymatic decomposition rate of the pyrrolidylthiocarbapenem derivative of the present invention by the action of renal dehydropeptidase I is 76% of that of imipenem, 40% of that of meropenem to show higher stability.

(4) Solubility in water:

[0041] The solubility in water of the derivative of the present invention is 10% or more in a form of free acid, enabling an intravenous injection. In contrast, the solubility of imipenem and meropenem is about 2% and they cannot be administered except for a drip infusion.

(5) Pharmacokinetics in vivo:

[0042] When the derivative of the present invention is intravenously injected to a cynomolgus (10 mg/kg), the half-life is 1.1 hours, a recovery from urine is 62.2%, and an integrated value of a concentration in blood is 24.9 $\mu\text{g}\cdot\text{hr}/\text{ml}$.
5 The half-life is 1.44 times, the recovery from urine is 1.36 times and the integrated value of a concentration in blood (Area under the curve: AUC) is 1.44 times as much as those of meropenem. The half-life is 1.87 times, the recovery from urine is 1.93 times, and AUC is 1.87 times as much as those of imipenem.

[0043] When the derivative is intravenously injected into a mouse (20 mg/kg), the recovery from urine is 36.3%, and the integrated value of a concentration in blood is 12.1 $\mu\text{g}\cdot\text{hr}/\text{ml}$. The recovery from urine is 2.18 times and AUC is 2.32 times as much as those of meropenem. The recovery from urine is 1.15 times and AUC is 1.37 times as much as those of imipenem. The recovery from urine is 1.48 times as much as that of mesylate derivative of meropenem.


[0044] In this way, the present invention provides a new pyrrolidylthiocarbapenem derivative having a wide range of antibacterial spectrum and a strong antimicrobial activity against both Gram positive bacteria and Gram negative bacteria, an antibacterial agent (composition) comprising the carbapenem derivative, and a method for preparing the carbapenem derivative. Furthermore, a new pyrrolidin derivative as an intermediate for preparing the carbapenem derivative and a method for preparing the same are provided.

[0045] A minimum bacterial growth inhibitory concentration and an effect for preventing bacterial infection of the pyrrolidylthiocarbapenem derivative of the present invention are compared with those of meropenem and imipenem, respectively to find that the derivative of the present invention is superior to meropenem against Gram positive bacteria and superior to imipenem against Gram negative bacteria. The derivative of the present invention has an antibacterial potency against *Pseudomonas aeruginosa*, a kind of a Gram negative bacterium, equal to or twice of that of imipenem, meropenem and the mesylamino derivative of a carbapenem. When compared with the urea derivative of a carbapenem, the derivative has an equal or twice the antibacterial potency against Gram positive bacteria, twice the potency against the Gram negative bacteria and twice to eight times the potency against *Pseudomonas aeruginosa*. The pyrrolidylthiocarbapenem derivative is less toxic to an organism than the conventional carbapenem derivatives. Since the derivative decomposes slowly in a body, the antimicrobial effect thereof lasts for a longer period of time. Moreover, since the derivative has a higher solubility in water than the conventional carbapenem derivatives, it can be applicable for injection.

[0046] Following Examples are given to show the present invention, but not to limit the scope thereof.

Preparative Example 1 of a pyrrolidine derivative

[0047]

Step 1. Preparation of an O-mesyl compound

[0048] To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid methyl ester (227.2 g; 0.735 mole) in dichloromethane (1.3 liter) stirring at -30°C, triethylamine (112.5 ml; 1.1 eq.) and methanesulfonyl chloride (56.8 ml; 1 eq.) are added. The mixture is stirred at the same temperature for 15 minutes. The reaction mixture is successively washed with dilute hydrochloric acid and water, dried over magnesium sulfate, and concentrated in vacuo to give (2S,4R)-1-p-methoxybenzyloxy-carbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (280.1 g). Yield: 98%.

NMR δ (CDCl₃) ppm: 3.02, 3.04(2 x s, 3H), 3.56, 3.78(2 x s, 3H), 3.81(s, 3H), 4.98, 5.08(ABq, J=12Hz, 1H), 5.04, 5.12(ABq, J=12Hz, 1H).

IR ν (CHCl₃) cm⁻¹: 1755, 1709, 1620.

Step 2. Preparation of a tritylthio compound

[0049] To a solution of triphenylmethylmercaptan (107.02 g; 1.5 eq.) in dimethylformamide (350 ml), an oil suspension containing 60% sodium hydride (13.42 g; 1.3 eq.) is added with stirring at 0°C. The mixture is stirred at room temperature for 1 hour. The reaction mixture is mixed with a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (100 g; 0.258 mole) in dimethylformamide (70 ml) with stirring at 0°C.

The mixture is stirred at 60°C for 30 minutes. The reaction mixture is poured into cold dilute hydrochloric acid, and extracted with ethyl acetate. The extract is successively washed with water and brine, dried, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 5 : 1) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-carboxylic acid methyl ester (127.1 g). Yield: 87%.

NMR δ (CDCl₃) ppm: 3.50, 3.71(2 x s, 3H), 3.78, 3.84(2 x s, 3H), 4.87, 5.13(ABq, J=12Hz, 1H), 4.89, 5.13(ABq, J=12Hz, 1H).

IR ν (CHCl₃) cm⁻¹: 1750, 1700, 1618.

Step 3. Preparation of a methylol compound

[0050] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-carboxylic acid methyl ester (127.1 g: 0.224 mole) in tetrahydrofuran (1 liter), lithium borohydride (4.88 g: 1 eq.) is added with stirring at room temperature. The mixture is stirred at 60°C for 30 minutes. The reaction mixture is allowed to cool to room temperature and water (100 ml) is added in small portions with stirring. The formed precipitate is removed by filtration and the filtrate is concentrated in vacuo. The residue is dissolved in dichloromethane, dried over magnesium sulfate, and concentrated under reduced pressure. The residue is washed with ether to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol as white crystals (82.3 g). Yield: 68%.

NMR δ (CDCl₃) ppm: 3.84(s, 3H), 4.93, 4.99(ABq, J=12Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3400, 1668, 1610.

Step 4. Preparation of a mesyl compound

[0051] A solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol (22.33 g: 41.37 mmole) is diluted with dichloromethane (300 ml) and the mixture is cooled to -30°C. To this mixture, triethylamine (6.92 ml: 1.2 eq.) and methanesulfonyl chloride (3.52 ml: 1.1 eq.) are added, and the mixture is stirred for 20 minutes. The reaction mixture is successively washed with dilute hydrochloric acid and water, dried over magnesium sulfate, and filtered. The filtrate is concentrated in vacuo to give crude (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol methanesulfonate (27.81 g: 45.02 mmole). Yield: 100%.

NMR δ (CDCl₃) ppm: 2.89(s, 3H), 3.81, 3.83(2 x s, 3H), 4.85 to 5.07(m, 2H).

IR ν (CHCl₃) cm⁻¹: 1725, 1690, 1610.

Step 5. Preparation of an azide compound

[0052] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol methanesulfonate (27.81 g) in dimethylformamide (120 ml), a solution (12 ml) of sodium azide (3.50 g: 53.8 mmole) in water is added. The mixture is stirred at 80°C for 8 hours. The reaction mixture is poured into ice water and extracted with ethyl acetate. The extract is successively washed with water and brine and concentrated. The residue is purified by silica gel column chromatography to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-azidomethyl-4-tritylthiopyrrolidine (17.27 g: 30.64 mmole). Total yield of Steps 4 and 5: 74%.

NMR δ (CDCl₃) ppm: 3.84(s, 3H), 4.82 to 5.15(m, 2H).

IR ν (CHCl₃) cm⁻¹: 2105, 1685.

Step 6. Preparation of an amino compound

[0053] A solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-azidomethyl-4-tritylthiopyrrolidine (17.27 g: 30.64 mmole) in a mixture of ethyl acetate (150 ml), methanol (200 ml), and acetic acid (2.63 ml: 46 mmole) is subjected to conventional hydrogenation over 5% palladium on carbon (5 g). After the reaction, the catalyst is filtered off and the filtrate is concentrated in vacuo to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-aminomethyl-4-tritylthiopyrrolidine acetate (17.33 g) as a residue. The residue is dissolved in dichloromethane, washed with aqueous sodium hydrogen carbonate, and concentrated to give (2S,4S)-2-aminomethyl-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine (16.82 g).

Step 7. Preparation of a phthalimido compound

[0054] Crude (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol methanesulfonate (115.4 g) produced from (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol (96.24 g: 178 mmole) in the same manner as in the above-mentioned Step 4 is dissolved in dimethylformamide (1 liter). After adding potassium phthalimide (65.94 g: 2 eq.), the mixture is stirred at 100°C for 1 hour. The reaction mixture is poured into ice water

and extracted with ethyl acetate. The extract is successively washed with water and brine, and concentrated. The residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-phthalimidomethyl-4-tritylthiopyrrolidine (99.4 g). Yield: 83.5%.

NMR δ (CDCl₃) ppm: 3.78, 3.84(2 x s, 3H), 4.65 to 5.00(m, 2H).

IR \checkmark (CHCl₃) cm⁻¹: 1770, 1712, 1693, 1611.

Step 8. Removal of a phthalyl group

[0055] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-phthalimidomethyl-4-tritylthiopyrrolidine (752 mg: 1.124 mmole) in a mixture of dichloromethane (3 ml) and methanol (12 ml), hydrazine hydrate (109 μ l: 2 eq.) is added. The mixture is heated for 5 hours. The reaction mixture is concentrated in vacuo. The residue is dissolved in dichloromethane (5 ml) and the solid is filtered off. The filtrate is washed with water and concentrated in vacuo. The residue is recrystallized from a mixture of dichloromethane and methanol to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-aminomethyl-4-tritylthiopyrrolidine (471 mg). Yield: 78%. mp. 165 to 167°C.

NMR δ (CDCl₃:CD₃OD=2:1) ppm: 3.46(s, 3H), 4.96, 4.89(ABq, J=12Hz, 2H).

IR \checkmark (CHCl₃) cm⁻¹: 1683, 1610.

Step 9. Preparation of a dimethylsulfamoyl compound

[0056] A solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-aminomethyl-4-tritylthiopyrrolidine (12.44 g: 23.13 mmole) in dichloromethane(70 ml) is cooled to -78°C. After adding triethylamine (4.21 ml: 1.3 eq.) and dimethylaminosulfonyl chloride (2.73 ml: 1.1 eq.), the mixture is warmed to room temperature over about 1 hour. The reaction mixture is successively washed with dilute hydrochloric acid and brine, and concentrated to give crude (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-N,N-dimethylsulfamoylaminomethyl-4-tritylthiopyrrolidine (15.02 g). Yield: 100%.

Step 10. Preparation of a mercapto compound by deprotection

[0057] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-N,N-dimethylsulfamoylaminomethyl-4-tritylthiopyrrolidine (3.55 g: 5.5 mmole) in a mixture of dichloromethane (70 ml) and methanol (35 ml), a solution of pyridine (0.66 ml: 1.5 eq.) and silver nitrate (1.40 g: 1.5 eq.) in water (3.5 ml) is added under ice cooling. The mixture is stirred for 10 minutes. The reaction mixture is poured into water and extracted with dichloromethane. The extract is dried over magnesium sulfate, bubbled with hydrogen sulfide, and filtered to remove solid. The filtrate is concentrated in vacuo and the residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-N,N-dimethylsulfamoylaminomethyl-4-mercaptopyrrolidine (1.93 g). Yield: 87.0%.

NMR δ (CDCl₃) ppm: 2.77(s, 6H), 3.81(s, 3H), 5.00 to 5.12(m, 2H).

IR \checkmark (CHCl₃) cm⁻¹: 3380, 1690, 1610.

Step 11. Preparation of a sulfamoyl compound

[0058] To a solution of chlorosulfonyl isocyanate (3.95 ml: 45.4 mmole) in dichloromethane (70 ml), p-methoxybenzyl alcohol (5.66 ml: 45.4 mmole) is added at -50°C. The mixture is stirred at -50°C for 15 minutes. The resulting solution of p-methoxybenzyloxycarbonylsulfamoyl chloride is added to a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-aminomethyl-4-tritylthiopyrrolidine (obtained in the above Steps 6 or 8) (12.21 g: 22.7 mmole) and triethylamine (6.38 ml: 45.6 mmole) in dichloromethane (300 ml) at -78°C, and the mixture is stirred for 10 minutes, successively washed with dilute hydrochloric acid and brine, and concentrated in vacuo. The residue is purified by silica gel column chromatography to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-p-methoxybenzyloxycarbonylsulfamoylaminomethyl-4-tritylthiopyrrolidine (16.31 g). Yield: 91.6%.

NMR δ (CDCl₃) ppm: 3.78(s, 3H), 3.81, 3.83(2 x s, 3H), 4.98, 4.89(ABq, J=12Hz, 2H), 5.09, 5.03(ABq, J=12Hz, 2H).

IR \checkmark (CHCl₃) cm⁻¹: 3390, 1740, 1685.

Step 12. Preparation of a mercapto compound by deprotection

[0059] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-p-methoxybenzyloxycarbonylsulfamoylaminomethyl-4-tritylthiopyrrolidine (2.35 g: 3.13 mmole) in a mixture of dichloromethane (60 ml) and methanol (30 ml), a solution of pyridine (0.38 ml: 4.75 mmole: 1.5 eq.) and silver nitrate (0.80 g: 1.5 eq.) in water (2 ml) is added under ice cooling. The mixture is stirred for 10 minutes. The reaction mixture is poured into water and extracted with dichloromethane. The extract is dried over magnesium sulfate and filtered. Hydrogen sulfide is passed through the filtrate and the resulting

precipitate is filtered off. The filtrate is concentrated in vacuo and the residue is purified by silica gel column chromatography to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-2-p-methoxybenzyloxycarbonylsulfamoylaminomethyl-4-mercaptopyrrolidine (1.56 g). Yield: 92.4%.

NMR δ (CDCl₃) ppm: 2.42 to 2.58(m, 1H), 3.80(s, 6H), 5.08, 5.02(ABq, J=12Hz, 2H), 5.12, 5.07(ABq, J=16Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3380, 1740, 1685, 1610.

Step 13. Preparation of an N-methyl compound

[0060] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthio-2-(p-methoxybenzyloxycarbonylamino-sulfonylaminomethyl)pyrrolidine (2.06 g; 2.63 mmole) in dimethylformamide (15 ml), a solution of 1M-lithium bis(trimethylsilyl)amide in tetrahydrofuran (2.76 ml; 1.05 eq.) is added with stirring under ice cooling. After stirring for 1 hour, iodomethane (491 μ l; 3 eq.) is added. The mixture is stirred at the same temperature for 3 hours. The reaction mixture is poured into a mixture of ethyl acetate and aqueous sodium sulfite and the ethyl acetate layer is taken. The organic layer is successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 4:1) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthio-2-(N-p-methoxybenzyloxycarbonyl-N-methylaminosulfonylamino)methylpyrrolidine (1.51 g). Yield: 72%.

NMR δ (CDCl₃) ppm: 1.4 to 1.6(m, 1H), 1.9 to 2.1(m, 1H), 2.5 to 3.3(m, 4H), 3.23(s, 3H), 3.5 to 3.8(m, 1H), 3.76(s, 3H), 3.81(s, 3H), 4.93(ABq, J=10.4Hz, 2H), 5.10(ABq, J=15.2Hz, 2H), 6.35 to 6.55(m, 1H), 6.8 to 7.5(m, 23H).

IR ν (CHCl₃) cm⁻¹: 1727, 1695.

Step 14. Preparation of a mercapto compound by deprotection

[0061] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-tritylthio-2-(N-p-methoxybenzyloxycarbonyl-N-methylaminosulfonyl)aminomethylpyrrolidine (1.5 g; 1.88 mmole) in a mixture of dichloromethane (4 ml) and methanol (10 ml), a solution of pyridine (381 μ l; 2.5 eq.) and silver nitrate (640 mg; 2 eq.) in water (6 ml) is added with stirring under ice cooling. The mixture is stirred at the same temperature for 30 minutes. The reaction mixture is diluted with dichloromethane, washed with water, dried over magnesium sulfate, and concentrated in vacuo to about 5 ml. The residue is dissolved in methanol (10 ml) and hydrogen sulfide is bubbled through it. The mixture freed from solid by filtering is concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 2:1) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-mercapto-2-(N-p-methoxybenzyloxycarbonyl-N-methylaminosulfonyl)aminomethylpyrrolidine (866 mg). Yield: 83%.

NMR δ (CDCl₃) ppm: 1.6 to 1.8(m, 1H), 2.3 to 2.6(m, 1H), 2.9 to 3.4(m, 5H), 3.3(s, 3H), 3.8(s, 6H), 3.8 to 4.2(m, 1H), 6.3 to 6.6(m, 1H), 6.88(d, J=8.6Hz, 2H), 7.2 to 7.4(m, 2H).

IR ν (CHCl₃) cm⁻¹: 1690.

Preparative Example 2 of a pyrrolidine derivative

[0062]


5

10

15

20

25



Step 1 Preparation of an O-mesyl compound

[0063] To a solution of (2S,4R)-1-p-nitrobenzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid methyl ester (59.44 g; 0.183 mole) in dichloromethane (150 ml) stirring at -20°C , triethylamine (30.5 ml; 1.2 eq.) and methanesulfonyl chloride (17 ml; 1 eq.) are added. The mixture is stirred at the same temperature for 35 minutes. To the mixture is added ice water and ethyl acetate. The organic layer is taken, washed with water, dried over magnesium sulfate, and concentrated in vacuo to give (2S, 4R)-1-p-nitrobenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (74.05 g). Yield: Quantitative.

NMR δ (CDCl_3) ppm: 2.20 to 2.42(m, 1H), 2.55 to 2.85(m, 1H), 3.07(s, 3H), 3.67(s, 1.5H), 3.78(s, 1.5H), 3.80 to 4.05(m, 2H), 4.53(t, J=7Hz, 1H), 5.06 to 5.40(m, 3H), 7.47(d, J=9Hz, 1H), 7.51(d, J=9Hz, 1H), 8.23(d, J=9Hz, 2H).

IR \checkmark (CHCl_3) cm^{-1} : 1748, 1712, 1608.

Step 2. Preparation of a tritylthio compound

[0064] To a solution of tritylmercaptan (37.69 g; 1.5 eq.) in tetrahydrofuran (180 ml), an oil suspension containing 60% sodium hydride (4.73 g; 1.3 eq.) is added with stirring at 0°C . The mixture is stirred at room temperature overnight. A solution of (2S,4R)-1-p-nitrobenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (36.58 g; 90.9 mmole) in tetrahydrofuran (180 ml) is added to the reaction mixture with stirring at 0°C , and the mixture is stirred at 60°C for 30 minutes. The reaction mixture is poured into cold dilute hydrochloric acid and extracted with ethyl acetate. The extract is successively washed with water and brine, dried, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 9:1 to 4:1) to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-4-tritylthiopyrrolidine-2-carboxylic acid methyl ester (25.48 g). Yield: 48.1%.

NMR δ (CDCl_3) ppm: 1.63 to 2.35(m, 2H), 2.68 to 3.50(m, 3H), 3.60(s, 1.5H), 3.72(s, 1.5H), 4.02 to 4.15(m, 1H), 4.95 to 5.28(m, 2H), 7.10 to 7.52(m, 17H), 8.17(d, J=9Hz, 1H), 8.24(d, J=9Hz, 1H).

IR \checkmark (CHCl_3) cm^{-1} : 1747, 1704, 1607.

Step 3. Preparation of a methylol compound

[0065] To a solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-4-tritylthiopyrrolidine-2-carboxylic acid methyl ester (5 g;

9.01 mmole) in tetrahydrofuran (180 ml) stirring under ice cooling, a solution of sodium borohydride (2.3 g: 1.4 eq.) in ethanol and a solution of lithium chloride (2.76 g: 1.5 eq.) in tetrahydrofuran (60 ml) are added. The mixture is stirred at room temperature for 1 hour. The reaction mixture is poured into a mixture of ice water and ethyl acetate and extracted with ethyl acetate. The extract is successively washed with cold dilute hydrochloric acid, aqueous sodium hydrogen carbonate, and saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is recrystallized from methanol to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol (15.9 g). Yield: 65.9%. mp. 122 to 125°C.

NMR δ (CDCl₃) ppm: 1.32 to 1.53(m, 1H), 1.90 to 2.12(m, 1H), 2.65 to 3.05(m, 3H), 3.32 to 3.84(m, 3H), 5.08, 5.17(ABq, J=12Hz, 2H), 7.08 to 7.55(m, 17H), 8.26(d, J=9Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3400br, 1681, 1607.

Step 4. Preparation of a mesyl compound

[0066] To a solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol (5.0 g: 9.01 mmole) in dichloromethane (50 ml) stirring at -15°C, triethylamine (1.63 ml: 1.3 eq.) and methanesulfonyl chloride (0.85 ml: 1.1 eq.) are added. The mixture is stirred at -15 to -10°C for 30 minutes. The reaction mixture is poured into water and extracted with dichloromethane. The extract is successively washed with dilute hydrochloric acid, aqueous sodium hydrogen carbonate, and water, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 9:1) to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol methanesulfonate (4.86 g). Yield: 85.2%.

NMR δ (CDCl₃) ppm: 1.65 to 1.93(m, 1H), 2.00 to 2.26(m, 1H), 2.68 to 2.92(m, 3H), 2.96(s, 3H), 3.78 to 3.98(m, 1H), 4.16 to 4.30(m, 1H), 4.38 to 4.52(m, 1H), 5.11(br s, 2H), 7.08 to 7.52(m, 17H), 8.24(d, J=9Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 1699, 1606.

Step 5. Preparation of a phthalimido compound

[0067] A solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-4-tritylthiopyrrolidine-2-methanol methanesulfonate (4.39 g: 6.93 mmole) and potassium phthalimide (2.57 g: 2 eq.) in dimethylformamide (30 ml) is stirred at 70°C for 6 hours. The reaction mixture is poured into ice water and the precipitate is filtered off. The precipitate is dissolved in ethyl acetate, washed with saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-phthalimidomethyl-4-tritylthiopyrrolidine (3.12 g). Yield: 64.3%.

NMR δ (CDCl₃) ppm: 1.40 to 2.30(m, 2H), 2.60 to 3.08(m, 2H), 3.10 to 3.40(m, 1H), 3.55 to 4.23(m, 3H), 4.92, 5.06(ABq, J=12Hz, 2H), 7.08 to 7.50 (m, 17H), 7.60 to 7.82(m, 4H), 8.10(d, J=9Hz, 1H), 8.19(d, J=9Hz, 1H).

IR ν (CHCl₃) cm⁻¹: 1720, 1701, 1607.

Step 6. Removal of a phthalyl group

[0068] To a solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-phthalimidomethyl-4-tritylthiopyrrolidine (10.46 g: 15.31 mmole) in a mixture of dichloromethane (80 ml) and methanol (160 ml), hydrazine hydrate (1.53 ml: 2 eq.) is added, and the mixture is concentrated to remove dichloromethane by warming and refluxed for 3 hours and 15 minutes. The reaction mixture is concentrated in vacuo. The residue is diluted with dichloromethane and filtered to remove solid. The filtrate is washed with water, dried over magnesium sulfate, and concentrated in vacuo to give crude (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-aminomethyl-4-tritylthiopyrrolidine (7.71 g). Yield: 91%.

NMR δ (CDCl₃:CD₃OD=2:1) ppm: 1.46 to 3.76(m, 10H), 5.04, 5.12(ABq, J= 15Hz, 2H), 7.10 to 7.56(m, 17H), 8.12 to 8.30(m, 2H).

IR ν (CHCl₃) cm⁻¹: 1695, 1606.

Step 7. Preparation of an N-sulfamoyl compound

[0069] A solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-aminomethyl-4-tritylthiopyrrolidine (4.7 g: 8.49 mmole) is dissolved in dichloromethane (45 ml) and cooled to a temperature of -70°C. To the mixture, a solution of diisopropylethylamine (3.4 ml: 2.3 eq.) and 1M t-butoxycarbonylamino sulfonyl chloride (prepared from chlorosulfonyl isocyanate and t-butanol before hand) in dichloromethane (21 ml), and the mixture is stirred for 1 hour and diluted with ice water. The reaction mixture is successively washed with dilute hydrochloric acid and aqueous sodium hydrogen carbonate, dried over magnesium sulfate, and concentrated. The residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-t-butoxycarbonyl-aminosulfonylamino methyl-4-tritylthiopyrrolidine (1.49 g). Yield: 24%.

NMR δ (CDCl_3) ppm: 1.40 to 2.30(m, 2H), 1.44(s, 9H), 2.60 to 3.40(m, 5H), 3.71 to 3.95(m, 1H), 5.08, 5.13(ABq, $J=12\text{Hz}$, 2H), 6.27(br s, 1H), 7.07 to 7.55(m, 17H), 8.21(d, $J=7\text{Hz}$, 1H), 8.26(d, $J=7\text{Hz}$, 1H).

IR \checkmark (CHCl_3) cm^{-1} : 3390, 1737, 1695, 1606.

5 Step 8. Removal of a Boc group

[0070] To a solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-t-butoxycarbonylamino-sulfonylaminomethyl-4-tritylthiopyrrolidine (1.46 g; 2 mmole) in dichloromethane (5 ml) under ice cooling, anisole (2.4 ml) and trifluoroacetic acid (3.9 ml) are added. The mixture is stirred at room temperature for 2 hours. The reaction mixture is diluted with ethyl acetate and ice water and extracted with ethyl acetate. The extract is successively washed with water and saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is recrystallized from n-hexane to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-sulfamoylamino-methyl-4-tritylthiopyrrolidine (1.4 g). Yield: Nearly quantitative.

NMR δ (CDCl_3) ppm: 1.43 to 1.70(m, 1H), 2.08 to 2.30(m, 1H), 2.65 to 3.50(m, 5H), 3.74 to 4.00(m, 1H), 5.03, 5.13(ABq, $J=15\text{Hz}$, 2H), 5.73(br s, 1H), 7.00 to 7.60(m, 17H), 8.25(d, $J=9\text{Hz}$, 2H).

IR \checkmark (CHCl_3) cm^{-1} : 3334br, 1688, 1607.

Step 9. Preparation of a mercapto compound by deprotection


[0071] To a solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-sulfamoylamino-methyl-4-tritylthiopyrrolidine (668 mg; 0.95 mmole) in tetrahydrofuran (6 ml), a solution of pyridine (0.254 ml; 2.7 eq.) and silver nitrate (403 mg; 2.5 eq.) in water (2 ml) is added under ice cooling. The mixture is stirred at room temperature for 1 hour. The reaction mixture is diluted with dichloromethane (3 ml) and methanol (3 ml), and hydrogen sulfide is bubbled through it under ice cooling for 10 minutes. The resulting precipitate is removed by filtering. The filtrate is diluted with dichloromethane, washed with water, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-sulfamoylamino-methyl-4-mercaptopyrrolidine (233 mg). Yield: 63%.

NMR δ (CDCl_3 - CD_3OD) ppm: 1.42(t, $J=7\text{Hz}$, 1H), 1.65 to 1.93(m, 1H), 2.48 to 2.70(m, 1H), 3.05 to 3.63(m, 4H), 3.93 to 4.16(m, 2H), 5.22(s, 2H), 7.53(d, $J=8\text{Hz}$, 2H), 8.23(d, $J=8\text{Hz}$, 2H).

IR \checkmark (CHCl_3) cm^{-1} : 3276br, 1692, 1607.

Preparative Example 3 of a pyrrolidine derivative

[0072]



Step 1. Preparation of a methylol compound

[0073] To a solution of (2S,4R)-1-p-nitrobenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (79.4 g; 0.197 mmole) in a mixture of ethanol (300 ml) and tetrahydrofuran (150 ml), sodium borohydride (10.44 g; 1.4 eq.) is added in small portions with stirring at 0°C. The mixture is stirred at 0°C for 1.5 hours and at room temperature for 5 hours. To the reaction mixture under ice cooling, 5N-hydrochloric acid (100 ml) is added. The mixture

is diluted with water, and extracted with ethyl acetate. The extract is washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue is recrystallized from a mixture of dichloromethane and ether to give (2S,4R)-1-p-nitrobenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (51.9 g). Yield: 70%.

NMR δ (CDCl₃) ppm: 1.93 to 2.14(m, 1H), 2.32 to 2.48(m, 1H), 3.06(s, 3H), 3.53 to 4.28(m, 6H), 5.26(s, 2H), 7.53(d, J=9Hz, 2H), 8.24(d, J=9Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3404, 1698, 1607.

Step 2. Preparation of a tosyl compound

[0074] To a solution of (2S,4R)-1-p-nitrobenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (28.8 g: 77 mmole) in dichloromethane (150 ml) under ice cooling, p-toluenesulfonyl chloride (19.11 g: 1.3 eq.), triethylamine (10.4 ml: 1.3 eq.) and dimethylaminopyridine (0.94 g: 0.1 eq.) are added. The mixture is stirred at 25°C for 7 hours. The reaction mixture is diluted with ice water. The resultant organic layer is taken, successively washed with aqueous sodium hydrogen carbonate and water, dried over magnesium sulfate, and concentrated in vacuo. The residue is recrystallized from n-hexane to give (2S,4R)-1-p-nitrobenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol p-toluenesulfonate (37.7 g). Yield: 93%.

NMR δ (CDCl₃) ppm: 2.20 to 2.50(m, 1H), 2.44(s, 3H), 3.05(s, 3H), 3.45 to 4.60(m, 5H), 5.18(s, 2H), 5.26(br s, 1H), 7.34(d, J=8Hz, 2H), 7.50(d, J=8Hz, 2H), 7.75(d, J=8Hz, 2H), 8.23(d, J=8Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 1700, 1599.

Step 3. Preparation of a phthalimido compound

[0075] A mixture of (2S,4R)-1-p-nitrobenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol p-toluenesulfonate (25 g: 47.3 mmole) and potassium phthalimide (17.52 g: 2 eq.) in dimethylformamide (250 ml) is stirred at 60°C for 7 hours. The reaction mixture is poured into ice water and filtrated. The resulting precipitate is dissolved in ethyl acetate, washed with saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is recrystallized from methanol to give (2S,4R)-1-p-nitrobenzyloxycarbonyl-2-phthalimidomethyl-4-methanesulfonyloxypyrrolidine (18.76 g). Yield: 79%. mp. 121 to 123°C.

NMR δ (CDCl₃) ppm: 2.03 to 2.60(m, 2H), 3.02(s, 3H), 3.50 to 4.15(m, 4H), 4.40 to 4.63(m, 1H), 5.10, 5.29(ABq, J=15Hz, 2H), 5.10 to 5.30(m, 1H), 7.46 (d, J=9Hz, 1H), 7.57(d, J=9Hz, 1H), 7.63 to 7.88(m, 4H), 8.20(d, J=9Hz, 2H)

IR ν (CHCl₃) cm⁻¹: 1773, 1715, 1605.

Step 4. Preparation of an acetylthio compound

[0076] A solution of (2S,4R)-1-p-nitrobenzyloxycarbonyl-2-phthalimidomethyl-4-methanesulfonyloxypyrrolidine (10 g: 19.88 mmole) and potassium thioacetate (4.54 g: 2 eq.) in dimethylformamide (60 ml) is stirred at 60°C for 3 hours. The reaction mixture is poured into ice water (200 ml) and filtered. The precipitate is dissolved in ethyl acetate, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-phthalimidomethyl-4-acetylthiopyrrolidine (8.7 g). Yield: 90%.

NMR δ (CDCl₃) ppm: 1.65 to 1.97(m, 1H), 2.47 to 2.67(m, 1H), 3.24 to 3.34(q, 1H), 3.73 to 4.24(m, 4H), 4.30 to 4.54(m, 1H), 5.02(dd, J=14Hz, J=7Hz, 1H), 5.20(d, J=14Hz, 1H), 7.42(d, J=9Hz, 1H), 7.45(d, J=9Hz, 1H), 7.60 to 8.86(m, 4H), 8.17(d, J=9Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 1773, 1714, 1605.

Step 5. Removal of a phthalyl and an acetyl groups

[0077] To a solution of (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-phthalimidomethyl-4-acetylthiopyrrolidine (4.92 g: 10.18 mmole) in a mixture of dichloromethane (15 ml) and methanol (75 ml), hydrazine hydrate (1.53 ml: 3 eq.) is added. The mixture is warmed to remove dichloromethane and heated to reflux for 1 hour and 10 minutes. The reaction mixture is concentrated in vacuo. The residue is diluted with dichloromethane and filtered. The filtrate is washed with water, dried over magnesium sulfate, and concentrated in vacuo to give crude (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-aminomethyl-4-mercaptopyrrolidine (3.3 g). Yield: Quantitative.

NMR δ (CDCl₃) ppm: 1.63 to 1.90(m, 1H), 2.48 to 2.68(m, 1H), 2.86 to 3.43(m, 4H), 3.65 to 4.23(m, 2H), 5.22(s, 2H), 7.52(d, J=9Hz, 2H), 8.23 (d, J=9Hz, 2H).

Step 6. Preparation of an N-sulfamoyl compound


[0078] To a solution of crude (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-aminomethyl-4-mercaptopyrrolidine (3.3 g: 10.18 mmole) in dichloromethane (100 ml) at -78°C, triethylamine (2.84 ml: 2.2 eq.) and trimethylchlorosilane (3.12 ml: 2.2 eq.) are dropwise added. After stirring for 20 minutes, triethylamine (4.25 ml: 3 eq.) and 1M-sulfamoyl chloride in dichloromethane (25 ml: 2.5 eq.) are dropwise added to the mixture. After 20 minutes stirring, the reaction mixture is acidified with hydrochloric acid, warmed to room temperature, and extracted with dichloromethane. The extract is washed with water, and 1N-hydrochloric acid (10 ml) and methanol (30 ml) are added thereto. The solution is stirred at room temperature for 30 minutes. The reaction mixture is washed with water, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (2S,4S)-1-p-nitrobenzyloxycarbonyl-2-sulfamoylaminoethyl-4-mercaptopyrrolidine (2.65 g). Yield: 66.7%.

NMR δ (CDCl₃-CD₃OD) ppm: 1.42(t, J=7Hz, 1H), 1.65 to 1.93(m, 1H), 2.48 to 2.70(m, 1H), 3.05 to 3.63(m, 4H), 3.93 to 4.16(m, 2H), 5.22(s, 2H), 7.53(d, J=8Hz, 2H), 8.23(d, J=8Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3276br, 1692, 1607.

Preparative Example 4 of a pyrrolidine derivative

[0079]

Step 1. Preparation of a Boc compound

[0080] To a suspension of trans-4-hydroxy-L-proline (50 g) in a mixture of water (300 ml) and t-butanol (100 ml) are added aqueous sodium hydrogen carbonate (32.3 g), di-t-butyl dicarbonate (104 g) and dioxane (200 ml). The mixture is stirred at room temperature overnight. The organic solvent is removed and the resulting aqueous solution is layered with methyl ethyl ketone and ethyl acetate, and acidified with conc. hydrochloric acid (34.5 ml) under ice cooling. The organic layer is taken, washed with saturated brine, dried over sodium sulfate, and concentrated in vacuo. The residue is recrystallized from ethyl acetate-toluene to give trans-1-t-butoxycarbonyl-4-hydroxy-L-proline (82.9 g). Colorless crystals. Yield: 94%. mp. 126 to 128°C.

NMR δ (CDCl₃) ppm: 1.43, 1.46(2 x s, 9H), 1.95 to 2.36(m, 2H), 3.36 to 3.6(m, 2H), 4.23 to 4.44(m, 2H).

IR ν (CHCl₃) cm⁻¹: 3360, 1735, 1656.

Elemental analysis (C ₁₀ H ₁₇ NO ₅)			
Calcd.:	C, 51.94;	H, 7.41;	N, 6.06.
Found :	C, 51.65;	H, 7.38;	N, 5.99.

Step 2. Preparation of a compound having mesyloxy and methoxycarbonyl groups

[0081] To a solution of trans-1-t-butoxycarbonyl-4-hydroxy-L-proline (8.5 g) in tetrahydrofuran (110 ml) at -30°C, triethylamine (12.8 ml) and methanesulfonyl chloride (6.27 ml) are added. The mixture is stirred at the same temperature for 30 minutes. To the mixture triethylamine (5.13 ml) and methanol (30 ml) are added. The mixture is stirred for 30 minutes. The reaction mixture is acidified with 1N-hydrochloric acid (37 ml) and extracted with ethyl acetate. The extract is successively washed with water, aqueous sodium hydrogen carbonate, water and saturated brine, dried over sodium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography and recrystallized from toluene-petroleum ether to give (2S,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (9.16 g). Colorless crystals. Yield: 77%. mp. 86 to 87°C.

NMR δ (CDCl₃) ppm: 1.42, 1.47, 1.50(3 x s, 9H), 2.19 to 2.35(m, 1H), 2.48 to 2.75(m, 1H), 3.06, 3.07, 3.26(3 x s, 3H), 3.59 to 4.12(m, 5H), 4.35 to 4.60(m, 1H), 5.18 to 5.32(m, 1H).

IR \checkmark (CHCl₃) cm⁻¹: 1748, 1698.

Step 3. Preparation of a methylol compound

[0082] To a solution of (2S,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (8.11 g) in tetrahydrofuran (49 ml) stirring under ice cooling, sodium borohydride (2.36 g) and methanol (20 ml) are added. The mixture is stirred at room temperature for 25 minutes and at 60°C for 25 minutes. The mixture is cooled with ice and filtered. The filtrate is concentrated, diluted with ethyl acetate, washed with water, dried over sodium sulfate, and concentrated in vacuo. The residue is recrystallized from petroleum ether-ether to give (2S,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (5.96 g). Colorless crystals. Yield: 80%. mp. 95 to 96°C.

NMR δ (CDCl₃) ppm: 1.48(s, 9H), 1.78 to 2.02(m, 1H), 2.3 to 2.48(m, 1H), 3.05(s, 3H), 3.5 to 3.65(m, 2H), 3.65 to 4.0(m, 2H), 4.03 to 4.25(m, 1H), 5.2(s, 1H).

IR \checkmark (CHCl₃) cm⁻¹: 3460, 1680.

Step 4. Preparation of a tosyl compound

[0083] To a solution of (2S,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (12.0 g) in dichloromethane (180 ml) stirring under ice cooling, triethylamine (6.23 ml), p-toluenesulfonyl chloride (8.52 g) and N,N-dimethylaminopyridine (993 mg) are successively added. The mixture is heated to reflux for 3 hours, supplemented with triethylamine (0.57 ml) and p-toluenesulfonyl chloride (775 mg), and heated to reflux for 1 hour. The reaction mixture is acidified with dilute hydrochloric acid. The organic layer is taken, washed with water, dried over sodium sulfate and concentrated in vacuo. The residue is purified by silica gel column chromatography and recrystallized from n-hexane to give (2S,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol p-toluenesulfonate (16.8 g). Yield: 92%. mp. 65 to 66°C.

NMR δ (CDCl₃) ppm: 1.42(s, 9H), 2.15 to 2.55(m, 2H), 2.45(s, 3H), 3.03(s, 3H), 3.3 to 4.5(m, 5H), 5.1 to 5.25(m, 1H), 7.35(d, J=8.0Hz, 2H), 7.76(d, J=8.0Hz, 2H).

IR \checkmark (CHCl₃) cm⁻¹: 1693.

Step 5. Preparation of a phthalimido compound

[0084] To a solution of (2S,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol p-toluenesulfonate (20.78 g) in dimethylformamide (200 ml), potassium phthalimide (9.61 g) is added. The mixture is stirred at 70°C for 3 hours. The reaction mixture is poured into a mixture of water and ethyl acetate. The organic layer is taken, successively washed with dilute aqueous sodium hydroxide and water, dried over sodium sulfate, and concentrated in vacuo. The residue is purified by 5% wet silica gel column chromatography to give (2S,4R)-1-t-butoxycarbonyl-2-phthalimidomethyl-4-methanesulfonyloxypyrrolidine (11.17 g). Yield: 60%. Colorless foam.

NMR δ (CDCl₃) ppm: 1.33, 1.42(2 x s, 9H), 2.0 to 2.55(m, 2H), 3.02(s, 3H), 3.4 to 4.6(m, 5H), 5.15 to 5.3(m, 1H), 7.6 to 7.95(m, 4H).

IR \checkmark (CHCl₃) cm⁻¹: 1775, 1716, 1693.

Step 6. Preparation of an acetylthio compound

[0085] To a solution of (2S,4R)-1-t-butoxycarbonyl-2-phthalimidomethyl-4-methanesulfonyloxypyrrolidine (3 g) in dimethylformamide (30 ml), potassium thioacetate (1.65 g) is added. The mixture is stirred at 60°C for 3.5 hours. The reaction mixture is poured into a mixture of ethyl acetate and dilute hydrochloric acid. The organic layer is taken, washed with water, dried over sodium sulfate, and concentrated in vacuo. The residue is purified by silica gel column

chromatography to give (2S,4S)-1-t-butoxycarbonyl-2-phthalimidomethyl-4-acetylthiopyrrolidine (2.12 g). Yield: 74%. Orange colored syrup.

NMR δ (CDCl₃) ppm: 1.30, 1.39(2 x s, 9H), 1.6 to 2.0(m, 1H), 2.34(s, 3H), 2.4 to 2.67(m, 1H), 3.15 to 3.3(m, 1H), 3.65 to 4.55(m, 5H), 7.6 to 8.0(m, 4H).

IR ν (CHCl₃) cm⁻¹: 1774, 1715, 1688.

Step 7. Removal of a phthalyl and an acetyl groups

[0086] To a solution of (2S,4S)-1-t-butoxycarbonyl-2-phthalimidomethyl-4-acetylthiopyrrolidine (8.58 g) in a mixture of dichloromethane (26 ml) and methanol (129 ml), hydrazine hydrate (4.11 ml) is added. The mixture is heated to reflux for 2 hours and 45 minutes and filtered. The filtrate is concentrated in vacuo. The residue is dissolved in dichloromethane, washed with water, dried over sodium sulfate, and concentrated in vacuo to give crude (2S,4S)-1-t-butoxycarbonyl-2-aminomethyl-4-mercaptopyrrolidine (4.1 g). Yellow syrup.

Step 8 Preparation of a sulfamoyl compound

[0087] To a solution of crude (2S,4S)-1-t-butoxycarbonyl-2-aminomethyl-4-mercaptopyrrolidine (4.1 g) in dichloromethane (250 ml) at -70°C under a stream of nitrogen, triethylamine (8.87 ml) and trimethylchlorosilane (6.73 ml) are added. The mixture is stirred for 1 hour and 40 minutes, mixed with triethylamine (8.87 ml) and a solution of 1M-sulfamoyl chloride in dichloromethane (64 ml), and stirred for 1 hour. The reaction mixture is acidified with dilute hydrochloric acid. The organic layer is taken, diluted with 1N-hydrochloric acid (21 ml) and methanol (50 ml), stirred for 35 minutes at room temperature, and poured into water. The organic layer is taken, washed with water, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography to give (2S,4S)-1-t-butoxycarbonyl-2-sulfamoylaminoethyl-4-mercaptopyrrolidine (4.57 g).


Yield: 69%. Colorless syrup.

NMR δ (CDCl₃) ppm: 1.46(s, 9H), 1.5 to 1.8(m, 1H), 1.71(d, J=6.6Hz, 1H), 2.5 to 2.67(m, 1H), 3.0 to 3.46(m, 4H), 3.85 to 4.2(m, 2H), 4.6 (br s, 2H).

IR ν (CHCl₃) cm⁻¹: 3420, 3340, 3270, 1679.

Preparative Example 5 of a pyrrolidine derivative

[0088]



Step. 1 Preparation of a methylol compound

[0089] To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylic acid methyl ester (79.4 g; 205 mmole) in a mixture of tetrahydrofuran (200 ml) and ethanol (300 ml), sodium borohydride (14 g) is added in several portions under ice cooling. The mixture is stirred at room temperature for 4 hours. The

reaction mixture is neutralized with conc. sulfuric acid, concentrated in vacuo to approximately a half volume, diluted with water, and extracted with ethyl acetate. The extract is successively washed with aqueous sodium hydrogen carbonate, water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 1:2) to give (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (58.7 g). Yield: 81.7%.

NMR δ (CDCl₃) ppm: 1.8 to 2.2(m, 1H), 2.3 to 2.5(m, 1H), 3.01(s, 3H), 3.57 (d, J=4.4Hz, 1H), 3.64(d, J=4.4Hz, 1H), 3.81(s, 3H), 3.82 to 4.3(m,3H), 5.09(s, 2H), 5.21(br s, 1H), 6.89(d, J=8.8Hz, 2H), 7.31(d, J=8.8Hz,2H).

Step 2. Preparation of a tosyl compound

[0090] To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (8.7 g: 24.2 mmole) in dichloromethane(80 ml) are added triethylamine (4.05 ml), p-toluenesulfonyl chloride (5.08 g) and 4-dimethylaminopyridine (148 mg). The mixture is stirred at room temperature overnight. The reaction mixture is washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 1 : 1) to give (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol p-toluenesulfonate (11.75 g). Yield: 95%.

NMR δ (CDCl₃) ppm: 2.2 to 2.5(m), 2.44(s, 3H), 2.98(s, 3H), 3.4 to 3.6(m, 2H), 3.82(s, 3H), 3.8 to 4.6(m), 5.03, 4.95(ABq, J=12Hz, 2H), 5.2 (br s, 1H), 6.89(d, J=8.6Hz, 2H), 7.18 to 7.4(m, 4H), 7.6 to 7.8(m, 2H).

IR \checkmark (CHCl₃) cm⁻¹: 1698, 1612.

Step 3. Preparation of a phthalimido compound

[0091] To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol p-toluenesulfonate (6.35 g: 12.27 mmole) in dimethylformamide (60 ml), potassium phthalimide (2.7 g) is added. The mixture is stirred at 70°C for 4 hours. The reaction mixture is poured into ice water and extracted with ethyl acetate. The extract is successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 2:1) to give (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxy-2-phthalimidomethylpyrrolidine (4.65 g). Yield: 77.5%.

NMR δ (CDCl₃) ppm: 2 to 2.3(m, 1H), 2.4 to 2.6(m, 1H), 2.95, 2.97(2 x s,3H), 3.43 to 4.2(m, 5H), 3.80(s, 3H), [5.01(s)+5.07, 4.96(ABq, 12.2Hz), 2H], 5.13 to 5.3(m, 1H).

IR \checkmark (CHCl₃) cm⁻¹: 1774, 1716, 1613.

Step 4. Preparation of an acetylthio compound

[0092] To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxy-2-phthalimidopyrrolidine (4.0 g: 8.19 mmole) in dimethylformamide (40 ml), potassium thioacetate (2.1 g) is added. The mixture is stirred at 60°C for 3 hours. The reaction mixture is diluted with ethyl acetate, successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate =2:1) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-acetylthio-2-phthalimidomethylpyrrolidine (3.2 g). Yield: 78%.

NMR δ (CDCl₃) ppm: 1.7 to 1.9(m, 1H), 2.4 to 2.7(m, 1H), 3.21, 3.26(2 x d, J=7Hz, 2H), 3.8(s, 3H), 3.7 to 4.2(m), 4.2 to 4.5(m, 1H), [4.95(s) +5.04, 4.83(ABq, J=12Hz), 2H], 6.83(d, J=7.6Hz, 2H), 7.18 to 7.3(m, 2H), 7.6 to 7.9(m, 4H).

IR \checkmark (CHCl₃) cm⁻¹: 1773, 1714.

Step 5. Removal of an acetyl and a phthalyl groups and introduction of a sulfamoyl group

[0093] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-acetylthio-2-phthalimidomethylpyrrolidine (4.3 g: 9.18 mmole) in a mixture of dichloromethane (13 ml) and methanol (65 ml), hydrazine hydrate (1.78 ml) is added. The mixture is heated to reflux for 4 hours. The reaction mixture is concentrated in vacuo. The residue is dissolved in dichloromethane and filtered under a stream of nitrogen to remove solid. The filtrate is washed with water, dried over magnesium sulfate, and concentrated in vacuo. The resulting residue containing (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-mercapto-2-aminomethylpyrrolidine is diluted with dichloromethane (100 ml), added triethylamine (2.63 g) and trimethylchlorosilane (2.4 ml) at -78°C, and stirred for 20 minutes. To the reaction mixture, triethylamine (2.63 ml) and a solution (16.5 ml) of 1M-sulfamoyl chloride in dichloromethane are added. The mixture is stirred for 20 minutes. The reaction mixture is washed with dilute hydrochloric acid, mixed with 1N-hydrochloric acid (9 ml) and methanol (20 ml), and stirred at room temperature for 30 minutes. The reaction mixture is successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 1:2) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-mercapto-2-sulfamoylaminomethyl-


pyrrolidine (2.71 g). Yield: 78.6%.

NMR δ (CDCl₃) ppm: 1.6 to 2.0(m, 2H), 2.4 to 2.7(m, 1H), 3.1 to 3.8(m, 4H), 3.81(s, 3H), 3.9 to 4.2(m, 2H), 4.6 to 5.0(m, 2H), 5.04(s, 2H), 5.97(br s, 1H), 6.89(d, J=8.6Hz, 2H), 7.30(d, J=8.6Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3668, 3424, 1683.

Preparative Example 6 of a pyrrolidine derivative

[0094]



Step 1. Preparation of a methylol compound

[0095] To a solution of trans-1-p-methoxybenzyloxycarbonyl-4-hydroxyproline (105.5 g: 357.5 mmole) in tetrahydrofuran (1 liter), triethylamine (54.8 ml) is added. After adding ethyl chloroformate (35.9 ml) dropwise at -30°C, the mixture is stirred for 20 minutes. To the reaction mixture, a solution of sodium borohydride (33.25 g) in water (120 ml) is added dropwise at a temperature in the range of -15 to -5°C, neutralized with conc. hydrochloric acid, and concentrated in vacuo. To the residue, ethyl acetate is added, washed with brine, dried over magnesium sulfate, and concentrated in vacuo to give (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-pyrrolidine-2-methanol.

NMR δ (CDCl₃) ppm: 1.6 to 1.8(m, 1H), 1.95 to 2.2(m, 1H), 3.4 to 3.8 (m, 4H), 3.8(s, 3H), 4.0 to 4.3(m, 1H), 4.37 (br s, 1H), 5.07(s, 2H), 6.88(d, J=8.8Hz, 2H), 7.30(d, J=8.8Hz, 2H).

Step 2. Preparation of a tosyl compound

[0096] To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxypyrrolidine-2-methanol (64 g: 227.6 mmole) in pyridine (350 ml), p-toluenesulfonyl chloride (48 g) is added. The mixture is stirred at room temperature for 4 hours. The reaction mixture is poured into ice water and extracted with ethyl acetate. The extract is successively washed with water, dilute hydrochloric acid and aqueous sodium hydrogen carbonate, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography to give (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxypyrrolidine-2-methanol p-toluenesulfonate (60 g).

NMR δ (CDCl₃) ppm: 2.0 to 2.4(m, 2H), 2.44(s, 3H), 3.3 to 3.7(m, 2H), 3.82(s, 3H), 3.9 to 4.6(m, 4H), 4.8 to 5.1 (m, 2H), 6.88(d, J=8.6Hz, 2H), 7.2 to 7.4(m, 4H), 7.6 to 7.8(m, 2H).

IR ν (CHCl₃) cm⁻¹: 3446, 1693.

Step 3. Preparation of an amino precursor (-NProc = azido)**[0097]**

1) To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxypyrrolidine-2-methanol p-toluenesulfonate (8.7 g: 20 mmole) in dimethylformamide (60 ml), a solution of sodium azide (1.56 g) in water (6 ml) is added. The mixture is stirred at 80°C overnight. The reaction mixture is poured into ice water and extracted with ethyl acetate. The extract is successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo to give crude (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-azidomethylpyrrolidine (5.6 g). Yield: 92%.

NMR δ (CDCl₃) ppm: 1.95 to 2.1(m, 2H), 3.2 to 3.8(m, 3H), 3.81(s, 3H), 3.83 to 4.6(m, 3H), 5.07(s, 2H), 6.89(d, J=8.8Hz, 2H), 7.31(d, J=8.8Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3420, 2100, 1689.

2) To a solution of the thus obtained (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-azidomethylpyrrolidine (5.57 g: 18.18 mmole) in methanol (30 ml) are added, 5% palladium on charcoal (560 mg) and ammonium formate (2.3 g). The mixture is stirred at 45°C for 2 hours. The reaction mixture is diluted with dichloromethane (50 ml), filtered to remove the catalyst, and concentrated in vacuo. The residue is crystallized from a mixture of dichloromethane and ether and washed with ether to give (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-aminomethylpyrrolidine formate (4.28 g). Yield: 72%.

NMR δ (CDCl₃-CD₃OD) ppm: 1.6 to 1.82(m, 1H), 2.1 to 2.3(m, 1H), 2.7 to 3.7(m, 4H), 3.81(s, 3H), 4.1 to 4.4(m, 2H), 5.04(s, 2H), 6.88(d, J=8.8 Hz, 2H), 7.28(d, J=8.8Hz, 2H), 8.47(s, 1H).

IR ν (CHCl₃) cm⁻¹: 3678, 3412, 1678, 1602.

Step 4. Introduction of a protected amino group, removal of the protection, and introduction of a sulfamoyl group (-NProc = phthalimido)**[0098]**

1) To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxypyrrolidine-2-methanol p-toluenesulfonate (24 g: 55.1 mmole) in dimethylformamide (200 ml), potassium phthalimide (15.3 g) is added. The mixture is stirred at 80°C for 4 hours. The reaction mixture is diluted with ethyl acetate, successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 1:2) to give (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-phthalimidomethylpyrrolidine (18.1 g). Yield: 80%.

NMR δ (CDCl₃) ppm: 1.9 to 2.2(m, 2H), 3.4 to 4.05(m, 5H), 3.80(s, 3H), 4.3 to 4.6(m, 2H), 4.8 to 5.1(m, 2H), 6.83(d, J=8.2Hz, 2H), 7.25(d, J=8.2Hz, 2H), 7.6 to 7.9(m, 4H).

IR ν (CHCl₃) cm⁻¹: 3458, 1773, 1712.

2) To a solution of (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-phthalimidomethylpyrrolidine (5.13 g: 12.5 mmole) in a mixture of dichloromethane (15 ml) and methanol (50 ml), hydrazine hydrate (1.0 ml) is added. The mixture is heated to reflux for 2 hours and concentrated in vacuo. The residue is diluted with dichloromethane, filtered to remove solid, washed with brine, dried over magnesium sulfate, and concentrated in vacuo to give a residue containing (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-aminomethylpyrrolidine as a main component.

3) To a solution of the above-mentioned residue in dichloromethane (70 ml) at -70°C, triethylamine (4.6 ml) and trimethylchlorosilane (3.7 ml) are added. The mixture is stirred for 20 minutes. To the reaction mixture, triethylamine (5.5 ml) and a solution of 1M-sulfamoyl chloride in dichloromethane (34 ml) are added. The mixture is stirred for 15 minutes. The reaction mixture is washed with dilute hydrochloric acid, mixed with methanol (50 ml), and then 4N-hydrochloric acid (3.3 ml) is added under ice cooling. After stirring the mixture, aqueous sodium hydrogen carbonate is added. The organic layer is taken, washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo to give crude (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-sulfamoylaminomethylpyrrolidine (3.96 g).

NMR δ (CDCl₃) ppm: 1.8 to 2.25(m, 2H), 3 to 4.5(m, 7H), 3.79(s, 3H), 5.03(s, 2H), 5.2 to 5.8(m, 2H), 6.08(br s, 1H), 6.87(d, J=8.8Hz, 2H), 7.29(d, J=8.8Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3456, 1689.

Step 5 Preparation of a mesyl compound

[0099] To a solution of crude (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-hydroxy-2-sulfamoylaminomethylpyrrolidine (1.8 g; 5 mmole) obtained in Step 4 in dichloromethane (20 ml) at -70°C, triethylamine (0.77 ml) and methanesulfonyl chloride (0.39 ml) are added. The mixture is stirred for 45 minutes. The reaction mixture is neutralized with dilute hydrochloric acid, successively washed with water and brine, and concentrated in vacuo to give crude (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxy-2-sulfamoylaminomethylpyrrolidine (2.26 g).

NMR δ (CDCl₃) ppm: 2 to 2.5(m, 2H), 2.99(s, 3H), 3.0 to 4.3(m, 5H), 3.79(s, 3H), 4.8 to 5.3(m, 3H), 5.05(s, 2H), 5.7 to 5.85(m, 1H), 6.88(d, J=8.8Hz, 2H), 7.29(d, J=8.8Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3606, 3416, 1690.

Step 6. Preparation of an acetylthio compound

[0100] To a solution of crude (2S,4R)-1-p-methoxybenzyloxycarbonyl-4-methanesulfonyloxy-2-sulfamoylaminomethylpyrrolidine (2.26 g) obtained in Step 5 in dimethylformamide (12 ml), potassium thioacetate (1.7 g) is added. The mixture is stirred at 60°C for 5 hours. The reaction mixture is diluted with ethyl acetate, successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 1 : 2) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-acetylthio-2-sulfamoylaminomethylpyrrolidine (971 mg).

NMR δ (CDCl₃) ppm: 1.8(br s, 1H), 2.33(s, 3H), 2.4 to 2.7(m, 1H), 3.1 to 3.5(m), 3.81(s, 3H), 3.9 to 4.2(m, 2H), 5.05(s, 2H), 6.89(d, J=8.8Hz, 2H), 7.30(d, J=8.8Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3414, 3276, 1688.

Step 7. Removal of an acetyl group


[0101] To a solution of (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-acetylthio-2-sulfamoylaminomethylpyrrolidine (982 mg; 2.35 mmole) in a mixture of dichloromethane (2 ml) and methanol (10 ml), 1N-sodium hydroxide (2.8 ml) is added under ice cooling. The mixture is stirred for 15 minutes. The reaction mixture is diluted with water and extracted with ethyl acetate. The extract is successively washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 1:2) to give (2S,4S)-1-p-methoxybenzyloxycarbonyl-4-mercapto-2-sulfamoylaminomethylpyrrolidine (783 mg). Yield: 89%.

NMR δ (CDCl₃) ppm: 1.6 to 2.0(m, 2H), 2.4 to 2.7(m, 1H), 3.1 to 3.8(m, 4H), 3.81(s, 3H), 3.9 to 4.2(m, 2H), 4.6 to 5.0(m, 2H), 5.04(s, 2H), 5.97(br s, 1 H), 6.89(d, J=8.6Hz, 2H), 7.30(d, J=8.6Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3668, 3424, 1683.

Preparative Example 7-A of a pyrrolidine derivative

[0102]



Step A-1. Preparation of an ester compound

[0103] To a suspension of cis-4-hydroxy-D-proline (16.46 g: 125.5 mmole) in methanol (66 ml), thionylchloride (9.16 ml: 125.5 mmole) is added in a nitrogen atmosphere under ice cooling, and the mixture is stirred at room temperature for 30 minutes. The mixture is further stirred to react at 40°C for 4 hours to give (2R,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride as crude crystals (25.74 g). Yield: 113 %. Colorless crystals.

NMR δ (D₂O) ppm: 2.3 to 2.6(m, 2H), 3.33(s, 1H), 3.4 to 3.5(m, 2H), 3.84(s, 3H), 4.6 to 4.7(m, 2H).

IR \checkmark (KBr) cm⁻¹: 3320, 2980, 1728.

Step A-2. Preparation of a Boc compound

[0104] To a suspension of (2R,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride (25.64 g: 125 mmole) in dichloromethane (125ml), triethylamine (19.11ml: 137.5 mmole) is added dropwise in a nitrogen atmosphere under ice cooling. The mixture is stirred for 5 minutes at room temperature. Then, a solution of di-t-butyl dicarbonate (34.11 g: 156.3 mmole) in dichloromethane (125 ml) is added dropwise, and the mixture is stirred for 40 minutes at room temperature to give (2R,4R)-1-t-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (26.85 g). Yield: 88%. Colorless crystals.

NMR δ (CDCl₃) ppm: 1.46(d, J=8.4Hz, 9H), 2.0 to 2.2(m, 1H), 2.2 to 2.5(m, 1H), 3.4 to 3.8(m, 2H), 3.79(d, J=3.0Hz, 3H), 4.2 to 4.5(m, 2H).

IR \checkmark (KBr) cm⁻¹: 3460, 1730, 1680.

Step A-3. Preparation of a mesyl compound

[0105] To a solution of (2R,4R)-1-t-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (9.81 g: 40 mmole) in dichloromethane (49 ml) in a nitrogen atmosphere under ice cooling, triethylamine (6.67 ml: 48 mmole) and methanesulfonyl chloride (3.70 ml: 48 mmole) are added. The mixture is stirred for 20 minutes to give (2R,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine as a crude oil (13.05 g). Yield: 101%.

NMR δ (CDCl₃) ppm: 1.46(d, J=9.6Hz, 9H), 2.5(m, 2H), 3.02(s, 3H), 3.76(s, 3H), 3.8(m, 2H), 4.3 to 4.6(m, 1H), 5.2 to 5.3(m, 1H).

Step A-4. Preparation of a methylol compound

[0106] To a solution of (2R,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine (11.21 g: 34.4 mmole) in a mixture of tetrahydrofuran (34 ml) and ethanol (51 ml), sodium borohydride (5.21 g: 137.7 mmole) is added in a nitrogen atmosphere under ice cooling. The mixture is stirred for 75 minutes at room temperature to give (2R,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (8.47 g). Yield: 83%. Colorless crystals.

NMR δ (CDCl₃) ppm: 1.48(s, 9H), 1.9 to 2.2(m, 1H), 2.3 to 2.5(m, 1H), 3.06 (s, 3H), 3.65(dd, J=11.2Hz, J=4.0Hz, 1H), 3.5 to 3.9(m, 2H), 3.84(dd, J=11.2Hz, J=7.6Hz, 1H), 4.1(m, 1H), 5.2(m, 1H).

IR \checkmark (KBr) cm⁻¹: 3490, 1688.

Step A-5. Preparation of an acetylthio compound

[0107] (2R,4R)-1-t-Butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (i.e., a substrate) and potassium thioacetate (KSAc) are dissolved in dimethylformamide (DMF), and the mixture is stirred. The conditions for this reaction are shown in Table 1, Step A-5. The reaction mixture is diluted with ethyl acetate, and ice water is added. The organic layer is taken, successively washed with aqueous sodium hydroxide, hydrochloric acid, water and saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel chromatography to give (2R,4S)-4-acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol.

NMR δ (CDCl₃) ppm: 1.47(s, 9H), 2.05(t, 2H), 2.34(s, 3H), 3.0 to 3.3(m, 1H), 3.40(dd, J=11.6Hz, J=5.2Hz, 1H), 3.5 to 3.9(m, 3H), 3.9 to 4.2(m, 2H).

Step A-6. Introduction of a sulfamide group

[0108]

a) Production of N-t-butoxycarbonylsulfamide A solution of t-butanol (4.72 ml: 50 mmole) in ethyl acetate (100 ml) is cooled to -40°C, chlorosulfonyl isocyanate (4.35 ml: 50 mmole) is dropwise added thereto, and the mixture is stirred at -18°C for 20 minutes. The reaction mixture is cooled to -72°C, gaseous ammonia (2 mole) is bubbled

with stirring, and the mixture is stirred for 50 minutes while warming up to 10°C. The reaction mixture is acidified with 5N-hydrochloric acid (30 ml) and the formed precipitate is filtered off. The organic layer is taken, successively washed with water and brine, dried over magnesium sulfate, and concentrated under reduced pressure. The crystalline residue is washed with hexane-ethyl acetate (1:5, 90 ml) and recrystallized from ethyl acetate-hexane to give N-t-butoxycarbonylsulfamide (8.81 g). Yield: 89%. Colorless crystals. mp. 130 to 131°C.

NMR δ (CD_3SOCD_3) ppm : 1.43(s, 9H), 7.27(s, 2H).

IR \checkmark (Nujol) cm^{-1} : 3360, 3270, 1718, 1548.

Elemental Analysis ($\text{C}_5\text{H}_{12}\text{N}_2\text{O}_4\text{S}$)				
Calcd.:	C, 30.60;	H, 6.17;	N, 14.28;	S, 16.34.
Found:	C, 30.39;	H, 6.11;	N, 14.30;	S, 16.30.

Calcd.:	C, 30.60;	H, 6.17;	N, 14.28;	S, 16.34.
Found:	C, 30.39;	H, 6.11;	N, 14.30;	S, 16.30.

b) Preparation of a sulfamide compound To a solution of (2R,4S)-4-acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol (i.e., a substrate) in tetrahydrofuran (THF), triphenylphosphine (PPh_3), N-t-butoxycarbonylsulfamide (BSMD), and azodicarboxylic acid diethyl ester (DEAD) are successively added under ice cooling. The conditions for this reaction are shown in Table 2, Step A-6. The reaction mixture is diluted with toluene, concentrated, diluted with toluene, and the formed crystals are filtered off. The filtrate is concentrated. The residue is purified by silica gel column chromatography to give (2R,4S)-4-acetylthio-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methylpyrrolidine.

NMR δ (CDCl_3) ppm: 1.41(s, 9H), 1.55(s, 9H), 1.9 to 2.0(m, 2H), 2.35(s, 3H), 3.32(dd, $J=11.4\text{Hz}$, $J=8.2\text{Hz}$, 1H), 3.6 to 3.9 (m, 3H), 3.9 to 4.1(m, 1H), 4.5(m, 1H), 6.15(s, 2H).

IR \checkmark (KBr) cm^{-1} : 3420, 3320, 1706, 1686, 1666.

Step A-7. Removal of an acetyl group

[0109] To a solution of (2R,4S)-4-acetylthio-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methylpyrrolidine (i.e., a substrate) in dichloromethane, 4.92 M sodium methoxide (NaOMe) in methanol is added. The mixture is stirred. The conditions for this reaction are shown in Table 3, Step A-7. The reaction mixture is diluted with water. The water layer is taken, toluene is added thereto, and acidified with conc. hydrochloric acid under ice cooling. The organic layer is taken, successively washed with water and saturated brine, dried over magnesium sulfate, and concentrated in vacuo to give (2R,4S)-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercapto-pyrrolidine. mp. 90.0 to 91.5°C.

NMR δ (CDCl_3) ppm: 1.43(s, 9H), 1.52(s, 9H), 1.72(d, $J=7.0\text{Hz}$, 1H), 1.9 to 2.0(m, 2H), 3.2 to 3.8(m, 5H), 4.5(m, 1H), 6.11(s, 2H).

IR \checkmark (KBr) cm^{-1} : 3220, 1698, 1683.

Elemental Analysis ($\text{C}_{15}\text{H}_{29}\text{O}_6\text{N}_3\text{S}_2$)				
Calcd.	C:43.78,	H:7.10,	N:10.21,	S:15.58.
Found.	C:43.55,	H:7.11,	N:10.37,	S:15.75.

Calcd.	C:43.78,	H:7.10,	N:10.21,	S:15.58.
Found.	C:43.55,	H:7.11,	N:10.37,	S:15.75.

Preparative Example 7-B of a pyrrolidine derivative


[0110]

5

10

15

20

Step B-1. Substitution for a formyloxy group

[0111] To a solution of (2R,4R)-1-t-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (2.45 g: 10 mmole) in tetrahydrofuran (10 ml), formic acid (453 μ l: 12 mmole), triphenylphosphine (3.15 g: 12 mmole), and diethyl azodicarboxylate (1.89 ml: 12 mmole) are successively added in a nitrogen atmosphere under ice cooling. The mixture is stirred for 30 minutes at the same temperature to give (2R,4S)-1-t-butoxycarbonyl-4-formyloxy-2-methoxycarbonylpyrrolidine (2.17 g). Yield: 79%. Colorless oil.

NMR δ (CDCl₃) ppm: 1.44(d, J=7.8Hz, 9H), 2.1 to 2.6(m, 2H), 3.5 to 3.9(m, 5H), 4.4(m, 1H), 5.4(m, 1H), 8.0(s, 1H).

Step B-2. Removal of a formyl group

[0112] To a solution of (2R,4S)-1-t-butoxycarbonyl-4-formyloxy-2-methoxycarbonylpyrrolidine (2.08 g: 7.6 mmole) in methanol (21.0 ml), aqueous 1N-sodium hydroxide (7.6 ml) is added under ice cooling. The mixture is stirred at the same temperature for 25 minutes to give (2R, 4S)-1-t-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (1.86 g). Yield: 100%. Colorless oil.

NMR δ (CDCl₃) ppm: 1.44(d, J=9.2Hz, 9H), 1.9 to 2.4(m, 2H), 3.4 to 3.7(m, 2H), 3.74 (s, 3H), 4.3 to 4.6(m, 2H).

Step B-3. Preparation of a mesyl compound

[0113] To a solution of (2R,4S)-1-t-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (3.17 g: 12.9 mmole) in dichloromethane (16 ml) in a nitrogen atmosphere under ice cooling, triethylamine (2.15 ml: 15.5 mmole) and methanesulfonyl chloride (1.19 ml: 15.5 mmole) are added. The mixture is stirred to react for 30 minutes to give (2R,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine as oil (4.13 g). Yield: 99%.

NMR δ (CDCl₃) ppm: 1.46(d, J=8.4Hz, 9H), 2.3(m, 1H), 2.5 to 2.8(m, 1H), 3.08(s, 3H), 3.8 to 4.0(m, 5H), 4.3 to 4.6(m, 1H), 5.3(m, 1H).

Step B-4. Preparation of a methylol compound

[0114] To a solution of (2R,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine (3.96 g: 12.2 mmole) in a mixture of tetrahydrofuran (12 ml) and ethanol (18 ml), sodium borohydride (1.85 g: 48.8 mmole) is added in a nitrogen atmosphere under ice cooling. The mixture is stirred for 45 minutes at room temperature to give (2R,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (2.97 g). Yield: 83%. Colorless crystals. mp. 95 to 96°C.

NMR δ (CDCl₃) ppm: 1.49(s, 9H), 1.7 to 2.1(m, 1H), 2.3 to 2.5(m, 1H), 3.06(s, 3H), 3.4 to 3.7(m, 2H), 3.7 to 4.0

(m, 2H), 4.0 to 4.3(m, 1H), 5.2(m, 1H).
IR \checkmark (KBr) cm^{-1} : 3400, 3420, 1648.

Step B-5. Substitution for an acetylthio group

[0115] (2R,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (i.e., a substrate) is allowed to react in the same manner as in Step A-5 in Preparative Example 7-A under a condition for Step B-5 shown in Table 1 to give (2R,4R)-4-acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol.

NMR δ (CDCl_3) ppm: 1.47(s, 9H), 2.34(s, 3H), 2.4 to 3.2 (m, 2H), 3.58 to 4.1 (m, 6H).

IR \checkmark (CHCl_3) cm^{-1} : 3380, 1690.

Step B-6. Introduction of a sulfamide group

[0116] N-t-butoxycarbonylsulfamide is prepared in the same manner as in the paragraph (a) of Step A-6 in Preparative Example 7-A. (2R,4R)-4-acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol (i.e., a substrate) is allowed to react with the obtained N-t-butoxycarbonylsulfamide in the similar manner as in paragraph (b) of Step A-6 in Preparative Example 7-A under a condition for Step B-6 shown in Table 2 to give (2R,4R)-4-acetylthio-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methylpyrrolidine.

NMR δ (CDCl_3) ppm : 1.43(s, 9H), 1.53(s, 9H), 2.34(s, 3H), 2.5(m, 1H), 3.15(dd, J=12.2Hz, J=6.2Hz, 1H), 3.58 (dd, J=14.8Hz, J=3.2Hz, 1H), 3.8 to 4.1(m, 2H), 4.16(dd, J=12.2Hz, J=7.8Hz, 1H), 4.4 to 4.7 (m, 1H), 6.11(s, 2H).

IR \checkmark (CHCl_3) cm^{-1} : 3360, 3200, 1710, 1688.

Step B-7. Removal of an acetyl group


[0117] (2R,4R)-4-acetylthio-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino) methylpyrrolidine (i.e., a substrate) is deacetylated in the similar manner as in Step A-7 of Preparative Example 7-A under a condition for Step B-7 shown in Table 3 to give (2R,4R)-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercaptopyrrolidine. mp. 92 to 93°C.

NMR δ (CDCl_3) ppm : 1.2 to 1.5(m, 1H), 1.42 (s, 9H), 1.54(s, 9H), 1.82(d, J=6.2Hz, 1H), 2.5 to 2.7(m, 1H), 4.09, 3.05 (ABX, J=12.0Hz, J=7.4Hz, J=8.2Hz, 2H), 4.06, 3.62(ABX, J=15.0Hz, J=10.8 Hz, J=3.2Hz, 2H), 4.2 to 4.6(m, 1H), 6.08(s, 2H).

IR \checkmark (CHCl_3) cm^{-1} : 3380, 3220, 1718, 1680.

Preparative Example 7-C of a pyrrolidine derivative

[0118]



Step C-1. Preparation of an ester compound

[0119] To a suspension of trans-4-hydroxy-L-proline (200 g: 1.525 mole) in methanol (800 ml), acetylchloride (163 ml: 2.288 mole) is added dropwise under ice cooling in a nitrogen atmosphere. The mixture is warmed to room temperature, mixed with thionyl chloride (55.7 ml: 0.763 mole), and stirred for 4 hours at 40°C to give (2S,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride (244.27 g). Yield: 88%. Colorless crystals.

NMR δ (D_2O) ppm: 1.8 to 2.0(m, 1H), 2.0 to 2.2(m, 1H), 2.9 to 3.1(m, 1H), 3.17(dd, $J=12.6\text{Hz}$, $J=3.6\text{Hz}$, 1H), 3.49(s, 3H), 4.2 to 4.4(m, 2H).

IR \checkmark (KBr) cm^{-1} : 3380, 3330, 2695, 2960, 1742.

Step C-2. Preparation of a Boc compound

[0120] To a suspension of (2S,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride (12.71 g: 70 mmole) in dichloromethane (70 ml), triethylamine (10.7 ml: 77 mmole) is added dropwise under ice cooling in a nitrogen atmosphere. The mixture is stirred for 5 min. at room temperature. A solution of di-*t*-butyl dicarbonate (19.10 g: 87.5 mmole) in dichloromethane (72 ml) is added dropwise thereto, and the mixture is stirred for 45 minutes at room temperature to give (2S,4R)-1-*t*-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (14.06 g). Yield: 82%. Colorless oil.

NMR δ ($CDCl_3$) ppm: 1.44(d, $J=9.6\text{Hz}$, 9H), 1.9 to 2.4(m, 3H), 3.4 to 3.7(m, 2H), 3.74 (s, 3H), 4.3 to 4.6(m, 2H).

Step C-3. Substitution with a formyloxy group

[0121] To a solution of (2S,4R)-1-*t*-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (7.36 g: 30 mmole) in tetrahydrofuran (30ml), formic acid (1.36 ml: 36 mmole), triphenylphosphine (9.44 g: 36 mmole) and diethyl azodicarboxylate (5.67 ml: 36 mmole) are successively added in a nitrogen atmosphere under ice cooling. The mixture is stirred to react for 40 minutes at the same temperature to give (2S,4S)-1-*t*-butoxycarbonyl-4-formyloxy-2-methoxycarbonylpyrrolidine (5.38 g). Yield: 66%. Colorless crystals.

NMR δ ($CDCl_3$) ppm: 1.45(d, $J=8.6\text{Hz}$, 9H), 2.2 to 2.4(m, 1H), 2.4 to 2.7(m, 1H), 3.5 to 3.9(m, 2H), 3.75(s, 3H), 4.3 to 4.6(m, 1H), 5.3 to 5.5(m, 1H), 7.98 (s, 1H).

IR \checkmark (KBr) cm^{-1} : 3420, 1748, 1712, 1681.

Step C-4. Removal of a formyl group

[0122] To a solution of (2S,4S)-1-t-butoxycarbonyl-4-formyloxy-2-methoxycarbonylpyrrolidine (5.12 g; 18.7 mmole) in methanol (51.0 ml), aqueous 1N-sodium hydroxide (18.7 ml) is added under ice cooling. The mixture is stirred at the same temperature for 20 minutes to give (2S,4S)-1-t-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (4.09 g). Yield: 89%. Colorless crystals.

NMR δ (CDCl₃) ppm: 1.44(d, J=8.2Hz, 9H), 2.0 to 2.2(m, 1H), 2.2 to 2.5(m, 1H), 3.2 to 3.8(m, 3H), 3.79(d, J=2.8Hz, 3H), 4.2 to 4.5(m, 2H).

IR \checkmark (KBr) cm⁻¹: 3460, 1728, 1677.

Step C-5. Preparation of a mesyl compound

[0123] In a manner similar to Step A-3 in Preparative Example 7-A, (2S,4S)-1-t-butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine in dichloromethane is mesylated with triethylamine and methanesulfonylchloride in a nitrogen atmosphere under ice cooling to give (2S,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine. mp. 90.0 to 91.5°C.

Step C-6. Preparation of a methylol compound

[0124] In a similar manner to that in Step A-4 in Production Example 7-A, (2S,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine is allowed to react to give (2S,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol.

Step C-7. Preparation of an acetylthio compound

[0125] (2S,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (i.e., a substrate) is allowed to react in a similar manner to Step A-5 in Preparative Example 7-A under a condition for Step C-7 shown in Table 1 to give (2S,4R)-4-acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol.

NMR δ (CDCl₃) ppm: 1.47(s, 9H), 2.05 (t, 2H), 2.34 (s, 3H), 3.0 to 3.3 (m, 1H), 3.40(dd, J=11.6Hz, J=5.2Hz, 1H), 3.5 to 3.9(m, 3H), 3.9 to 4.2(m, 2H).

Step C-8. Introduction of a sulfamide group

[0126] N-t-butoxycarbonylsulfamide is prepared in the same manner as in the paragraph (a) in Step A-6 in Preparative Example 7-A. (2S,4R)-4-Acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol (i.e., a substrate) is allowed to react with N-t-butoxycarbonylsulfamide in the similar manner as in the paragraph (b) in Step A-6 in Production Example 7-A under a condition for Step C-8 shown in Table 2 to give (2S,4R)-4-acetylthio-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino) methylpyrrolidine.

NMR δ (CDCl₃) ppm: 1.41(s, 9H), 1.55(s, 9H), 1.9 to 2.0 (m, 2H), 2.35(s, 3H), 3.32(dd, J=11.4Hz, J=8.2Hz, 1H), 3.6 to 3.9(m, 3H), 3.9 to 4.1(m, 1H), 4.5(m, 1H), 6.15(s, 2H).

IR \checkmark (KBr) cm⁻¹: 3420, 3320, 1706, 1686, 1666.

Step C-9. Removal of an acetyl group

[0127] (2S,4R)-4-acetylthio-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino) methylpyrrolidine (i.e., a substrate) is allowed to react in the similar manner as in Step A-7 in Preparative Example 7-A under a condition for Step C-9 shown in Table 3 to give (2S,4R)-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino) methyl-4-mercaptopyrrolidine. mp. 90.0 to 91.5°C.

NMR δ (CDCl₃) ppm: 1.43(s, 9H), 1.52(s, 9H), 1.72(d, J=7.0Hz, 1H), 1.9 to 2.0(m, 2H), 3.2 to 3.8(m, 5H), 4.5 (m, 1H), 6.11(s, 2H).

IR \checkmark (KBr) cm⁻¹: 3220, 1698, 1683.

Preparative Example 7-D of a pyrrolidine derivative

[0128]

5

10

15

20

25


30

35

45

50

55

Step D-1. Preparation of an N-Boc compound

[0129] To a suspension of trans-4-hydroxy-L-proline (50 g: 0.381 mole) in methanol (250 ml), a solution of 4N-sodium hydroxide (95.4 ml: 0.381 mole) and di-t-butyl dicarbonate (91.6 g: 0.42 mole) in methanol (55 ml) is added at -20°C. The mixture is stirred at 20°C for 3 hours. The reaction mixture is concentrated and then diluted with toluene (100 ml) and shaken. The aqueous layer is taken, and mixed with conc. hydrochloric acid (36 ml) under ice cooling, saturated brine (100 ml), and ethyl acetate (800 ml). The organic layer is taken, washed with saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue is recrystallized from a toluene-ethyl acetate mixture to give (2S,4R)-1-t-butoxycarbonyl-2-carboxy-4-hydroxypyrrolidine (84.7 g). Yield: 96%. Colorless crystals. mp. 126 to 128°C.

NMR δ (CDCl₃) ppm: 1.43, 1.46(2 x s, 9H), 1.95 to 2.36(m, 2H), 3.36 to 3.6(m, 2H), 4.23 to 4.44(m, 2H).

IR ν (CHCl₃) cm⁻¹: 3360, 1735, 1656.

Step D-2. Protection of a carboxyl group

[0130] To a solution of (2S,4R)-1-t-butoxycarbonyl-2-carboxy-4-hydroxypyrrolidine (84.5 g: 0.365 mole) in dichloromethane (1.27 liter) in a nitrogen atmosphere at -30°C, triethylamine (61.1 ml: 0.438 mole) and ethyl chloroformate (38.4 ml: 0.402 mole) are added, and the mixture is stirred for 40 minutes.

Step D-3. Preparation of an O-mesyl compound

[0131] The resulting reaction mixture containing (2S,4R)-1-t-butoxycarbonyl-2-ethoxycarbonyloxycarbonyl-4-hydroxypyrrolidine obtained in Step D-2 is cooled to -40°C, triethylamine (61.1 ml: 0.438 mole) and methanesulfonyl chloride (31.1 ml: 0.402 mole) are added thereto, and the mixture is stirred for 40 minutes.

Step D-4. Reduction

[0132] To the resulting reaction mixture containing (2S,4R)-1-t-butoxycarbonyl-2-ethoxycarbonyloxycarbonyl-4-methanesulfonyloxypyrrolidine obtained in Step D-3 cooling at -40°C, tetra-n-butylammonium bromide (11.8 g: 0.0365 mole) and a solution of sodium borohydride (52.5 g: 1.35 mole) in water (55 ml) are added. The mixture is allowed to warm to -10°C and stirred for 1 hour. The aqueous layer is acidified with dilute hydrochloric acid to pH 3. The organic layer is taken, successively washed with aqueous sodium hydrogen carbonate and water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue is recrystallized from a toluene-hexane mixture to give (2S,4R)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (101.3 g). Yield: 94%. Color-

less crystals. mp. 95 to 96°C.

NMR δ (CDCl₃) ppm: 1.48(s, 9H), 1.78 to 2.02(m, 1H), 2.3 to 2.48(m, 1H), 3.05 (s, 3H), 3.5 to 3.65(m, 2H), 3.65 to 4.0(m, 2H), 4.03 to 4.25 (m, 1H), 5.2(s, 1H).

IR \checkmark (CHCl₃) cm⁻¹: 3460, 1680.

Step D-5. Substitution for an acetylthio group

[0133] A solution of (2R,4S)-1-t-butoxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (i.e., a substrate) (11.8 g: 40 mmole) and potassium thioacetate (5.94 g: 52 mmole) in dimethylformamide (120 ml) is stirred at 65°C for 3.75 hours. The reaction mixture is mixed with ethyl acetate (330 ml), ice water (100 ml), and 1N-hydrochloric acid (20 ml) to adjust the aqueous layer at pH 4. The organic layer is taken, successively washed with water and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue is purified by silica gel chromatography (toluene-ethyl acetate = 2:1) to give (2S,4S)-4-acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol (9.48 g). Yield: 86%. Pale orange colored oil.

NMR δ (CDCl₃) ppm : 1.47(s, 9H), 2.34(s, 3H), 2.4 to 3.2(m, 2H), 3.58 to 4.1(m, 6H).

IR \checkmark (CHCl₃) cm⁻¹: 3380, 1690.

Step D-6. Introduction of a sulfamide group

[0134] N-t-butoxycarbonylsulfamide is prepared in the same manner as in the paragraph (a) of Step A-6 in Preparative Example 7-A. To a solution of (2S,4S)-4-acetylthio-1-t-butoxycarbonylpyrrolidine-2-methanol (i.e., a substrate) (9.04 g: 32.8 mmole) in tetrahydrofuran (THF) (95 ml), triphenylphosphine (PPh₃) (10.16 g: 38.7 mmole), N-t-butoxycarbonylsulfamide (BSMD) (9.66 g: 49.2 mmole), and azodicarboxylic acid diethyl ester (DEAD) (6.20 ml: 39.4 mmole) are successively added under ice cooling. The conditions for this reaction are shown in Table 2, Step D-6. The reaction mixture is diluted with toluene (30 ml), concentrated, diluted with toluene (60 ml), and the formed crystals are filtered off. The filtrate is concentrated.

Step D-7. Removal of an acetyl group

[0135] The residue obtained in Step D-6 is dissolved in toluene (95 ml), then, 4.92M sodium methoxide in methanol (20 ml: 98.4 mmole) is added at -35°C, and the mixture is stirred for 30 minutes. The reaction mixture is diluted with water (100 ml). The aqueous layer is taken, ethyl acetate (300 ml) is added, mixed with concentrated hydrochloric acid (10 ml) under ice cooling, and the mixture is stirred. The organic layer is taken, successively washed with water and brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue is purified by silica gel chromatography. Obtained colorless oil is recrystallized from toluene-hexane mixture to give (2S,4S)-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino) methyl-4-mercaptopyrrolidine (9.32 g). Yield: 69%. Colorless crystals. mp. 92 to 93°C.

NMR δ (CDCl₃) ppm : 1.2 to 1.5(m, 1H), 1.42(s, 9H), 1.54(s, 9H), 1.82 (d, J=6.2Hz, 1H), 2.5 to 2.7(m, 1H), 4.09, 3.05(ABX, J=12.0Hz, J=7.4Hz, J=8.2Hz, 2H), 4.06, 3.62(ABX, J=15.0Hz, J=10.8Hz, J=3.2Hz, 2H), 4.2 to 4.6(m, 1H), 6.08(s, 2H).

IR \checkmark (CHCl₃) cm⁻¹: 3380, 3220, 1718, 1680.

Elemental Analysis (C₁₅H₂₉N₃O₆S₂)

Calcd. :	C, 43.78;	H, 7.10;	N, 10.21;	S, 15.58
Found :	C, 43.64;	H, 7.10;	N, 10.19;	S, 15.34

Table 1

Step	KSAc equiv. ^{a)}	DMF vol. ^{b)}	Temp. °C	Time	Yield min. %
A-5	1.55	20 fold	70	90	75
B-5	1.20	5 fold	70	300	81
C-7	1.30	10 fold	65	105	70
D-5	1.30	10 fold	65	225	86

^{a)} Molar ratio to the substrate

^{b)} The volume (ml) of the solvent to the weight (g) of the substrate

Table 2

Step	THF vol. ^{c)}	PPh ₃ equiv. ^{d)}	BSMD equiv. ^{d)}	DEAD equiv. ^{d)}	Temp.	Time	Yield min. %
A-6	20 fold	1.34	1.20	1.30	45°C	150	76
B-6	7 fold	1.50	1.66	1.50	0°C	300	84
C-8	10 fold	1.28	1.50	1.30	room temp.	240	82
D-6	11 fold	1.18	1.50	1.20	room temp.	180	..e)

^{c)} The volume (ml) of the solvent to the weight (g) of the substrate

^{d)} Molar ratio to the substrate

^{e)} Not measured

Table 3

Step	NaOMe equiv. ^{f)}	Solvent ^{g)} vol. ^{h)}	Temp. °C	Time min.	Yield %
A-7	1.5	15 fold	-40	120	72
B-7	2.0	5 fold	-10	60	70
C-9	3.0	4 fold	-35	30	85
D-7	3.0	11 fold	-35	30	69


^{f)} Molar ratio to the substrate

^{g)} Dichloromethane is used in Steps A-7, B-7, C-9 and toluene is used in Step D-7.

^{h)} The volume (ml) of the solvent to the weight (g) of the substrate

Preparative Example 8 of a pyrrolidine derivative

[0136]



Step 1. Preparation of a p-chlorobenzenesulfonyl compound

[0137] To a solution of (2S,4R)-1-allyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (13.4 g: 50 mmole) in dichloromethane (50 ml), p-chlorobenzenesulfonyl chloride (12.66 g: 60 mmole) is added in a nitrogen atmosphere at room temperature and a solution of triethylamine (8.69 ml: 62.5 mmole) in dichloromethane (10 ml) is further added dropwise. The mixture is stirred at room temperature overnight. The reaction mixture is successively washed with aqueous sodium hydrogen carbonate and saturated brine, dried over magnesium sulfate, concentrated in vacuo, and purified by silica gel chromatography (toluene-ethyl acetate) to give crude (2S,4R)-1-allyloxycarbonyl-2-p-chlorobenzenesulfonyloxymethyl-4-methanesulfonyloxypyrrolidine (23.73 g) as oil. Yield: 105%.

NMR δ (CDCl₃) ppm: 2.2 to 2.6(m, 2H), 3.04(s, 3H), 3.58(dd, J=5.0Hz, J=11.4Hz, 1H), 3.8 to 4.0(m, 1H), 4.1 to 4.3(m, 3H), 4.5(m, 3H), 5.1 to 5.4(m, 3H), 5.7 to 6.0(m, 1H).

Step 2. Preparation of a phthalimide compound

[0138] To a solution of (2S,4R)-1-allyloxycarbonyl-2-p-chlorobenzenesulfonyloxymethyl-4-methanesulfonyloxypyrrolidine (23.7 g: ca. 50 mmole) in dimethylformamide (50 ml), potassium phthalimide (10.2 g: 55 mmole) is added in a nitrogen atmosphere, and the mixture is stirred at 60°C for 3.5 hours. The reaction mixture is poured into a stirring mixture of ice water (500ml) and ethyl acetate (500 ml). The organic layer is successively washed with water (4 times) and saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is recrystallized from a mixture of n-hexane and toluene. The solid is filtered off and the filtrate is purified by silica gel chromatography (toluene-ethyl acetate) to give crude (2S,4R)-1-allyloxycarbonyl-2-phthalimidomethyl-4-methanesulfonyloxypyrrolidine (12.41 g). Yield: 61%. Colorless oil.

Step 3. Preparation of an acetylthio compound

[0139] A solution of (2S,4R)-1-allyloxycarbonyl-2-phthalimidomethyl-4-methanesulfonyloxypyrrolidine (12.4 g: 30.46 mmole) and 90% potassium thioacetate (5.22 g: 45.69 mmole) in dimethylformamide (130 ml) is heated with stirring at 60°C for 4 hours. The reaction mixture is diluted with ethyl acetate (200 ml) and ice water (200 ml). The organic layer is taken, successively washed with water (3 times) and saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel chromatography to give crude (2S,4S)-4-acetylthio-1-allyloxycarbonyl-2-phthalimidomethylpyrrolidine (9.33 g). Yield: 81%.

NMR δ (CDCl₃) ppm: 1.7 to 1.9(m, 1H), 2.33(s, 3H), 2.4 to 2.7(m, 1H), 3.25 (dd, J=6.8Hz, J=11.4Hz, 1H), 3.7 to 4.0(m, 2H), 4.0 to 4.2(m, 2H), 4.3 to 4.6(m, 3H), 5.0 to 5.3(m, 2H), 5.7 to 5.9(m, 1H), 7.7(m, 2H), 7.85(m, 2H).

Step 4. Removal of a phthalyl and an acetyl groups

[0140] To a solution of crude (2S,4S)-1-acetylthio-1-allyloxycarbonyl-2-phthalimidomethylpyrrolidine (5.61 g: 14.90 mmole) in dichloromethane (5.4 ml), and methanol (5.4 ml), hydrazine monohydrate (2.17 ml: 44.7 mmole) is added. The mixture is heated at 60°C with stirring for 4 hours. The solid in the reaction mixture is filtered off, washed with dichloromethane (70 ml) and the washing is combined with the filtrate. The mixture is concentrated to give crude (2S,4S)-2-aminomethyl-1-allyloxycarbonyl-4-mercaptopyrrolidine (2.80 g). Yield: 68%. Oil.

Step 5. Preparation of a sulfamoyl compound

[0141] To a solution of (2S,4S)-2-aminomethyl-1-allyloxycarbonyl-4-mercaptopyrrolidine (2.80 g: ca. 13.14 mmole) in dichloromethane (66 ml) at -50°C, triethylamine (4.02 ml: 28.91 mmole) and trimethylchlorosilane (3.76 ml: 28.91 mmole) are added dropwise over 15 minutes. The mixture is stirred at the same temperature for 20 minutes. To the reaction mixture triethylamine (0.92 ml: 6.57 mmole) and a solution of sulfamoyl chloride (19.37 mmole) in dichloromethane (6.8 ml) are added dropwise over 20 minutes at -70°C, and the mixture is stirred for 30 minutes. To the reaction mixture triethylamine (3.84 ml: 27.59 mmole) is again added over 1 hour at -50°C. The reaction mixture is kept at the same temperature overnight and concentrated in vacuo. The residual oil is purified by silica gel chromatography (ethyl acetate) to give (2S,4S)-1-allyloxycarbonyl-2-(sulfamoylamino)methyl-4-mercaptopyrrolidine (2.64 g). Yield: 68%. White powder.

NMR δ (CDCl₃) ppm: 1.4 to 1.6(m, 1H), 1.83(d, J=6.2Hz, 1H), 2.5 to 2.7(m, 1H), 3.11(dd, J=8.2Hz, J=11.6Hz, 1H), 3.3 to 3.4(m, 1H), 3.71(dd, J=2.9Hz, J=15.2Hz, 1H), 4.13(dd, J=7.3Hz, J=11.7Hz, 1H), 4.16(dd, J=10.3, 14.9Hz, 1H), 4.3 to 4.6(m, 3H), 4.7(m, 2H), 5.2 to 5.4(m, 4H), 5.8 to 6.0(m, 2H), 6.0(m, 2H).

IR ν (CHCl₃) cm⁻¹: 684, 1158.


Preparative Example 9 of a pyrrolidine derivative

[0142]

5

10

15



Step 1. Preparation of an N-protected and an O-mesyl compound

20

25

30

[0143] To a suspension of (2S,4R)-4-hydroxy-2-methoxycarbonylpyrrolidine hydrochloride (17.0 g; 100 mmole) in dichloromethane (200 ml), triethylamine (29.2 ml; 210 mmole) is added in a nitrogen atmosphere under ice cooling. The mixture is stirred for 5 minutes at room temperature, mixed dropwise with a solution of allyl chloroformate (11.2 ml; 100 mmole) in dichloromethane (20 ml), stirred for 1 hour at room temperature, and diluted with water (250 ml). The organic layer is taken, successively washed with water and saturated brine, dried over magnesium sulfate, and concentrated in vacuo to give (2S,4R)-1-allyloxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (21.82 g) as oil. To a solution of this product in dichloromethane (100 ml), triethylamine (16.7 ml; 120 mmole) and methanesulfonylchloride (9.2 ml; 120 mmole) are added in a nitrogen atmosphere under ice cooling, and the mixture is stirred for 10 minutes. The reaction mixture is successively washed with aqueous sodium hydrogen carbonate and saturated brine, dried over magnesium sulfate, concentrated in vacua, and purified by silica gel chromatography (toluene-ethyl acetate) to give (2S,4R)-1-allyloxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine (27.62 g) as oil. Yield: 90%.

NMR δ (CDCl₃) ppm: 2.2 to 2.4(m, 1H), 2.2 to 2.5(m, 1H), 2.5 to 2.8(m, 2H), 3.06(s, 3H), 3.74 & 3.77(2 x s; 3H), 3.8 to 4.0(m, 2H), 4.4 to 4.7(m, 3H), 5.2 to 5.4(m, 3H), 5.8 to 6.0(m, 1H).

35

Step 2. Preparation of a methylol compound

40

45

[0144] To a solution of (2S,4R)-1-allyloxycarbonyl-4-methanesulfonyloxy-2-methoxycarbonylpyrrolidine (27.12 g; 74.0 mmole) in a mixture of tetrahydrofuran (94 ml) and ethanol (140 ml), sodium borohydride (12 g; 31.7 mmole) is added in a nitrogen atmosphere under ice cooling. The mixture is stirred for 4 hours at room temperature. To the reaction mixture concentrated sulfuric acid (8.8 ml; 158.4 mmole) is added dropwise under ice cooling. The reaction mixture is concentrated to half a volume in vacuo, and diluted with ethyl acetate (100 ml) and ice water (100 ml). The organic layer is taken, successively washed with aqueous sodium hydrogen carbonate and saturated brine, dried over magnesium sulfate, and concentrated in vacuo to give (2S,4R)-1-allyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (19.33 g). Yield: 77 %. Colorless oil.

NMR δ (CDCl₃) ppm: 1.9 to 2.1(m, 1H), 2.3 to 2.5(m, 1H), 3.05(s, 3H), 3.5 to 3.7(m, 2H), 3.7 to 4.1(m, 2H), 4.1 to 4.3(m, 1H), 4.6(m, 2H), 5.2 to 5.4(m, 3H), 5.8 to 6.1(m, 1H).

Step 3. Preparation of an acetylthio compound

50

55

[0145] A solution of (2S,4R)-1-allyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-methanol (19.32 g; 69.17 mmole) and 90% potassium thioacetate (10.73 g; 89.9 mmole) in dimethylformamide (217 ml) is heated with stirring at 65°C for 5 hours. To the reaction mixture ethyl acetate (200 ml) and ice water (200 ml) are added. The organic layer is taken, successively washed with aqueous 0.05N-sodium hydroxide, 0.1N-hydrochloric acid, water and saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel chromatography to give (2S, 4S)-4-acetylthio-1-allyloxycarbonylpyrrolidine-2-methanol (15.34 g). Yield: 90%.

NMR δ (CDCl₃) ppm: 1.5 to 1.7(m, 1H), 2.34(s, 3H), 2.4 to 2.6(m, 1H), 3.19(dd, J=8.0Hz, J=11.5Hz, 1H), 3.6 to 3.8(m, 2H), 3.8 to 4.0(m, 1H), 4.0 to 4.2(m, 2H), 4.6(m, 2H), 5.2 to 5.4(m, 2H), 5.8 to 6.1(m, 1H).

Step 4. Preparation of a sulfamide compound

[0146] To a solution of (2S,4S)-4-acetylthio-1-allyloxycarbonylpyrrolidine-2-methanol (8.02 g: ca. 30 mmole) in ethyl acetate (83 ml) under ice cooling, triphenylphosphine (9.44 g: 13.6 mmole), N-allyloxycarbonylsulfamide (3.12 g: 15.9 mmole), and azodicarboxylic acid diethylester (5.67 ml: 36 mmole) are successively added. The mixture is stirred under ice cooling for 55 minutes and at room temperature for 4 hours. The reaction mixture is dissolved in toluene (60 ml), concentrated, diluted with toluene (60 ml), filtered to remove separating crystals, and the filtrate is concentrated. The residue is purified by silica gel chromatography to give (2S,4S)-4-acetylthio-1-allyloxycarbonyl-2-(N-sulfamoyl-N-allyloxycarbonylamino)methylpyrrolidine (6.74 g). Yield: 55%. Colorless oil.


NMR δ (CDCl₃) ppm: 1.5 to 1.7(m, 1H), 2.35(s, 3H), 2.5 to 2.7(m, 1H), 3.19 (dd, J=6.3Hz, J=11.5Hz, 1H), 3.68 (dd, J=3.8Hz, J=14.5Hz, 1H), 3.9 to 4.3(m, 3H), 4.3 to 4.7(m, 5H), 5.2 to 5.4(m, 4H), 5.8 to 6.1(m, 4H).

Step 5. Removal of an acetyl group


[0147] To a solution of (2S,4S)-4-acetylthio-1-allyloxycarbonyl-2-(N-sulfamoyl-N-allyloxycarbonylamino)methylpyrrolidine (6.70 g: 16.4 mmole) in toluene (50 ml), 4.92 M solution of sodium methoxide in methanol (5.0 ml: 24.7 mmole) is added at -30°C. The mixture is stirred for 30 minutes, and diluted with water (55 ml). The aqueous layer is taken, diluted with toluene (50 ml), acidified with concentrated hydrochloric acid (2.3 ml) under ice cooling, and stirred. The organic layer is taken, successively washed with water and saturated brine, dried over magnesium sulfate and concentrated in vacuo. The residual oil is purified by silica gel chromatography (toluene-ethyl acetate) to give (2S,4S)-1-allyloxycarbonyl-2-(N-sulfamoyl-N-allyloxycarbonylamino)methyl-4-mercaptopyrrolidine (4.89 g). Yield: 78%. Colorless oil.



NMR δ (CDCl₃) ppm: 1.5 to 1.7(m, 1H), 2.35(s, 3H), 2.5 to 2.7(m, 1H), 3.19(dd, J=6.3Hz, J=11.5Hz, 1H), 3.68 (dd, J=3.8Hz, J=14.5Hz, 1H), 3.9 to 4.3(m, 3H), 4.3 to 4.7(m, 5H), 5.2 to 5.4(m, 4H), 5.8 to 6.1(m, 4H).

IR ν (CHCl₃) cm⁻¹: 1718, 1684, 1179, 1160.

Examples[0148]

Example	X ¹	X ²	Y ²	$\begin{array}{c} \text{R}^4 \\ \\ -\text{NSO}_2\text{N} \begin{array}{l} \nearrow \text{R}^2 \\ \searrow \text{R}^3 \end{array} \end{array}$
1	H	PMB	Boc	-NHSO ₂ NH ₂
2	H	PNB	Pnz	-NHSO ₂ NH ₂
3	H	PMB	Pnz	-NHSO ₂ N $\begin{array}{l} \nearrow \text{H} \\ \searrow \text{Pnz} \end{array}$
4	H	PMB	Pnz	-NHSO ₂ N $\begin{array}{l} \nearrow \text{Pnz} \\ \searrow \text{Me} \end{array}$
5	H	PMB	Pnz	-NHSO ₂ N $\begin{array}{l} \nearrow \text{Me} \\ \searrow \text{Me} \end{array}$
6	SiMe ₃	CHPh ₂	Boc	-N $\begin{array}{l} \nearrow \text{Boc} \\ \searrow \text{SO}_2\text{NH}_2 \end{array}$
7	H	PMB	Pnz	-NHSO ₂ NHCH ₂ CH ₂ OH
8	H	PMB	Pnz	$\begin{array}{c} \text{---} \text{N} \text{---} \text{S} \text{---} \text{N} \text{Pnz} \\ \diagup \quad \diagdown \\ \text{O} \quad \text{O} \end{array}$
9	H	PMB	Pnz	$\begin{array}{c} \text{---} \text{N} \text{---} \text{S} \text{---} \text{N} \text{Pnz} \\ \diagup \quad \diagdown \\ \text{O} \quad \text{O} \end{array}$



5	Example	$\begin{array}{c} R^4 \\ \\ -NSO_2N < \begin{array}{l} R^2 \\ R^3 \end{array} \end{array}$
	1	$-NHSO_2NH_2$
10	2	$-NHSO_2NH_2$
	3	$-NHSO_2NH_2$
15	4	$-NHSO_2NHMe$
	5	$-NHSO_2N < \begin{array}{l} Me \\ Me \end{array}$
20	6	$-NHSO_2NH_2$
	7	$-NHSO_2NHCH_2CH_2OH$
25	8	
30	9	

Example 1. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative

Step 1. Preparation of a protected pyrrolidylthiocarbapenem derivative.

[0149] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-oxo-1-methyl-1-carbapenam-3-carboxylic acid p-methoxybenzylester (1.45 g) in acetonitrile (15 ml) at -25°C, diphenylphosphoric acid chloride (0.953 ml) and diisopropylethylamine (0.872 ml) are successively added. The mixture is stirred at room temperature for 1 hour. To this mixture 2-sulfamoylaminomethyl-1-t-butoxycarbonyl-4-mercaptopyrrolidine (1.69 g) and diisopropylethylamine (0.945 ml) are added under ice cooling, and the mixture is stirred for 22 hours. The reaction mixture is mixed with 1N-hydrochloric acid (15 ml) and diluted with ethyl acetate. The organic layer is taken, washed with water, dried over sodium sulfate and concentrated. The residue is purified by column chromatography over 10% wet silica gel to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminomethyl-1-t-butoxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penam-3-carboxylic acid p-methoxybenzylester (1.61 g). Yield: 60%. Pale yellow foam.

NMR δ (CDCl₃) ppm: 1.25(d, J=7.2Hz, 3H), 1.32(d, J=6.4Hz, 3H), 1.47(s, 9H), 1.75 to 2.0(m, 1H), 2.4 to 2.65(m, 1H), 2.61(br s, 4H), 3.1 to 3.7 (m, 6H), 3.81(s, 3H), 3.75 to 4.25(m, 4H), 5.19, 5.25(ABq, J=12.1Hz, 2H), 6.89(d, J=8.6Hz, 2H), 7.39(d, J=8.6Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3400, 3290, 1770, 1682.

Step 2. Deprotection

[0150] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminomethyl-1-t-butoxycarbo-

nylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (1.083 g) in a mixture of dichloromethane (16.5 ml), anisole (1.52 ml) and nitromethane (3.1 ml) at -60°C, a solution of 1.0M aluminum chloride in nitromethane (12.93 ml) is added dropwise. The mixture is stirred for 2 hours slowly warming up to -40°C. The reaction mixture is poured into a solution of sodium acetate (3.18 g) in water (24 ml), successively washed with ether and ether-petroleum ether, desalted and purified by styrene-divinylbenzene copolymer resin column chromatography, and lyophilized the objective fraction to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminomethyl-1-pyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (0.429 g). Yield: 67%. Pale yellow foam.

NMR δ (D_2O) ppm: 1.22(d, J=7.2Hz, 3H), 1.27(d, J=6.3Hz, 3H), 1.64 to 1.82(m, 1H), 2.62 to 2.80(m, 1H), 3.26 to 3.59(m, 5H), 3.63 to 3.76(m, 1H), 3.84 to 4.10 (m, 2H), 4.16 to 4.29(m, 2H).

IR \checkmark (KBr) cm^{-1} : 3400, 1750.

MIC (γ / ml) : Staphylococcus aureus strain 3626: 25, Streptococcus pyogenes C203: <0.003.

Example 2. Coupling 2 of a (3S,5S)-pyrrolidylthiocarbapenem derivative

Step 1. Preparation of a Protected pyrrolidylthiocarbapenem derivative

[0151] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-diphenoxyphosphonyloxy-1-methyl-1-carba-2-penem-3-carboxylic acid p-nitrobenzylester (3.04 g: 5.12 mmole) in acetonitrile (30 ml) under ice cooling, a solution of diisopropylethylamine (1.16 ml: 1.3 eq.) and 2-sulfamoylaminomethyl-1-p-nitrobenzyloxycarbonyl-4-mercaptopyrrolidine (2.4 g: 1.2 eq.) in acetonitrile (20 ml) is added. The mixture is stirred under ice cooling for 140 minutes. The reaction mixture is diluted with ethyl acetate, successively washed with water and saturated brine, dried over magnesium sulfate and concentrated. The residue is purified by silica gel column chromatography (toluene : ethyl acetate) to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminomethyl-1-p-nitrobenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-nitrobenzylester (3.35 g). Yield: 89%.

NMR δ ($CDCl_3$) ppm: 1.28(d, J=7Hz, 3H), 1.37(d, J=6Hz, 3H), 4.68(s, 2H), 5.22, 5.50(ABq, J=14Hz, 2H), 5.23(s, 2H), 7.52(d, J=9Hz, 2H), 7.65 (d, J=9Hz, 2H), 8.21(d, J=2.5Hz, 2H), 8.26(d, J=2.5Hz, 2H).

IR \checkmark ($CHCl_3$) cm^{-1} : 1773, 1720, 1704.

Step 2. Deprotection

[0152] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminomethyl-1-p-nitrobenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-nitrobenzylester (3 g) in a mixture of tetrahydrofuran (60 ml) and 0.1M-MES buffer (pH 7.0), 10% palladium on carbon (2 g) as a catalyst is added. The mixture is shaken under a stream of hydrogen at atmospheric pressure for 4 hours. The reaction mixture is filtered to remove the catalyst, washed with ethyl acetate to remove a neutral substance, and concentrated. The residual aqueous solution is purified by styrene-divinylbenzene copolymer resin column chromatography. The fraction eluting with 5 to 10% ethanol water is lyophilized to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminomethyl-1-pyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (1.42 g). Yield: 84.8%.

Example 3. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative

Step 1. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0153] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-diphenoxyphosphonyloxy-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (1 mmole) in acetonitrile (10 ml) under ice cooling, diisopropylethylamine (1.2 mmole) and 2-p-methoxybenzyloxycarbonylsulfamoylaminomethyl-1-p-methoxybenzyloxycarbonyl-4-mercaptopyrrolidine (1 mmole) are added. The mixture is allowed to stand overnight. The reaction mixture is diluted with dichloromethane, successively washed with dilute hydrochloric acid, water, aqueous sodium hydrogen carbonate, and brine, dried and concentrated. The residue is purified by silica gel column chromatography to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-p-methoxybenzyloxycarbonylsulfamoylaminomethyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester. Yield : 50 to 80%.

NMR δ ($CDCl_3$) ppm: 1.20(d, J=6.4Hz, 3H), 1.34(d, J=6.1Hz, 3H), 3.79(s,9H), 5.00 to 5.12(m, 4H), 5.23, 5.15(ABq, J=14.0Hz, 2H).

IR \checkmark ($CHCl_3$) cm^{-1} : 3390, 1770, 1740, 1693, 1610.

Step 2. Deprotection

[0154] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-p-methoxybenzyloxycarbonylsulfamoylami-

nomethyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (1 mmole) in dichloromethane (20 ml) at -40°C, anisole (10 mmole) and a solution of 2M aluminum chloride in nitromethane (3 to 4 ml) are added. The mixture is stirred at the same temperature for 1 to 1.5 hours. The reaction mixture is poured into a solution of sodium acetate (19 to 25 mmole) in water (100 ml), washed with dichloromethane to remove a neutral substance. The aqueous layer is purified by styrene-divinylbenzene copolymer resin column chromatography. The objective eluate is lyophilized to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamoylaminoethyl-1-pyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid. Yield: 60 to 70%.

Example 4. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative

Step 1. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0155] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-diphenoxyphosphonyloxy-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (700 mg) in acetonitrile (4 ml) at -30°C, a solution of diisopropylethylamine (182 μ l) and 1-p-methoxybenzyloxycarbonyl-4-mercapto-2-(N-p-methoxybenzyloxycarbonyl-N-methylaminosulfonylaminoethyl)pyrrolidine (401 mg) in acetonitrile (3 ml) is added. The mixture is stirred under ice cooling for 90 minutes. The reaction mixture is poured into a mixture of ethyl acetate and dilute hydrochloric acid. The ethyl acetate layer is taken, successively washed with water, aqueous sodium hydrogen carbonate, and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel column chromatography (toluene : ethyl acetate = 1 : 2) to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-1-p-methoxybenzyloxycarbonyl-5-(N-p-methoxybenzyloxycarbonyl-N-methylaminosulfonylaminoethyl)pyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (512 mg).

NMR δ (CDCl₃) ppm: 1.22(d, J=7.0Hz, 3H), 1.34(d, J=6.4Hz, 3H), 1.6 to 1.9(m, 1H), 2.25 to 2.5(m, 1H), 3 to 3.6(m, 7H), 3.778(s, 3H), 3.783(s, 3H), 3.788(s, 3H), 5.05(s, 2H), 5.13(s, 2H), 5.2(ABq, J=12Hz, 2H), 6.3 to 6.5(m, 1H), 6.8 to 7.0(m, 6H), 7.2 to 7.4(m, 6H).

IR ν (CHCl₃) cm⁻¹: 1767, 1697.

Step 2. Deprotection

[0156] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-1-p-methoxybenzyloxycarbonyl-5-(N-p-methoxybenzyloxycarbonyl-N-methylaminosulfonylaminoethyl)pyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (610 mg) in a mixture of dichloromethane (6 ml), nitromethane (2 ml) and anisole (4 ml) stirring at -40°C, 2M-solution of aluminum chloride in nitromethane (2.6 ml: 7.5 equivalents) is added. The mixture is stirred at -35 \pm 5°C for 1 hour and 30 minutes. The reaction mixture is poured into a mixture of sodium acetate (1.34 g), water (20 ml) and dichloromethane (20 ml). The aqueous layer is taken, subjected to a styrene-divinylbenzene copolymer resin column chromatography, and the fraction eluting with 8% ethanol is lyophilized to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-N-methylaminosulfonylamino-methylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (206 mg). Yield : 68.6%.

NMR δ (CDCl₃) ppm: 1.22(d, J=7.0Hz, 3H), 1.27(d, J=6.4Hz, 3H), 1.5 to 1.8(m, 1H), 2.63(s, 3H), 2.6 to 2.8(m, 1H), 3.1 to 3.6(m, 5H), 3.65, 3.72(dd, J=6.6Hz, J=7.6Hz, 1H), 3.8 to 4.4(m, 4H).

IR ν (CHCl₃) cm⁻¹: 1750, 1585.

MIC (γ / ml) : Staphylococcus aureus strain 3626: 25, Streptococcus pyogenes C203: <0.003.

Example 5. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative

Step 1. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0157] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-diphenoxyphosphonyloxy-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (1 mmole) in acetonitrile (10 ml) under ice cooling, di-isopropylethylamine (1.2 mmole) and 2-N,N-dimethylsulfamoylaminoethyl-1-p-methoxybenzyloxycarbonyl-4-mercaptopyrrolidine (1 mmole) are added. The mixture is allowed to stand overnight. The reaction mixture is diluted with dichloromethane, successively washed with dilute hydrochloric acid and water, dried, and concentrated. The residue is purified by silica gel column chromatography to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-N,N-dimethylsulfamoylaminoethyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester. Yield: 50 to 80%.

NMR δ (CDCl₃) ppm: 1.22(d, J=7.2Hz, 3H), 1.34(d, J=6.2Hz, 3H), 2.76(s, 6H), 3.79(s, 3H), 3.81(s, 3H), 5.06(s, 2H), 5.24, 5.18(ABq, J=12Hz, 2H).

IR ν (CHCl₃) cm⁻¹: 3390, 1770, 1725, 1690, 1610.

Step 2. Deprotection

[0158] A solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-N,N-dimethylsulfamoylamino-methyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (1 mmole) in dichloromethane (20 ml) is cooled to -40°C. Anisole (10 mmole) and a solution of 2M aluminum chloride in nitromethane (3 to 4 ml) are added thereto, and the mixture is stirred at the same temperature for 1 to 1.5 hours. The reaction mixture is poured into a solution of sodium acetate (19 to 25 mmole) in water (100 ml), and washed with dichloromethane to remove a neutral material. The aqueous layer is purified by styrene-divinylbenzene copolymer resin column chromatography and the objective eluate is lyophilized to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-N,N-dimethylsulfamoylamino-methylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid. Yield: 60 to 70%.

NMR δ (D₂O) ppm: 1.2(d, J=7.4Hz, 3H), 1.28(d, J=6.4Hz, 3H), 1.65 to 1.80(m, 1H), 2.65 to 2.80(m, 1H), 2.81(s, 6H), 3.29 to 3.55(m, 5H), 3.65 to 3.75(m, 1H), 3.80 to 4.10(m, 2H), 4.16 to 4.30(m, 2H).

IR ν (KBr) cm⁻¹: 3400, 1750.

MIC (γ / ml) : Staphylococcus aureus strain 3626: 25, Streptococcus pyogenes C203: <0.003.

Example 6. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivativeStep 1. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0159] To a solution of (1R,5S,6S)-2-diphenoxyphosphonyloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid diphenylmethylester (6.88 g: 11 mmole) in dichloromethane (70 ml) under ice cooling, trimethylchlorosilane (1.81 ml: 14.3 mmole) and triethylamine (1.99 ml: 14.3 mmole) are added. The mixture is stirred for 25 minutes. The reaction mixture is poured into aqueous sodium hydrogen carbonate. The organic layer is taken, washed with water and brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue containing the product, (1R,5S,6S)-2-diphenoxyphosphonyloxy-1-methyl-6-[(1R)-1-trimethylsilyloxyethyl]-1-carba-2-penem-3-carboxylic acid diphenylmethylester is dissolved in acetonitrile (70 ml), and (2S,4S)-1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercaptopyrrolidine (5.43 g: 13.2 mmole) and diisopropylethylamine (2.30 g: 13.2 mmole) are added thereto under ice cooling. The obtained mixture is stirred for 4.5 hours. To the reaction mixture containing the product, (1R,5S,6S)-2-[(3S,5S)-1-t-butoxycarbonyl-5-(N-t-butoxycarbonyl-N-sulfamoylamino)methylpyrrolidin-3-yl]thio-1-methyl-6-[(1R)-1-trimethylsilyloxyethyl]-1-carba-2-penem-3-carboxylic acid diphenylmethylester, 1N-hydrochloric acid (5.5 ml) is added, and the mixture is stirred for 20 minutes, diluted with ethyl acetate (150 ml), and the mixture is poured into ice water. The organic layer is taken, successively washed with aqueous sodium hydrogen carbonate, water, and brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue is recrystallized from toluene to give (1R,5S,6S)-2-[(3S,5S)-1-t-butoxycarbonyl-5-(N-t-butoxycarbonyl-N-sulfamoylamino)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid diphenylmethylester (7.53 g). Yield: 87%. Colorless crystals. mp. 163 to 164°C.

NMR δ (CDCl₃) ppm : 1.27(d, J=7.2Hz, 3H), 1.39(s, 9H), 1.42(s, 9H), 2.45 to 2.65(m, 1H), 3.1 to 3.35(m, 2H), 3.28(dd, J=7.2Hz, J=2.6Hz, 1H), 3.5 to 3.77(m, 2H), 3.9 to 4.15(m, 2H), 4.26(dd, J=7.0Hz, J=2.6Hz, 1H), 4.2 to 4.37(m, 1H), 4.45 to 4.66(m, 1H), 6.07(s, 2H), 6.95(s, 1H), 7.2 to 7.6(m, 10H).

IR ν (CHCl₃) cm⁻¹: 3385, 3230, 1778, 1715, 1685.

Elemental Analysis (C₃₈H₅₀N₄O₁₀S₂)

Calcd.:	C, 57.99; H, 6.40; N, 7.12; S, 8.15.
Found :	C, 57.87; H, 6.46; N, 6.99; S, 7.93.

Step 2. Deprotection

[0160] To a solution of aluminum chloride (3.20 g: 24 mmole) in a mixture of anisole (24 ml) and dichloromethane (24 ml) at -40°C, a solution of (1R,5S,6S)-2-[(3S,5S)-1-t-butoxycarbonyl-5-(N-t-butoxycarbonyl-N-sulfamoyl-amino)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxy-ethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid diphenylmethylester (2.36 g: 3 mmole) in dichloromethane (12 ml) is dropwise and gradually added. The mixture is vigorously stirred at -25 to -30°C for 3.5 hours. The reaction mixture is poured into a solution of sodium acetate (5.91 g: 72mmole) in water (48 ml). The aqueous layer is taken, washed with dichloromethane, concentrated in vacuo to remove remaining organicsolvent and subjected to styrene-divinylbenzene copolymer resin column chromatography. The fraction eluting with methanol-water (1:9) is lyophilized to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamidomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (910 mg). Yield: 72%. Colorless foam.

NMR δ (D_2O) ppm: 1.22(d, J=7.2Hz, 3H), 1.27(d, J=6.3Hz, 3H), 1.64 to 1.82(m, 1H), 2.62 to 2.80(m, 1H), 3.26 to 3.59(m, 5H), 3.63 to 3.76(m, 1H), 3.84 to 4.10(m, 2H), 4.16 to 4.29(m, 2H).

IR \checkmark (KBr) cm^{-1} : 3400, 1750.

MIC (γ /ml) : Staphylococcus aureus 3626: 25. Blood level: mice i.v., after 15 min. (γ /ml): 9.8. Urinary recovery: mice i.v., (%): 36.3.

Example 7. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative

Step 1. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0161] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-1-methyl-2-oxo-1-carbapenam-3-carboxylic acid p-methoxybenzylester (277 mg) in acetonitrile (4 ml) under ice cooling, diphenylphosphoric acid chloride (198 μ l) and diisopropylethylamine (166 μ l) are successively added. The mixture is stirred at room temperature for 1 hour. To the reaction mixture containing the product, (1R,5S,6S)-2-diphenoxyphosphonyloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penam-3-carboxylic acid p-methoxybenzylester, (2S,4S)-2-(2-hydroxyethyl)sulfamoylaminomethyl-1-p-methoxybenzyloxy-carbonyl-4-mercaptopyrrolidine (344 mg) and diisopropylethylamine (166 μ l) are added under ice cooling, and the mixture is stirred at the same temperature for 2 hours. The reaction mixture is diluted with ethyl acetate, successively washed with water, dilute hydrochloric acid, water, aqueous sodium hydrogen carbonate and water, dried over magnesium sulfate, and concentrated. The residue is purified by silica gel column chromatography to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-(2-hydroxyethyl)sulfamoylaminomethyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penam-3-carboxylic acid p-methoxybenzylester (156 mg). Yield: 26%.

NMR δ ($CDCl_3$) ppm: 1.22(d, J=7.0Hz, 3H), 1.34(d, J=6.2Hz, 3H), 3.79(s, 3H), 3.80(s, 3H), 5.05(s, 2H), 5.17, 5.24(ABq, J=12.2Hz, 2H).

IR \checkmark ($CHCl_3$) cm^{-1} : 1775, 1690.

Step 2. Deprotection

[0162] To a solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-(2-hydroxyethyl)sulfamoylaminomethyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penam-3-carboxylic acid p-methoxybenzylester (148 mg) in a mixture of dichloromethane (3 ml) and nitromethane (750 μ l) in a nitrogen atmosphere at $-40^\circ C$, a solution of 1.0M aluminum chloride in nitromethane (1.8 ml) and anisole (258 μ l) is added. The mixture is stirred at the same temperature for 1.5 hours. The reaction mixture is poured into a solution of sodium acetate (454 mg) in water (8 ml) and washed with an ether-hexane mixture. The aqueous layer is concentrated in vacuo to 4 ml, and purified by styrene-divinylbenzene copolymer resin column chromatography to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-(2-hydroxyethyl)sulfamoylaminomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penam-3-carboxylic acid (42 mg). Yield: 46%.

NMR δ (D_2O) ppm: 1.21(d, J=7.4Hz, 3H), 1.28(d, J=6.4Hz, 3H), 1.66 to 1.81(m, 1H), 2.66 to 2.81(m, 1H), 3.15(t, J=5.6Hz, 2H), 3.32 to 3.54(m, 5H), 3.65 to 3.75(m, 3H), 3.87 to 4.07(m, 2H), 4.18 to 4.27(m, 2H).

IR \checkmark (KBr) cm^{-1} : 3400, 1750.

Blood level: mice i.v., after 15 min (γ /ml): 29.3.

Example 8. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative

Step 1. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0163] To a solution of (1R,5S,6S)-2-diphenoxyphosphonyloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penam-3-carboxylic acid p-methoxybenzylester (456 mg) in acetonitrile (3 ml) under ice cooling, diisopropylethylamine (165 μ l) and (2S,4S)-2-(1,1-dioxo-2-p-methoxybenzyloxycarbonyl-1,2,5-thiadiazolidin-5-yl) methyl-4-mercapto-1-p-methoxybenzyloxycarbonylpyrrolidine (445 mg) are added. The mixture is allowed to stand at $0^\circ C$ overnight. The reaction mixture is diluted with ethyl acetate, successively washed with water, dilute hydrochloric acid and water, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel chromatography to give (1R,5S,6S)-2-[(3S,5S)-5-(1,1-dioxo-2-p-methoxybenzyloxycarbonyl-1,2,5-thiadiazolidin-5-yl)methyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penam-3-carboxylic acid p-methoxybenzylester (510 mg). Yield: 72%.

NMR δ ($CDCl_3$) ppm: 1.22(d, J=7.4Hz, 3H), 1.34(d, J=6.2Hz, 3H), 5.04(s, 2H), 5.23(s, 2H), 5.18, 5.24(ABq, J=11.9Hz, 2H).

IR \checkmark ($CHCl_3$) cm^{-1} : 1773, 1735, 1700.

Step 2 Deprotection

[0164] To a solution of (1R,5S,6S)-2-[(3S,5S)-5-(1,1-dioxo-2-p-methoxybenzyloxycarbonyl-1,2,5-thiadiazolidin-5-yl)methyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (500 mg) in a mixture of dichloromethane (8 ml) and nitromethane (3 ml) in a nitrogen atmosphere at -40°C, anisole (729 µl) and a solution (5.03 ml) of 1.0M aluminum chloride in nitromethane are added. The mixture is stirred at the same temperature for 1.5 hours. The reaction mixture is poured into a solution of sodium acetate (1.28 g) in water (50 ml), then aqueous layer is taken, and washed with an ether-hexane mixture. The aqueous layer is concentrated under reduced pressure to about 15 ml, and is purified by styrene-divinylbenzene copolymer resin column chromatography to give (1R,5S,6S)-2-[(3S,5S)-5-(1,1-dioxo-1,2,5-thiadiazolidin-5-yl)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid (180 mg). Yield: 72%.

NMR δ (D₂O) ppm: 1.21(d, J=7.4Hz, 3H), 1.28(d, J=6.4Hz, 3H), 1.68 to 1.84(m, 1H), 2.71 to 2.85(m, 1H), 3.28 to 3.77(m, 10H), 3.94 to 4.12(m, 2H), 4.17 to 4.31(m, 2H).

IR ν̄ (KBr) cm⁻¹: 3400, 1750.

MIC (γ/ml): Staphylococcus aureus strain 3626: 25.

Blood level: mice i.v., after 15 min (γ/ml): 31.8.

Example 9 Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivativeStep 1. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0165] To a solution of (1R,5S,6S)-2-diphenoxyphosphonyloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzyl ester (638 mg) in acetonitrile (6 ml) under ice cooling, diisopropylethylamine (230 µl) and (2S,4S)-2-(1,1-dioxo-2-p-methoxybenzyloxycarbonyl-3,4,5,6-tetrahydro-1,2,6-thiadiazin-6-yl)methyl-4-mercaptopto-1-p-methoxybenzyloxycarbonylpyrrolidine (700 mg) are added. The mixture is stirred at 5°C for 2 hours and at room temperature for 1 hour. The reaction mixture is diluted with ethyl acetate, successively washed with water, dilute hydrochloric acid, water, aqueous sodium hydrogen carbonate and water, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel chromatography to give (1R,5S,6S)-2-[(3S,5S)-5-(1,1-dioxo-2-p-methoxybenzyloxycarbonyl-3,4,5,6-tetrahydro-1,2,6-thiadiazin-6-yl)methyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzyl ester (640 mg). Yield: 64%.

NMR δ (CDCl₃) ppm: 1.22(d, J=7.4Hz, 3H), 1.34(d, J=6.4Hz, 3H), 5.04(s, 2H), 5.17, 5.25(ABq, J=12.3Hz, 2H), 5.19(s, 2H).

IR ν̄ (CHCl₃) cm⁻¹: 1700, 1770.

Step 2. Deprotection

[0166] To a solution of (1R,5S,6S)-2-[(3S,5S)-5-(1,1-dioxo-2-p-methoxybenzyloxycarbonyl-3,4,5,6-tetrahydro-1,2,6-thiadiazin-6-yl)methyl-1-p-methoxybenzyloxycarbonylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid p-methoxybenzylester (600 mg) in a mixture of dichloromethane (9 ml) and nitromethane (3.5 ml) in a nitrogen atmosphere at -40°C, anisole (861 µl) and a solution of 1.0M aluminum chloride in nitromethane (5.94 ml) are added. The mixture is stirred at the same temperature for 1.5 hours. The reaction mixture is poured into a solution of sodium acetate (1.52 g) in water (50 ml), and washed with a mixture of ether and hexane. The aqueous layer is concentrated in vacuo to about 15 ml, and the mixture is purified by styrene-divinylbenzene copolymer resin column chromatography to give (1R,5S,6S)-2-[(3S,5S)-5-(1,1-dioxo-3,4,5,6-tetrahydro-1,2,6-thiadiazin-6-yl)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid (190 mg). Yield: 63%.


NMR δ (D₂O) ppm: 1.20(d, J=7.2Hz, 3H), 1.27(d, J=6.4Hz, 3H), 1.65 to 1.80(m, 3H), 2.65 to 2.80(m, 1H), 3.27 to 3.56(m, 9H), 3.64 to 3.74(m, 1H), 3.91 to 4.10(m, 2H), 4.15 to 4.30(m, 2H).

IR ν̄ (KBr) cm⁻¹: 3400, 1750.

MIC (γ/ml): Staphylococcus aureus strain 3626: 25. Blood level: mice i.v., after 15 min. (γ/ml): 28.4.

Examples 10 to 12. Synthesis of (3R,5R), (3R,5S) and (3S,5R) pyrrolidylthiocarbapenem derivatives

[0167]



Step 1. Preparation of a protected pyrrolidylthiocarbapenem derivatives

[0168] To a solution of (1R,5S,6S)-2-diphenoxyphosphonyloxy-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penam-3-carboxylic acid diphenylmethyl ester (i.e., a substrate) and 1-t-butoxycarbonyl-2-(N-t-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercaptopyrrolidine (Pyld) in acetonitrile (MeCN) under ice cooling, diisopropylethylamine (HNPr-i) is added dropwise. The mixture is stirred to react under a condition shown in Table 4. The reaction mixture is diluted with ethyl acetate, and ice water is added thereto. The organic layer is taken, successively washed with water and saturated brine, dried over magnesium sulfate, and concentrated in vacuo. The residue is purified by silica gel chromatography to give (1R,5S,6S)-2-[1-t-butoxycarbonyl-5-(N-t-butoxycarbonyl-N-sulfamoylamino) methylpyrrolidin-3-yl]-thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penam-3-carboxylic acid diphenylmethyl ester.

Table 4

Example	Configuration ^{l)} of Pyld	Pyld ^{j)} equiv.	HNPr-i ^{j)} equiv.	MeCN ^{k)} vol.	Temp.	Time min.	Yield %
Ex. 10	3R5R	1.17	1.30	7 fold	ice cooling	240	86
Ex. 11	3R5S	1.20	1.30	7 fold	ice cooling	120	88
Ex. 12	3S5R	1.14	1.27	7 fold	ice cooling	270	73

^{l)} Configuration of a pyrrolidine ring

^{j)} Molar ratio to the substrate

^{k)} The volume (ml) of the solvent to the weight (g) of the substrate

Physical properties of the products

[0169] (3R,5R) Isomer:

NMR δ (CDCl₃) ppm: 1.26(d, J=7.2Hz, 3H), 1.39(d, J=6.2Hz, 3H), 1.43 (s, 9H), 1.51(s, 9H), 2.5(m, 1H), 3.1 to 3.9(m, 6H), 4.0 to 4.7(m, 4H), 6.1(m,1H), 6.98(s, 1H), 7.1 to 7.6(m, 10H).

IR \checkmark (KBr) cm⁻¹: 3400, 3240, 1770, 1710, 1670.

(3S,5R) Isomer:

NMR δ (CDCl₃) ppm: 1.28(d, J=7.0Hz, 3H), 1.36(s, 9H), 1.40(d, J=6.2 Hz, 3H), 1.52(s, 9H), 2.0(m, 1H), 3.2 to 3.9(m, 7H), 4.2 to 4.4 (m, 2H), 4.4 to 4.6(m, 1H), 6.01(s, 2H), 6.94(s, 1H), 7.1 to 7.6(m, 10H).

IR \checkmark (KBr) cm⁻¹: 3400, 3240, 1772, 1708, 1682.

(3R,5S) Isomer:

NMR δ (CDCl₃) ppm: 1.76(d, J=7.2Hz, 3H), 1.3 to 1.5(m, 12H), 1.52(s, 9H), 1.9 to 2.1(m, 1H), 3.2 to 3.9(m, 7H), 4.1 to 4.4(m, 2H), 4.4 to 4.6(m, 1H), 6.04(s, 2H), 6.94(s, 1H), 7.1 to 7.6(m, 10H).

IR \checkmark (KBr) cm⁻¹: 3420, 1770, 1710.

Step 2. Deprotection

[0170] A solution of (1R,5S,6S)-2-[1-t-butoxycarbonyl-5-(N-t-butoxycarbonyl-N-sulfamoylamino)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid diphenylmethyl ester (i.e., a substrate) in dichloromethane (DCM) is added dropwise in a nitrogen atmosphere into a solution of aluminum chloride (AlCl_3) in a mixture of dichloromethane (DCM) and anisole (PhOMe). The mixture is stirred to react under the condition shown in Table 5. To the reaction mixture, aqueous sodium acetate is added. The aqueous layer is taken, washed with dichloromethane, and purified by column chromatography over styrene-divinylbenzene copolymer resin to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[5-sulfamidomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid.

Table 5

Example	Configuration ^{l)} of Pyld	AlCl_3 ^{m)} equiv.	DCM ⁿ⁾ vol. (fold)	PhOMe ⁿ⁾ vol. (fold)	Temp. °C	Time min.	Yield %
Ex. 10	3R5R	8.0	16	10	-30	300	86
Ex. 11	3R5S	8.0	17	10	-30	150	88
Ex. 12	3S5R	8.0	17	10	-30	150	73

^{l)} Configuration of a pyrrolidine ring

^{m)} Molar ratio to the substrate

ⁿ⁾ The volume (ml) of the solvent to the weight (g) of the substrate

Physical properties of the products

[0171] (3R,5R) Isomer:

NMR δ (D_2O) ppm: 1.18(d, $J=7.2\text{Hz}$, 3H), 1.27(d, $J=6.2\text{Hz}$, 3H), 1.9(m, 1H), 2.7(m, 1H), 3.2 to 3.6(m, 5H), 3.6 to 3.8(m, 1H), 3.8 to 4.1(m, 2H), 4.2(m, 2H).

IR \checkmark (KBr) cm^{-1} : 3360, 1750.

(3S,5R) Isomer:

NMR δ (CD_3SOCD_3) ppm: 1.09(d, $J=7.0\text{Hz}$, 3H), 1.14(d, $J=6.2\text{Hz}$, 3H), 1.7 to 2.0(m, 1H), 1.9 to 2.2(m, 1H), 2.9 (m, 1H), 3.0 to 3.3(m, 4H), 3.3 to 3.6(m, 1H), 3.6 to 3.8(m, 2H), 3.9(m, 1H), 4.1(m, 1H).

IR \checkmark (KBr) cm^{-1} : 3340, 1765, 1740, 1620, 1575, 1548.


(3R,5S) Isomer:

NMR δ (D_2O) ppm: 0.86(d, $J=7.4\text{Hz}$, 3H), 0.93(d, $J=6.4\text{Hz}$, 3H), 2.43(d, $J=6.4\text{Hz}$, 3H), 1.90(dd, $J=9.0\text{Hz}$, $J=4.4\text{Hz}$, 2H), 2.9 to 3.3(m, 5H), 3.48(dd, $J=13.2\text{Hz}$, $J=7.2\text{Hz}$, 1H), 3.7 to 3.8(m, 2H), 3.8 to 4.0 (m, 2H), 4.47 DHO.

IR \checkmark (KBr) cm^{-1} : 3400, 1750, 1585.

Example 13. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative using a monoallyloxycarbonyl intermediate

[0172]



Step 1. Preparation of a trimethylsilyl compound

[0173] To a solution of (3S,4S)-3-[(1R)-1-hydroxy-ethyl]-4-[(1R)-1-phenylthiocarbonyl-ethyl]-1-allyloxy-carbonylmethyl-2-azetidinone (5.04 g: 13.35 mmole) in toluene (40 ml) under ice cooling, pyridine (1.51 ml: 18.69 mmole) is added and trimethylchlorosilane (2.26 ml: 17.36 mmole) is added dropwise. The mixture is stirred at room temperature for 1.5 hours. Water (80 ml) is added to the reaction mixture, and aqueous layer is extracted with toluene. The extract and the organic layer are combined, washed with water (2 times) and saturated brine, dried over magnesium sulfate, and concentrated in vacuo to give crude (3S,4S)-3-[(1R)-1-trimethylsilyloxyethyl]-4-[(1R)-1-phenylthiocarbonyl-ethyl]-1-allyloxycarbonylmethyl-2-azetidinone (5.614 g) as oily residue. Yield: 94%.

Step 2. Ring closure

[0174] To a solution of the crude (3S,4S)-3-[(1R)-1-trimethylsilyloxyethyl]-4-[(1R)-1-phenylthiocarbonyl-ethyl]-1-allyloxycarbonylmethyl-2-azetidinone (5.60 g: 12.454 mmole) obtained in Step 1 in tetrahydrofuran (62 ml) at -60°C, a solution of 1M-potassium t-butoxide (24.9 mmole) in tetrahydrofuran (24.9 ml) is added dropwise. The mixture is stirred for 10 minutes. After adding iodomethane (0.48 ml: 14.94 mmole) and stirring at the same temperature for 20 minutes, diphenylphosphoryl chloride (2.73 ml: 12.45 mmole) is added thereto. After allowing to warm to an ice water temperature over 1 hour, the reaction mixture is diluted with toluene (120 ml) and water (120 ml). The aqueous layer is extracted with toluene. The extract and the organic layer are combined, successively washed with water (2 times), aqueous sodium hydrogen carbonate, and saturated brine, dried over magnesium sulfate, and concentrated in vacuo to give crude (1R,5S,6S)-2-diphenoxyphosphoryloxy-6-[(1R)-1-trimethylsilyloxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester (3.795 g) as oily residue. Yield: 104%.

IR \checkmark (CHCl₃) cm⁻¹: 3008, 1778, 1722, 1636, 1589, 1489.

NMR δ (CDCl₃) ppm: 0.12(9H, s), 1.19(3H, d, J=7.2Hz), 1.25(3H, d, J=6.2Hz), 3.24(1H, dd, J=3.0Hz, J=6.8Hz), 3.3 to 3.6(1H, m), 4.11(1H, dd, J=3.0Hz, J=10.2Hz), 4.1 to 4.3(1H, m), 4.6 to 4.7(2H, m), 5.1 to 5.5(2H, m), 5.7 to 6.0(1H, m), 7.1 to 7.5(10H, m).

Step 3. Preparation of a protected pyrrolidylthiocarbapenem derivative

[0175] To a solution of crude (1R,5S,6S)-2-diphenoxy-phosphoryloxy-6-[(1R)-1-trimethylsilyloxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester (2.56 g: 4.2 mmole) obtained in Step 2 and (2S,4S)-1-allyloxycarbonyl-2-(N-sulfamoylamino)methyl-4-mercaptopyrrolidine (1.48 g: 5.0 mmole) in acetonitrile (13 ml) under ice cooling, diisopropylethylamine (0.95 ml: 5.46 mmole) is added dropwise, and the mixture is stirred at the same temperature for 7.5 hours. The reaction mixture is acidified with 1N-hydrochloric acid (6.3 ml), stirred at the same temperature for 30 minutes, and ethyl acetate (80 ml) and ice water (80 ml) are added thereto. The organic layer is taken, successively washed with water and saturated brine, dried over magnesium sulfate and concentrated in vacuo. The residue is purified by silica gel chromatography (toluene-ethyl acetate) to give (1R,5S,6S)-2-[(3S,5S)-1-allyloxycarbonyl-5-(N-sulfamoylamino)methyl-pyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester (1.63 g). Yield: 71%.

IR \checkmark (CHCl₃) cm⁻¹: 1772, 1691, 1410.

¹HNMR δ (CDCl₃) ppm: 1.26(3H, d, J=7.0Hz), 1.35(3H, d, J=6.0Hz), 1.7 to 2.7(3H, m), 3.1 to 3.5(5H, m), 3.5 to 3.8(1H, m), 3.9 to 4.4(4H, m), 4.5 to 4.9 (4H, m), 5.0 to 5.5(5H, m), 5.8 to 6.1(2H, m).

Step 4. Deprotection

[0176] To a solution of (1R,5S,6S)-2-[(3S,5S)-1-allyloxycarbonyl-5-(N-sulfamoylamino) methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester (379 mg: 0.695 mmole) in acetone (14 ml), triphenylphosphine (55 mg: 0.21 mmole) and tri-n-butyltin hydride (0.424 ml: 1.53 mmole) are added. Under ice cooling palladium tetrakis(triphenylphosphine) (81 mg: 0.07 mmole) is further added. After stirring at the same temperature for 45 minutes and at room temperature for 1 hour, water (35 ml) and methylene chloride (50 ml) are added to the reaction mixture. The aqueous layer is taken, washed with methylene chloride and lyophilized to give (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamidomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (238 mg). Yield: 32%. (HPLC purity : 85%)

NMR δ (D₂O) ppm: 1.22(d, J=7.2Hz, 3H), 1.27(d, J=6.3Hz, 3H), 1.64 to 1.82(m, 1H), 2.62 to 2.80(m, 1H), 3.26 to 3.59(m, 5H), 3.63 to 3.76(m, 1H), 3.84 to 4.10(m, 2H), 4.16 to 4.29(m, 2H).

IR \checkmark (KBr) cm⁻¹: 940, 1750.

Example 14. Synthesis of a (3S,5S)-pyrrolidylthiocarbapenem derivative using a diallyloxycarbonyl intermediate


[0177]

5

10

15

20

Step 1. Preparation of a trimethylsilyl compound

25

[0178] (3S,4S)-3-[(1R)-1-hydroxyethyl]-4-[(1R)-1-phenylthiocarbonylethyl]-1-allyloxycarbonylmethyl-2-azetidinone is trimethylsilylated in the same manner as in Step 1 in Example 13 to give (3S,4S)-3-[(1R)-1-trimethylsilyloxyethyl]-4-[(1R)-1-phenylthiocarbonylethyl]-1-allyloxycarbonylmethyl-2-azetidinone.

Step 2. Ring closure

30

[0179] The crude (3S,4S)-3-[(1R)-1-trimethylsilyloxyethyl]-4-[(1R)-1-phenylthiocarbonylethyl]-1-allyloxy-carbonyl-methyl-2-azetidinone obtained in Step 1 is allowed to react to close the ring in the similar manner as in Step 2 of Example 13 to give crude (1R,5S,6S)-2-diphenoxyphosphoryloxy-6-[(1R)-1-trimethylsilyloxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester.

35

Step 3 Preparation of a protected pyrrolidylthio carbapenem derivative

40

[0180] Under similar reaction condition, the crude (1R,5S,6S)-2-diphenoxyphosphoryloxy-6-[(1R)-1-trimethylsilyloxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester (5.05 g: 8.3 mmole) obtained in Step 2 and (2S,4S)-1-allyloxycarbonyl-2-(N-allyloxycarbonyl-N-sulfamoylamino)methyl-4-mercaptopyrrolidine (3.77 g: 9.94 mmole) are reacted to give (1R,5S,6S)-2-[(3S,5S)-1-allyloxycarbonyl-5-(N-allyloxycarbonyl-N-sulfamoylamino)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester (3.65 g). Yield: 70%.

IR \checkmark (CHCl₃) cm⁻¹: 1777, 1718, 1686, 1395.

NMR δ (CDCl₃) ppm: 1.27(3H, d, J=7.2Hz), 1.37(3H, d, J=6.2Hz), 2.5 to 2.7(1H, m), 3.1 to 3.3(3H, m), 3.6 to 3.8(2H, m), 4.0 to 4.3(4H, m), 4.4 to 4.9(6H, m), 5.2 to 5.5(6H, m), 5.7 to 6.1(5H, m).

45

Step 4 Deprotection

50

[0181] Under similar reaction condition to that in Step 4 in Example 13, (1R,5S,6S)-2-[(3S,5S)-1-allyloxycarbonyl-5-(N-allyloxycarbonyl-N-sulfamoylamino)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid allyl ester (369 mg: 0.586 mmole) is deprotected with triphenylphosphine (83 mg: 0.32 mmole), tri-n-butyltin hydride (0.64 ml: 2.3 mmole), and palladium tetrakis(triphenylphosphine) (122mg: 0.11 mmole) to give (1R, 5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamidomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (206 mg). Yield: 84%. (HPLC purity : 85%)

NMR δ (D₂O) ppm: 1.22(d, J=7.2Hz, 3H), 1.27(d, J=6.3Hz, 3H), 1.64 to 1.82(m, 1H), 2.62 to 2.80(m, 1H), 3.26 to 3.59(m, 5H), 3.63 to 3.76(m, 1H), 3.84 to 4.10(m, 2H), 4.16 to 4.29(m, 2H).

55

IR \checkmark (KBr) cm⁻¹: 3400, 1750.

Example 15

[0182] A solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-sulfamidomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (0.5 g) in aqueous sodium hydrogen carbonate (5 ml) at pH 7.0 is filled in a vial (10 ml) and lyophilized. The lyophilizate is dissolved in water for infection (5 ml) before use and injected thrice a day intravenously to a patient suffering from urinary tract infection caused by a sensitive strain of Staphylococcus aureus to cure the disease.

Example 16

[0183] A solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-(methylsulfamoyl)aminomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (0.5 g) in aqueous sodium hydrogen carbonate (5 ml) at pH 7.0 is filled in a vial (10 ml) and lyophilized. The lyophilizate is dissolved in water for infection (5 ml) before use and injected thrice a day intravenously to a patient suffering from pneumonia caused by a sensitive strain of Klebsiella pneumoniae to treat the disease.


Example 17

[0184] A solution of (1R,5S,6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S,5S)-5-(2-hydroxyethylsulfamoyl)aminomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid (2.0 g) in aqueous sodium hydrogen carbonate (10 ml) at pH 7.0 is filled in vial (100 ml) and lyophilized. The lyophilizate is dissolved in water for injection (50 ml) before use and administered by infusion four times a day intravenously to a patient severely suffering from the respiratory tract infection caused by a sensitive strain of Enterobacter cloacae to cure the disease.

[0185] Various other modifications will be apparent to and can be readily made by those skilled in the art without departing from the scope and spirit of this invention. Accordingly, it is not intended that the scope of the claims appended hereto be limited to the description as set forth herein, but rather that the claims be broadly construed.

Claims

1. A pyrrolidylthiocarbapenem derivative represented by Formula I:




wherein R¹ is hydrogen or alkyl having 1 to 6 carbon atoms; R², R³ and R⁴ are independently hydrogen, alkyl having 1 to 6 carbon atoms which can be substituted by hydroxy, or an amino protecting group, or R² and R³ together with a nitrogen atom to which R² and R³ are bonded form a cyclic group selected from the group consisting of pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, imidazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl, morpholino and thiomorpholino, or R² and R⁴, or R³ and R⁴ together with two nitrogen atoms and one sulfur atom in the sulfamide group form a cyclic group selected from the group consisting of 1,1-dioxothiadiazinyl, 1,1-dioxodihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazolinyl, 1,1-dioxothiadiazolinyl, and 1,1,3-trioxothiadiazolinyl, X¹ is hydrogen or a hydroxy protecting group; X² is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and Y² is hydrogen or an amino protecting group.

2. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein R¹ is methyl.


3. A pyrrolidylthiocarbapenem derivative according to claim 2, wherein R⁴ is hydrogen.

4. A pyrrolidylthiocarbapenem derivative according to claim 3, wherein X^1 and Y^2 are hydrogens and X^2 is hydrogen or alkali metal.
5. A pyrrolidylthiocarbapenem derivative according to claim 4, wherein R^2 and R^3 are hydrogens; R^2 is methyl and R^3 are hydrogen; both R^2 and R^3 are methyl; or R^2 is 2-hydroxyethyl, and R^3 are hydrogen.
6. A pyrrolidylthiocarbapenem derivative according to claim 2, wherein R^3 is hydrogen, and R^2 and R^4 are bonded to each other to form $-CH_2-CH_2-$.
7. A pyrrolidylthiocarbapenem derivative according to claim 2, wherein R^3 is hydrogen, and R^2 and R^4 are bonded to each other to form $-CH_2-CH_2-CH_2-$.
8. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein at least one group selected from the group consisting of R^2 , R^3 , R^4 and Y^2 is selected from the group consisting of t-butyloxy carbonyl, allyloxycarbonyl, p-nitrobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl and diazo.
9. A pyrrolidylthiocarbapenem, derivatrive according to claim 1, wherein X^1 is selected from the group consisting of hydrogen, trimethylsilyl, triethylsilyl and t-butoxydimethylsilyl.
10. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein X^2 is selected from the group consisting of hydrogen, sodium, potassium, t-butyl, allyl, p-nitrobenzyl, p-methoxybenzyl and diphenylmethyl.
11. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein the pyrrolidine ring in Formula I has a configuration of (3S, 5S).
12. A pyrrolidine derivative represented by Formula II:



wherein R^2 , R^3 and R^4 are independently hydrogen, alkyl having 1 to 6 carbon atoms which can be substituted by hydroxy, or an amino protecting group, or R^2 and R^3 together with a nitrogen atom to which R^2 and R^3 are bonded form a cyclic group selected from the group consisting of pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, imidazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl, morpholino and thiomorpholino, or R^2 and R^4 , or R^3 and R^4 together with two nitrogen atoms and one sulfur atom in the sulfamide group form a cyclic group selected from the group consisting of 1,1-dioxothiadiazinyl, 1,1-dioxo-dihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazoliziny, 1,1-dioxothiadiazolinyl, and 1,1,3-trioxothiadiazolinyl, Y^1 is hydrogen or a mercapto protecting group; and Y^2 is hydrogen or an amino protecting group.

13. A pyrrolidine derivative according to claim 12, wherein R^4 is hydrogen.
14. A method for producing a pyrrolidine derivative represented by Formula II:




10 wherein R², R³ and R⁴ are independently hydrogen, alkyl having 1 to 6 carbon atoms which can be substituted by hydroxy, or an amino protecting group, or R² and R³ together with a nitrogen atom to which R² and R³ are bonded form a cyclic group selected from the group consisting of pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, imidazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl, morpholino and thiomorpholino, or R² and R⁴, or R³ and R⁴ together with two nitrogen atoms and one sulfur atom in the sulfamide group form a cyclic group selected from the group consisting of 1,1-dioxothiadiazinyl, 1,1-dioxo-
 15 dihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazoliziny, 1,1-dioxothiadiazolinyl, and 1,1,3-trioxothiadiazolinyl, Y¹ is hydrogen or a mercapto protecting group; and Y² is hydrogen or an amino protecting group; the method comprising of the steps of:

20 converting a hydroxy group at the 4-position of a 4-hydroxypyrrolidine-2-carboxylic acid derivative into a mercapto group;
 converting a carboxy group at the 2-position into a hydroxymethyl group;
 converting a hydroxy group in the hydroxy-methyl group into an amino group; and
 25 converting the amino group into a sulfamido group.

15. A method according to claim 14, wherein R⁴ is hydrogen.

16. A method for producing a pyrrolidylthiocarbapenem derivative comprising the step of:


30 allowing a carbapenem derivative to react with the pyrrolidine derivative of claim 12 to obtain the pyrrolidylthiocarbapenem derivative of claim 1;
 the carbapenem derivative being represented by Formula III:



45 wherein R¹ is hydrogen or alkyl having 1 to 6 carbon atoms; X¹ is hydrogen or a hydroxy protecting group; X² is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and X³ is a leaving group.

17. A method for producing a pyrrolidylthiocarbapenem derivative comprising the step of:

50 allowing a carbapenem derivative to react with the pyrrolidine derivative according to claim 13 to obtain the pyrrolidylthiocarbapenem derivative of claim 2;
 the carbapenem derivative being represented by Formula III:




wherein R¹ is hydrogen or alkyl having 1 to 6 carbon atoms; X¹ is hydrogen or a hydroxy protecting group; X² is hydrogen, a carboxy protecting group, an ammonio group, an alkali metal or an alkaline-earth metal; and X³ is a leaving group.

18. An antibacterial agent comprising as an active ingredient an effective amount of the pyrrolidylthiocarbapenem derivative of claim 1 other than those pyrrolidylthiocarbapenem derivatives in which any one or more of R², R³, R⁴, X¹, X² and Y² is a protecting group.
19. An antibacterial agent comprising as an active ingredient an effective amount of the pyrrolidylthiocarbapenem derivative of claim 4 other than those pyrrolidylthiocarbapenem derivatives in which any one or more of R², R³, R⁴, X¹, X² and Y² is a protecting group.
20. An antibacterial agent comprising as an active ingredient an effective amount of the pyrrolidylthiocarbapenem derivative of claim 5 other than those pyrrolidylthiocarbapenem derivatives in which any one or more of R², R³, R⁴, X¹, X² and Y² is a protecting group.
21. An antibacterial agent comprising as an active ingredient an effective amount of the pyrrolidylthiocarbapenem derivative of claim 11 other than those pyrrolidylthiocarbapenem derivatives in which any one or more of R², R³, R⁴, X¹, X² and Y² is a protecting group.
22. A pyrrolidylthiocarbapenem derivative as claimed in claim 1, other than those pyrrolidylthiocarbapenem derivatives in which any one or more of R², R³, R⁴, X¹, X² and Y² is a protecting group, for use in a method for inhibiting growth of bacteria sensitive to the said derivative in which the sensitive bacterium is contacted with an effective amount of the said derivative.
23. A pyrrolidylthiocarbapenem derivative according to claim 1, which is (1R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S, 5S)-5-sulfamoylaminomethyl-1-pyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid, (1R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-2-[(3S, 5S)-5-N-methylaminosulfonyl-aminomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-carboxylic acid or (1R, 5S, 6S)-2-[(3S, 5S)-5-C(1,1-dioxo-1,2,5-thiadiazolidin-5-yl)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid.
24. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein R¹ is hydrogen or alkyl having 1 to 6 carbon atoms; R², R³ and R⁴ are independently hydrogen, alkyl having 1 to 6 carbon atoms which can be substituted by hydroxy, or R² and R³ together with a nitrogen atom to which R² and R³ are bonded form a cyclic group selected from the group consisting of pyrrolidin-1-yl, pyrrol-1-yl, imidazolidin-1-yl, imidazol-1-yl, pyrazolidin-1-yl, pyrazol-1-yl, piperidino, dihydro- or tetrahydropyridin-1-yl, piperazino, piperazin-1-yl, morpholino and thiomorpholino, or R² and R⁴, or R³ and R⁴ together with two nitrogen atoms and one sulfur atom in the sulfamide group form a cyclic group selected from the group consisting of 1,1-dioxothiadiazinyl, 1,1-dioxodihydrothiadiazinyl, 1,1,3-trioxodihydrothiadiazinyl, 1,1-dioxothiadiazoliziny, 1,1-dioxothiadiazolinyl, and 1,1,3-trioxothiadiazolinyl, X¹ is hydrogen, X² is hydrogen, an ammonio group, an alkali metal or an alkaline-earth metal; and Y² is hydrogen.
25. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein X² is a carboxy protecting group and Y² is an amino protecting group.
26. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein X² is a carboxy protecting group, Y² is an amino protecting group; and one of R² and R³ is an amino protecting group.
27. A pyrrolidylthiocarbapenem derivative according to claim 1, wherein X¹ is a hydroxy protecting group, X² is a carboxy protecting group, Y² is an amino protecting group and R⁴ is an amino protecting group.

Patentansprüche

1. Pyrrolidylthiocarbapenemderivat, dargestellt durch Formel I:



bei der R¹ Wasserstoff oder Alkyl mit 1 bis 6 Kohlenstoffatomen ist; R², R³ und R⁴ unabhängig voneinander Wasserstoff, Alkyl mit 1 bis 6 Kohlenstoffatomen, das mit Hydroxy substituiert sein kann, oder eine Aminoschutzgruppe sind, oder R² und R³ zusammen mit einem Stickstoffatom, an das R² und R³ gebunden sind, eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus Pyrrolidin-1-yl, Pyrrol-1-yl, Imidazolidin-1-yl, Imidazol-1-yl, Pyrazolidin-1-yl, Pyrazol-1-yl, Piperidino, Dihydro- oder Tetrahydropyridin-1-yl, Piperazino, Piperazin-1-yl, Morpholino und Thiomorpholino, oder R² und R⁴, oder R³ und R⁴ zusammen mit zwei Stickstoffatomen und einem Schwefelatom in der Sulfamidgruppe eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus 1,1-Dioxothiadiazinyl, 1,1-Dioxodihydrothiadiazinyl, 1,1,3-Trioxodihydrothiadiazinyl, 1,1-Dioxothiadiazoliziny, 1,1-Dioxothiadiazoliny, und 1,1,3-Trioxothiadiazoliny, X¹ Wasserstoff oder eine Hydroxyschutzgruppe ist; X² Wasserstoff, eine Carboxyschutzgruppe, eine Ammoniumgruppe, ein Alkalimetall oder ein Erdalkalimetall ist; und Y² Wasserstoff oder eine Aminoschutzgruppe ist.

2. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem R¹ Methyl ist.

3. Pyrrolidylthiocarbapenemderivat nach Anspruch 2, bei dem R⁴ Wasserstoff ist.

4. Pyrrolidylthiocarbapenemderivat nach Anspruch 3, bei dem X¹ und Y² Wasserstoffe sind und X² Wasserstoff oder ein Alkalimetall ist.

5. Pyrrolidylthiocarbapenemderivat nach Anspruch 4, bei dem R² und R³ Wasserstoffe sind; R² Methyl ist und R³ Wasserstoff ist; sowohl R² und R³ Methyl sind; oder R² 2-Hydroxyethyl ist und R³ Wasserstoff ist.

6. Pyrrolidylthiocarbapenemderivat nach Anspruch 2, bei dem R³ Wasserstoff ist, und R² und R⁴ aneinander gebunden sind, um -CH₂-CH₂- zu bilden.

7. Pyrrolidylthiocarbapenemderivat nach Anspruch 2, bei dem R³ Wasserstoff ist, und R² und R⁴ aneinander gebunden sind, um -CH₂-CH₂-CH₂- zu bilden.


8. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem mindestens eine Gruppe, die ausgewählt ist aus der Gruppe bestehend aus R², R³, R⁴ und Y², ausgewählt ist aus der Gruppe bestehend aus tert.-Butyloxycarbonyl, Allyloxycarbonyl, p-Nitrobenzyloxycarbonyl, p-Methoxybenzyloxycarbonyl und Diazo.

9. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem X¹ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Trimethylsilyl, Triethylsilyl und tert.-Butoxydimethylsilyl.

10. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem X² ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, Natrium, Kalium, tert.-Butyl, Allyl, p-Nitrobenzyl, p-Methoxybenzyl und Diphenylmethyl.

11. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem der Pyrrolidinring in Formel I eine Konfiguration von (3S, 5S) aufweist.


12. Pyrrolidinderivat dargestellt durch Formel II:



bei der R², R³ und R⁴ unabhängig voneinander Wasserstoff, Alkyl mit 1 bis 6 Kohlenstoffatomen, das mit Hydroxy substituiert sein kann, oder eine Aminoschutzgruppe sind, oder R² und R³ zusammen mit einem Stickstoffatom, an das R² und R³ gebunden sind, eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus Pyrrolidin-1-yl, Pyrrol-1-yl, Imidazolidin-1-yl, Imidazol-1-yl, Pyrazolidin-1-yl, Pyrazol-1-yl, Piperidino, Dihydro- oder Tetrahydropyridin-1-yl, Piperazino, Piperazin-1-yl, Morpholino und Thiomorpholino, oder R² und R⁴, oder R³ und R⁴ zusammen mit zwei Stickstoffatomen und einer Schwefelgruppe in der Sulfamidgruppe eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus 1,1-Dioxothiadiazinyl, 1,1-Dioxodihydrothiadiazinyl, 1,1,3-Trioxodihydrothiadiazinyl, 1,1-Dioxothiadiazoliziny, 1,1-Dioxothiadiazoliny, und 1,1,3-Trioxothiadiazoliny, Y¹ Wasserstoff oder eine Mercaptoschutzgruppe ist; und Y² Wasserstoff oder eine Aminoschutzgruppe ist.

13. Pyrrolidinderivat nach Anspruch 12, bei dem R⁴ Wasserstoff ist.

14. Verfahren zur Herstellung eines Pyrrolidinderivats dargestellt durch Formel II:



bei der R², R³ und R⁴ unabhängig voneinander Wasserstoff, Alkyl mit 1 bis 6 Kohlenstoffatomen, das mit Hydroxy substituiert sein kann, oder eine Aminoschutzgruppe sind, oder R² und R³ zusammen mit einem Stickstoffatom, an das R² und R³ gebunden sind, eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus Pyrrolidin-1-yl, Pyrrol-1-yl, Imidazolidin-1-yl, Imidazol-1-yl, Pyrazolidin-1-yl, Pyrazol-1-yl, Piperidino, Dihydro- oder Tetrahydropyridin-1-yl, Piperazino, Piperazin-1-yl, Morpholino und Thiomorpholino, oder R² und R⁴, oder R² und R⁴ zusammen mit zwei Stickstoffatomen und einer Schwefelgruppe in der Sulfamidgruppe eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus 1,1-Dioxothiadiazinyl, 1,1-Dioxodihydrothiadiazinyl, 1,1,3-Trioxodihydrothiadiazinyl, 1,1-Dioxothiadiazoliziny, 1,1-Dioxothiadiazoliny, und 1,1,3-Trioxothiadiazoliny, Y¹ Wasserstoff oder eine Mercaptoschutzgruppe ist; und Y² Wasserstoff oder eine Aminoschutzgruppe ist; wobei das Verfahren die Schritte umfasst:

Konvertieren einer Hydroxygruppe an der 4-Position eines 4-Hydroxypyrrolidin-2-Carbonsäurederivats in eine Mercaptogruppe;

Konvertieren einer Carboxygruppe an der 2-Position in eine Hydroxymethylgruppe;


Konvertieren einer Hydroxygruppe in der Hydroxymethylgruppe in eine Aminogruppe; und

Konvertieren der Aminogruppe in eine Sulfamidogruppe.

15. Verfahren nach Anspruch 14, bei dem R⁴ Wasserstoff ist.

16. Verfahren zum Herstellen eines Pyrrolidylthiocarbapenemderivats, mit dem Schritt:


Reagieren lassen eines Carbapenemderivats mit dem Pyrrolidinderivat nach Anspruch 12, um das Pyrrolidylthiocarbapenemderivat nach Anspruch 1 zu erhalten; wobei das Carbapenemderivat durch die Formel III dargestellt ist:



10 bei der R¹ Wasserstoff oder Alkyl mit 1 bis 6 Kohlenstoffatomen ist; X¹ Wasserstoff oder eine Hydroxyschutzgruppe ist; X² Wasserstoff, eine Carboxyschutzgruppe, eine Ammoniumgruppe, ein Alkalimetall oder ein Erdalkalimetall ist; und X³ eine austretende Gruppe ist.

15 17. Verfahren zur Herstellung eines Pyrrolidylthiocarbapenemderivats mit dem Schritt:

Reagieren lassen eines Carbapenemderivats mit dem Pyrrolidinderivat nach Anspruch 13, um das Pyrrolidylthiocarbapenemderivat nach Anspruch 2 zu erhalten;
wobei das Carbapenemderivat dargestellt ist durch die Formel III ist:



30 bei der R¹ Wasserstoff oder Alkyl mit 1 bis 6 Kohlenstoffatomen ist; X¹ Wasserstoff oder eine Hydroxyschutzgruppe ist; X² Wasserstoff, eine Carboxyschutzgruppe, eine Ammoniumgruppe, ein Alkalimetall oder ein Erdalkalimetall ist; und X³ eine austretende Gruppe ist.

35 18. Antibakterielles Mittel, das als einen aktiven Bestandteil eine wirksame Menge des Pyrrolidylthiocarbapenemderivats nach Anspruch 1 außer denjenigen Pyrrolidylthiocarbapenemderivaten umfasst, in denen irgendeines oder mehrere von R², R³, R⁴, X¹, X² und Y² eine Schutzgruppe sind.

40 19. Antibakterielles Mittel, das als einen aktiven Bestandteil eine wirksame Menge des Pyrrolidylthiocarbapenemderivats nach Anspruch 4 außer denjenigen Pyrrolidylthiocarbapenemderivaten umfasst, in denen irgendeines oder mehrere von R², R³, R⁴, X¹, X² und Y² eine Schutzgruppe sind.

45 20. Antibakterielles Mittel, das als aktiven Bestandteil eine wirksame Menge des Pyrrolidylthiocarbapenemderivats nach Anspruch 5 außer denjenigen Pyrrolidylthiocarbapenemderivaten umfasst, bei denen irgendeines oder mehrere von R², R³, R⁴, X¹, X² und Y² eine Schutzgruppe sind.

50 21. Antibakterielles Mittel, das als einen aktiven Bestandteil eine wirksame Menge des Pyrrolidylthiocarbapenemderivats nach Anspruch 11 außer denjenigen Pyrrolidylthiocarbapenemderivaten umfasst, in denen irgendeines oder mehrere von R², R³, R⁴, X¹, X² und Y² eine Schutzgruppe sind.

55 22. Pyrrolidylthiocarbapenemderivat wie in Anspruch 1 beansprucht, außer denjenigen Pyrrolidylthiocarbapenemderivaten in denen irgendeine oder mehrere von R², R³, R⁴, X¹, X² und Y² eine Schutzgruppe sind, zur Verwendung in einem Verfahren zum Inhibieren des Wachstums von Bakterien, die gegenüber diesem Derivat sensitiv sind, bei dem das sensitive Bakterium mit einer wirksamen Menge des Derivats in Kontakt gebracht wird.


23. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, das (1R, 5S, 6S) -6- [(1R)-1-Hydroxyethyl]-2- [(3S,5S)-5-sulfamoylaminomethyl-1-pyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-Carbonsäure, (1R,5S,6S)-6-[(1R)-1-Hy-

droxyethyl]-2-[(3S,5S)-5-N-methylaminosulfonyl-aminomethylpyrrolidin-3-yl]thio-1-methyl-1-carba-2-penem-3-Carbonsäure oder (1R,5S,6S)-3=[(3S,5S)-5-C]1,1-Dioxo-1,2,5-thiadiazolidin-5-yl)methylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carba-2-penem-3-Carbonsäure ist.

24. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem R¹ Wasserstoff oder Alkyl mit 1 bis 6 Kohlenstoffatomen ist; R², R³ und R⁴ unabhängig voneinander Wasserstoff, Alkyl mit 1 bis 6 Kohlenstoffatomen, das mit Hydroxy substituiert sein kann, oder R² und R³ zusammen mit einem Stickstoffatom, an das R² und R³ gebunden sind, eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus Pyrrolidin-1-yl, Pyrrol-1-yl, Imidazolidin-1-yl, Imidazol-1-yl, Pyrazolidin-1-yl, Pyrazol-1-yl, Piperidino, Dihydro- oder Tetrahydropyridin-1-yl, Piperazino, Piperazin-1-yl, Morpholino und Thiomorpholino, oder R² und R⁴, oder R³ und R⁴ zusammen mit zwei Stickstoffatomen und einem Schwefelatom in der sulfamidgruppe eine cyclische Gruppe bilden, ausgewählt aus der Gruppe bestehend aus 1,1-Dioxothiadiazinyl, 1,1-Dioxodihydrothiadiazinyl, 1,1,3-Trioxodihydrothiadiazinyl, 1,1-Dioxothiadiazoliziny, 1,1-Dioxothiadiazoliny, und 1,1,3-Trioxothiadiazoliny, X¹ Wasserstoff ist, X² Wasserstoff, eine Ammoniumgruppe, ein Alkalimetall oder ein Erdalkalimetall; und Y² Wasserstoff ist.
25. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem X² eine Carboxyschutzgruppe und Y² eine Aminoschutzgruppe sind.
26. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem X² eine Carboxyschutzgruppe, Y² eine Aminoschutzgruppe; und eines von R² und R³ eine Aminoschutzgruppe sind.
27. Pyrrolidylthiocarbapenemderivat nach Anspruch 1, bei dem X¹ eine Hydroxyschutzgruppe, X² eine Carboxyschutzgruppe, Y² eine Aminoschutzgruppe und R⁴ eine Aminoschutzgruppe sind.

Revendications

1. Dérivé de pyrrolidylthiocarbapénème représenté par la Formule I:




dans laquelle R¹ est un hydrogène ou un alkyle ayant 1 à 6 atomes de carbone; R², R³ et R⁴ sont indépendamment un hydrogène, un alkyle ayant 1 à 6 atomes de carbone qui peut être substitué par un hydroxy, ou un groupe protecteur de l' amino, ou R² et R³ ensemble avec un atome d'azote auquel R² et R³ sont liés forment un groupe cyclique choisi dans le groupe constitué par un pyrrolidin-1-yle, un pyrrol-1-yle, un imidazolidin-1-yle, un imidazol-1-yle, un pyrazolidin-1-yle, un pyrazol-1-yle, un pipéridino, un dihydro- ou tétrahydropyridin-1-yle, un pipérazino, un pipérazin-1-yle, un morpholino et un thiomorpholino, ou R² et R⁴, ou R³ et R⁴ ensemble avec deux atomes d'azote et un atome de soufre dans le groupe sulfamide forment un groupe cyclique choisi dans le groupe constitué par un 1,1-dioxothiadiazinyle, un 1,1-dioxodihydrothiadiazinyle, un 1,1,3-trioxodihydrothiadiazinyle, un 1,1-dioxothiadiazoliziny, un 1,1-dioxothiadiazoliny, et un 1,1,3-trioxothiadiazoliny; X¹ est un hydrogène ou un groupe protecteur de l'hydroxy; X² est un hydrogène, un groupe protecteur du carboxy, un groupe ammonio, un métal alcalin ou un métal alcalino-terreux; et Y² est un hydrogène ou un groupe protecteur de l' amino.

2. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel R¹ est un méthyle.
3. Dérivé de pyrrolidylthiocarbapénème selon la revendication 2, dans lequel R⁴ est un hydrogène.
4. Dérivé de pyrrolidylthiocarbapénème selon la revendication 3, dans lequel X¹ et Y² sont des hydrogènes, et X²


est un hydrogène ou un métal alcalin.

5. Dérivé de pyrrolidylthiocarbapénème selon la revendication 4, dans lequel R² et R³ sont des hydrogènes; R² est un méthyle et R³ est un hydrogène; à la fois R² et R³ sont un méthyle; ou R² est un 2-hydroxyéthyle, et R³ est un hydrogène.
6. Dérivé de pyrrolidylthiocarbapénème selon la revendication 2, dans lequel R³ est un hydrogène, et R² et R⁴ sont liés l'un à l'autre pour former -CH₂-CH₂-.
7. Dérivé de pyrrolidylthiocarbapénème selon la revendication 2, dans lequel R³ est un hydrogène, et R² et R⁴ sont liés l'un à l'autre pour former -CH₂-CH₂-CH₂-.
8. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel au moins un groupe choisi dans le groupe constitué par R², R³, R⁴ et Y² est choisi dans le groupe constitué par un t-butyloxycarbonyl, un allyloxycarbonyl, un p-nitrobenzyloxycarbonyl, un p-méthoxybenzyloxycarbonyl et un diazo.
9. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel X¹ est choisi dans le groupe constitué par un hydrogène, un triméthylsilyl, un triéthylsilyl et un t-butoxydiméthylsilyl.
10. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel X² est choisi dans le groupe constitué par un hydrogène, un sodium, un potassium, un t-butyle, un allyle, un p-nitrobenzyle, un p-méthoxybenzyle et un diphenylméthyle.
11. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel le cycle pyrrolidine dans la Formule I a une configuration (3S,5S).
12. Dérivé de pyrrolidylthiocarbapénème représenté par la Formule II :



dans laquelle R², R³ et R⁴ sont indépendamment un hydrogène, un alkyle ayant 1 à 6 atomes de carbone qui peut être substitué par un hydroxy, ou un groupe protecteur de l'amino, ou R² et R³ ensemble avec un atome d'azote auquel R² et R³ sont liés forment un groupe cyclique choisi dans le groupe constitué par un pyrrolidin-1-yle, un pyrrol-1-yle, un imidazolidin-1-yle, un imidazol-1-yle, un pyrazolidin-1-yle, un pyrazol-1-yle, un pipéridino, un dihydro- ou tétrahydropyridin-1-yle, un pipérazino, un pipérazin-1-yle, un morpholino et un thiomorpholino, ou R² et R⁴, ou R³ et R⁴ ensemble avec deux atomes d'azote et un atome de soufre dans le groupe sulfamide forment un groupe cyclique choisi dans le groupe constitué par un 1,1-dioxothiadiazinyle, un 1,1-dioxodihydrothiadiazinyle, un 1,1,3-trioxodihydrothiadiazinyle, un 1,1-dioxothiadiazolizynyle, un 1,1-dioxothiadiazolynyle, et un 1,1,3-trioxothiadiazolynyle; Y¹ est un hydrogène ou un groupe protecteur du mercapto; et Y² est un hydrogène ou un groupe protecteur de l'amino.

13. Dérivé de pyrrolidine selon la revendication 12, dans lequel R⁴ est un hydrogène.
14. Procédé de préparation d'un dérivé de pyrrolidine représenté par la Formule II :




10 dans laquelle R², R³ et R⁴ sont indépendamment un hydrogène, un alkyle ayant 1 à 6 atomes de carbone qui peut être substitué par un hydroxy, ou un groupe protecteur de l'amino, ou R² et R³ ensemble avec un atome d'azote auquel R² et R³ sont liés forment un groupe cyclique choisi dans le groupe constitué par un pyrrolidin-1-yle, un pyrrol-1-yle, un imidazolidin-1-yle, un imidazol-1-yle, un pyrazolidin-1-yle, un pyrazol-1-yle, un pipéridino, un dihydro- ou tétrahydropyridin-1-yle, un pipérazino, un pipérazin-1-yle, un morpholino et un thiomorpholino, ou R² et R⁴, ou R³ et R⁴ ensemble avec deux atomes d'azote et un atome de soufre dans le groupe sulfamide forment un groupe cyclique choisi dans le groupe constitué par un 1,1-dioxothiadiazinyle, un 1,1-dioxodihydrothiadiazinyle, un 1,1,3-trioxodihydrothiadiazinyle, un 1,1-dioxothiadiazolizinyne, un 1,1-dioxothiadiazolinyne, et un 1,1,3-trioxothiadiazolinyne; Y¹ est un hydrogène ou un groupe protecteur du mercapto; et Y² est un hydrogène ou un groupe protecteur de l'amino; le procédé comprenant les étapes consistant à :

transformer un groupe hydroxy en position 4 d'un dérivé d'acide 4-hydroxypyrrolidine-2-carboxylique en un groupe mercapto;
transformer un groupe carboxy en position 2 en un groupe hydroxyméthyle;
transformer un groupe hydroxy dans le groupe hydroxyméthyle en un groupe amino; et
transformer le groupe amino en un groupe sulfamido.

15. Procédé selon la revendication 14, dans lequel R⁴ est un hydrogène.

16. Procédé pour préparer un dérivé de pyrrolidylthiocarbapénème comprenant les étapes consistant à :


laisser un dérivé de carbapénème réagir avec le dérivé de pyrrolidine de la revendication 12 pour obtenir le dérivé de pyrrolidylthiocarbapénème de la revendication 1; le dérivé de carbapénème étant représenté par la Formule III :



45 dans laquelle R¹ est un hydrogène ou un alkyle ayant 1 à 6 atomes de carbone; X¹ est un hydrogène ou un groupe protecteur de l'hydroxy; X² est un hydrogène, un groupe protecteur du carboxy, un groupe ammonio, un métal alcalin ou un métal alcalino-terreux; et X³ est un groupe partant.

17. Procédé pour préparer un dérivé de pyrrolidylthiocarbapénème comprenant les étapes consistant à :

laisser un dérivé de carbapénème réagir avec le dérivé de pyrrolidine selon la revendication 13 pour obtenir le dérivé de pyrrolidylthiocarbapénème de la revendication 2;
le dérivé de carbapénème étant représenté par la Formule III :



(III)

dans laquelle R¹ est un hydrogène ou un alkyle ayant 1 à 6 atomes de carbone; X¹ est un hydrogène ou un groupe protecteur de l'hydroxy; X² est un hydrogène, un groupe protecteur du carboxy, un groupe ammonio, un métal alcalin ou un métal alcalino-terreux; et X³ est un groupe partant.

18. Agent antibactérien comprenant en tant qu'ingrédient actif une quantité efficace du dérivé de pyrrolidylthiocarbapénème de la revendication 1 autre que les dérivés de pyrrolidylthiocarbapénème dans lesquels l'un quelconque ou plusieurs de R², R³, R⁴, X¹, X² et Y² est un groupe protecteur.
19. Agent antibactérien comprenant en tant qu'ingrédient actif une quantité efficace du dérivé de pyrrolidylthiocarbapénème de la revendication 4 autre que les dérivés de pyrrolidylthiocarbapénème dans lesquels l'un quelconque ou plusieurs de R², R³, R⁴, X¹, X² et Y² est un groupe protecteur.
20. Agent antibactérien comprenant en tant qu'ingrédient actif une quantité efficace du dérivé de pyrrolidylthiocarbapénème de la revendication 5 autre que les dérivés de pyrrolidylthiocarbapénème dans lesquels l'un quelconque ou plusieurs de R², R³, R⁴, X¹, X² et Y² est un groupe protecteur.
21. Agent antibactérien comprenant en tant qu'ingrédient actif une quantité efficace du dérivé de pyrrolidylthiocarbapénème de la revendication 11 autre que les dérivés de pyrrolidylthiocarbapénème dans lesquels l'un quelconque ou plusieurs de R², R³, R⁴, X¹, X² et Y² est un groupe protecteur.
22. Dérivé de pyrrolidylthiocarbapénème tel que revendiqué dans la revendication 1, autre que les dérivés de pyrrolidylthiocarbapénème dans lesquels l'un quelconque ou plusieurs de R², R³, R⁴, X¹, X² et Y² est un groupe protecteur, pour utilisation dans un procédé pour inhiber la croissance de bactéries sensibles audit dérivé dans lequel ladite bactérie sensible est mise en contact avec une quantité efficace dudit dérivé.
23. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1 qui est l'acide (1R, 5S, 6S)-6-[(1R)-1-hydroxyéthyl]-2-[(3S, 5S)-5-sulfamoylaminométhyl-1-pyrrolidin-3-yl]thio-1-méthyl-1-carba-2-pénèm-3-carboxylique, l'acide (1R, 5S, 6S)-6-[(1R)-1-hydroxyéthyl]-2-[(3S, 5S)-5-N-méthylaminosulfonyl-aminométhyl-pyrrolidin-3-yl]thio-1-méthyl-1-carba-2-pénèm-3-carboxylique ou l'acide (1R, 5S, 6S)-2-[(3S, 5S)-5-C1,1-dioxo-1,2,5-thiadiazolidin-5-yl)méthylpyrrolidin-3-yl]thio-6-[(1R)-1-hydroxyéthyl]-1-méthyl-1-carba-2-pénèm-3-carboxylique.
24. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel R¹ est un hydrogène ou un alkyle ayant 1 à 6 atomes de carbone; R², R³ et R⁴ sont indépendamment un hydrogène, un alkyle ayant 1 à 6 atomes de carbone qui peut être substitué par un hydroxy, ou R² et R³ ensemble avec un atome d'azote auquel R² et R³ sont liés forment un groupe cyclique choisi dans le groupe constitué par un pyrrolidin-1-yle, un pyrrol-1-yle, un imidazolidin-1-yle, un imidazol-1-yle, un pyrazolidin-1-yle, un pyrazol-1-yle, un pipéridino, un dihydro- ou tétrahydropyridin-1-yle, un pipérazino, un pipérazin-1-yle, un morpholino et un thiomorpholino, ou R² et R⁴, ou R³ et R⁴ ensemble avec deux atomes d'azote et un atome de soufre dans le groupe sulfamide forment un groupe cyclique choisi dans le groupe constitué par un 1,1-dioxothiadiazinyle, un 1,1-dioxodihydrothiadiazinyle, un 1,1,3-trioxodihydrothiadiazinyle, un 1,1-dioxothiadiazolizynyle, un 1,1-dioxothiadiazolynyle, et un 1,1,3-trioxothiadiazolynyle; X¹ est un hydrogène; X² est un hydrogène, un groupe ammonio, un métal alcalin ou un métal alcalino-terreux; et Y² est un hydrogène.
25. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel X² est un groupe protecteur du carboxy et Y² est un groupe protecteur de l'amino.
26. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel X² est un groupe protecteur du carboxy, Y² est un groupe protecteur de l'amino; et l'un de R² et R³ est un groupe protecteur de l'amino.

27. Dérivé de pyrrolidylthiocarbapénème selon la revendication 1, dans lequel X¹ est un groupe protecteur de l'hydroxy, X² est un groupe protecteur du carboxy, Y² est un groupe protecteur de l'amino et R⁴ est un groupe protecteur de l'amino.

5

10

15

20

25

30

35

40

45

50

55